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Abstract
Five atherosclerotic carotid and femoral plaques were sliced longitudinally. Each section was
analysed for the concentrations of neopterin, α-tocopherol, TBARS, DOPA, dityrosine, protein
carbonyl, protein and cholesterol. The spatial concentrations of the oxidative and inflammatory
markers were diverse across and between the individual plaques suggested by the lack of consistent
correlations and trends. The only correlation that occurred twice within the individual plaques was a
positive correlation between α-tocopherol and cholesterol levels. In the combined plaque analysis
which included data from eight previously studied plaques, neopterin, protein carbonyl and protein
concentrations all had significant positive correlations and α-tocopherol concentrations positively
correlated to cholesterol and negatively to TBARS. Thus overall the level of protein may influence
protein carbonyl concentration and α-tocopherol may provide an antioxidant effect towards lipid
peroxidation. Furthermore, the plaques were divided into three zones, pre-bifurcation, bifurcation
and post-bifurcation, associated with shear stress levels. The neopterin concentrations were
significantly high within the pre- and post-bifurcation region and the opposite trend occurred with
the to peroxyl radical driven TBARS levels. The protein and cholesterol content in the post-
bifurcation was high, possibly due to the low and/or oscillatory shear stress occurring at these sites.
The overall composition of the plaque, either thrombosed, heavily calcified or neither, also
identified significant trends in marker concentrations between the plaques. The calcified plaques
had significantly low levels of protein, cholesterol, α-tocopherol, DOPA and dityrosine whereas the
thrombosed plaques had significantly high protein, α-tocopherol and dityrosine concentrations. The
medication and symptoms presented by the patient had no major influence of the overall
concentration of the markers within the plaques. Therefore even though individually the plaques
have varied biochemical compositions, common influences were dictate the spatial and overall
concentration of the markers within and across the plaques. Further potential markers were
investigated for detection within plaque. AAS and GGS for replacement of the protein carbonyl
assay as a more specific marker for protein oxidation, as well as the oxysterol 7-ketocholesterol
detected simultaneously during α-tocopherol analysis. The 7-ketocholesterol would increase the
information on lipid oxidation occurring in the plaque without increasing the volume of the limited
homogenate required for the analysis. Investigation was also carried out on the mechanism of
protein oxidation in human plasma that may provide mechanisms and interactions to protein
oxidation within plaques.
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Introduction
1.1 Atherosclerosis
Cardiovascular disease is the number one cause of mortality, accounting for 40% of deaths (Hay,
2004), and hospital admissions within New Zealand (Wells et al., 2006). Atherosclerosis, a
cardiovascular disease, literally means ‘gruel hardening’, that is a mass accumulation of cellular and
lipid material within the arterial wall that eventually leads to hardening and occlusion of the artery.
It is now fully acknowledged as a chronic inflammatory multi-factorial disease (Gieseg et al.,
2008a; Libby et al., 2002; Stadler et al., 2004) and this reflects in its complexity. It is a disease that
develops over time spanning many decades, where clinical events generally occur later in life. Risk
factors associated with this disease includes hypertension, smoking, hypercholesteromia, obsesity,
insulin resistance and dyslipidemia and of these factors many occur in conjugation with one another
(Libby et al., 2002; Scott, 2004; Wilson et al., 1999). Although this disease has long been studied, it
is still not completely understood and theories to its genesis continue to be debated. By revealing
processes involved in plaque initiation, progression and events leading to clinical outcomes,
subsequent intervention may be able to reduce what ultimately makes this disease the leading cause
of mortality and morbidity within the developed world (Danilevicius et al., 2007; Helderman et al.,
2007; Stocker and Keaney, 2004).
1.1.1 Plaque development from early lesion to complex atherosclerotic plaque
Arteries are made up of three defined layers the intima, media and adventitia (Figure 1.1). The
intimal layer begins with a continuous monolayer of endothelial cells. These cells provide a
permeable barrier between the blood flow and the arterial components. The endothelial cells
synthesize and secrete extracellular materials like collagen, proteoglycans and fibronectin and under
normal conditions are thromoboresistant. Endothelial cells are also involved in the regulation of
vascular tone and contraction through various factors like the endothelial derived relaxation factor,
involving nitric oxide and the activation of cyclic GMP production via smooth muscle cells (SMC)
resulting in a cellular contractibility response (Stary et al., 1992). Endothelial cells are able to detect
differences in shear stress by the distortion of cytoskeletal components. This mechantransduction
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Figure 1.1 Defined layers of the arterial vessel wall
A single layer of endothelial cells provides the barrier between tissue and flowing blood. The
intima, site of plaque formation, and the media consists mostly of smooth muscle cells. The
adventitia and the basement membrane form the outer layers of the artery. Adapted from Libby
(2002a).
triggers different physiological responses by the activation of cellular membrane proteins for
example integrins and activating intracellular signallers like the GTPase (Helderman et al., 2007).
Endothelial cells are also involved in the inflammatory and immune responses (Stary et al., 1992).
Oxidised LDL induces the expression of growth factors like the macrophage colony stimulating
factor (Rakjavashisth et al., 1990) and for leukocyte recruitment the expression of adhesion
molecules for example the endothelial-leukocyte adhesion molecule-1 (Bevilacqua et al., 1987).
The endothelial cells are underlayed with a region rich in connective tissue, SMC generally as
single cells and isolated macrophages, followed by a third region of layered SMC, elastic fibres and
a high concentration of collagen. It is this region that borders the medial layer. The intimal SMC are
involved in the maintenance of the structure of the vessel through synthesis and secretion of
connective tissue components such as collagen, proteoglycans and elastin. Like endothelial cells
they help regulate the contractibility and vascular tone of the artery. SMC have been identified to
phagocytose lipoproteins therefore are involved in lipid metabolism. The isolated macrophages
present in healthy arteries function to remove antigens including dead cells and bacteria and can
also mediate the inflammatory and immune response. The macrophages are also involved in
remodelling of the artery through the production of growth factors (Stary et al., 1992) for example
type β transforming growth factor and platelet derived growth factor (Assoian et al., 1987), and
lipid metabolism by the uptake of native and modified lipoproteins (Goldstein et al., 1979; Stary et
al., 1992). The underlying medial layer is primarily SMC bound together with collagen and elastin
Introduction 3
(Stocker and Keaney, 2004). The third layer, the adventita, is predominantly connective tissue and
functions to provide elasticity and dynamic rigidity to the artery.
The process of plaque formation can be briefly described by the accumulation of lipids overtime
within the intimal layer via low density lipoproteins (LDL). LDL and monocytes permeate across
the endothelial layer and it is at this site that oxidation of LDL can occur (Ross and Glomset, 1973),
and monocytes differentiate into macrophages. The migration of monocytes and T cells through the
endothelial layer is mediated by adhesion molecules. Vascular cell adhesion molecule-1 (VCAM-1)
is present within early atheromas and are able to binds these leukocytes. Nuclear factor-κB (NF-
κB), an inflammatory mediator, can upregulation gene expression of VCAM-1 in the endothelial
cells. The cytokines interleukin 1-β and tumor necrosis factor as well as disturbed shear stress can
also induce the expression of VCAM-1 in endothelial cells (Libby, 2002a). Within the intimal layer
these macrophages can rapidly take up oxidise LDL (oxLDL) via scavenger receptor A and CD36
receptors resulting in the formation of the macrophage foam cells (Libby, 2002a). There are three
main hypotheses to the of initiation of plaque formation (discussed below), however regardless of
genesis all lesions at the beginning have similar characteristic features. The growth and progression
of the plaque occur in defined stages which have been characterised into a progression of types.
Type 1 has a thickening of the wall, attributed to the formation and accumulation of macrophage
foam cells. Type 1 lesions can start to form as early as at birth. The foam cells are situated in small
microlocations as discrete droplets at sites within the arterial wall prone to lesion formation. The
initial lesion progresses into a type II lesion by the continual accumulation of the lipid laden foam
cells (Stary et al., 1994), and due to the death of these cells, by apoptotic and necrotic mechanisms,
the precursor of the acellular lipid core starts to form (Ball et al., 1995; Hegyi et al., 1996). The
‘fatty streak’ a lesion that provides the first visible sign by the naked eye of plaque growth is
defined as a type II lesion. The major cell type in these lesions are macrophages and this is where
the majority of the lipids are localised, however native intimal SMC can also contain a high level of
these lipids. The macrophages are stratified with the cells located at the bottom of the proteoglycan
layer within the intima containing higher concentration of lipids compared to the macrophages
closest to the endothelial layer containing fewer to no lipids. Also localised within these lesions are
T cells. Type III lesions have only recently been acknowledged as an intermediate between the
Type II fatty streaks and Type IV atheromas. They are defined by an increased number of
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Figure 1.2 Processes involved in the formation and progression of atherosclerotic plaques
LDL and monocytes from the blood channel migrate into the intimal layer of the artery. The LDL
becomes oxidised and the monocytes differentiate into macrophages. The macrophages accumulate
cholesterol by the uncontrollable uptake of oxLDL leading to the formation of foam cells.
Continuation of this process leads to the formation of the complex plaque. Symptoms can occur
through occlusion of blood flow and/or plaque rupture. Adapted from Libby (2002b).
extracellular lipid droplets underneath the layers of macrophage and macrophage foam cells. The
lipid droplets begin to replace the proteoglycan intercellular matrix and these droplets also cause the
separation of SMC from other SMC (Stary et al., 1994).
Type IV, an atheroma lesion, enters the definition of an advanced plaque having a greater
proportion of extracellular lipids in between layers of SMC, resulting in the deformation of the
arterial lumen and disordered environment of intimal components (Stary et al., 1994). The intimal
SMC proliferate and are involved in developing the abundant extracellular matrix (Libby, 2002a).
Continual death of the macrophage foam cells and coalescence of the lipid pools contributes to the
enlargement of the acellular lipid core, sourced from the dead macrophages which had taken up the
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LDL (Jang et al., 1993; Stary et al., 1995). Type IV plaques are associated with compensatory
expansive remodelling, where the artery intrudes into the outer layers of the wall maintaining the
lumen structure and size (Chatzizisis et al., 2007; Stary et al., 1995). The macrophages and SMC
are predominantly located on the peripheral of the lipid core where the SMC and matrix have a
scattered arrangement. Microvessels within the plaque can start to form along with the process of
calcification. The fibrous cap consisting of connective tissue and collagen starts to appear, and
when this cap becomes significant in size the plaque is classified as Type V (Stary et al., 1995).
1.1.2 Plaque progression from the advanced plaque to clinical events
After the progression from the type IV to the more complex type V lesion, plaques are more
diverse, creating many different compositional and morphological types (Stary et al., 1995) which
maybe responsible for the variable clinical outcomes. Within this type are subtypes classified based
on the degree of fibrous material, number and size of the lipid cores and calcification. These
subtypes are formed through remodelling and repeated cycles of thrombus formation and lipid
accumulation. Type V plaques contain a fibrous cap which are a distinct structure overlaying the
lipid core and is rich in collagen and SMC. Fractures within the cap can result in exposure of plaque
components to circulating blood which can induce events such as the thrombotic cascade event
(Stary et al., 1995). Within these plaques the SMC now occupy the fibrous cap, media and outer
regions of the intima (Ball et al., 1995). The plaques can continue onto a type VI classification
termed complicated lesions based on the presence of hematomas or thrombi (Stary et al., 1995).
The strength of the fibrous cap is dependent on the balance between SMC maintenance and matrix
degradation. The fibrous cap consists predominantly of collagen, but also SMC, proteoglycans,
elastin and glycoproteins and provides a barricade between the acellular lipid core and blood. The
cap of the shoulder region is thinner and more prone to rupture as it is also abundant in
macrophages, foam cells and SMC (Chapman, 2007; Jang et al., 1993; Stary et al., 1995).
Macrophages can secrete proteases like elastase and collagenase which digest the extracellular
matrix (Jang et al. 1993), contributing to the weakening of the cap. Thrombosis is a prevalent event
in determining the clinical outcome of patients. Disturbed haemodynamic forces can cause fracture
of the fibrous cap and subsequent exposure of pro-thrombotic materials such as tissue factor and
collagen inducing the adhesion of circulating platelets and co-augulation resulting in a thrombus
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(Chapman, 2007; Libby, 2002a). Thrombus formation may also be triggered by superficial
disruption to the overlying endothelial cells. Another common pathway involves the foam cells
where it is thought they release proteolytic enzymes that may contribute to the disintegration of the
fibrous cap (Jang et al., 1993; Stary et al., 1995). One study identified that with an increasing mass
volume of the extracellular lipid core correlated with the presence of thrombotic events within
aortic plaques. These plaques also had a greater proportion of macrophage cells within the cap and
shoulder region of the plaque relative to SMC (Davies et al., 1993). The occurrence of a thrombotic
event is responsible for the majority of the mortality and mobility rates associated with
atherosclerosis (Stary et al., 1995). These clinical events when triggered from a carotid plaque can
result in stokes or transient ischemic attacks, the temporary blockage within the blood flow leading
to lack of oxygen to the brain and/or face. If a blockage occurs due to a femoral plaque significant
tissue death can occur which can lead to the development of gangrene.
The process of calcification in plaques, likened to osteoporosis, involves the production of bone like
material by the mineralisation of tissue. It is estimated that over 90% of plaques have some form of
calcification (Danilevicius et al., 2007). It is now know that this process within the artery is not
passive but occurs through a regulatory pathway (Abedin et al., 2004; Demer et al., 1994; Tanimura
et al., 1983). A primary mineral in bone is hydroxyapaptite and has been identified within carotid
and aortic plaques (Guo et al., 2000; Li et al., 2006). Osteogenic differentiation factor and bone
morphogenetic protein 2a which are bone related proteins involved in bone matrix formation
(Bostrom et al., 1993) as well as numerous other proteins have also been identified in plaques
(Demer and Tintut, 2003). Therefore within plaques, bone morphogenetic protein along with other
proteins stimulates the differentiation (Demer et al., 1994) of multipotent vascular cells into
osteogenic cells (Abedin et al., 2004) and the laying down of a bone like matrix including
hydroxyapaptite (Demer et al., 1994).
Plaques can undergo numerous types of remodelling depending on the type of plaque and the
response of the artery. As plaques grow the arterial vessel can undergo expansive remodelling as
the system tries to compensate for the increased thickness associated with the plaque. In expansive
remodelling the plaque encroaches into the medial layer to maintain lumen structure and
physiological endothelial shear stress. Excessive expansive remodelling refers to an over
compensation of the vessel where it ultimately over enlarges the lumen of the artery compared to
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the normal artery. A lowered endothelial shear stress (ESS) can increase inflammation and
oxidative stress which can lead to the degradation of the extracellular matrix. Constrictive
remodelling in which the plaque intrudes into the lumen hampering the flow of blood may be
induced by continual rupture/healing cycles resulting in protrusion of the plaque into the lumen and
stenosis (Chatzizisis et al., 2007). Stenosis is defined by the percentage of the blood flow loss
within the plaque narrowed artery compared to the what it would be in a normal healthy artery
(Stary et al., 1995).
1.1.3 The main hypotheses to the genesis of atherosclerotic plaques
One of the hypotheses for initiation is the ‘oxidative modification hypothesis’. It is based upon the
formation of cytotoxic oxLDL by oxidation of LDL lipids within the intima with subsequent
modification of the apolipoprotein B100 (apoB) the only protein in LDL. This oxLDL is taken up by
scavenger receptors, expressed on the surface of macrophage cells. This process is not regulated by
the level of free cholesterol within the cell so could be described as unregulated. The scavenger
receptors have a high binding affinity towards oxLDL, but do not bind native LDL (Goldstein et al.,
1979). The internalisation of oxLDL into the macrophages has many consequences, including the
formation of the foam cells, macrophage cell death and the triggering of the inflammatory response.
Endothelial cells (Dayuan et al., 1998) and SMC (Nishio et al., 1996) also take up oxLDL which is
cytotoxic to these cells at high levels.
Another hypothesis outlined by Ross and Glomset (1973) termed the ‘response-to-injury’
hypothesis is based upon the injury or dysfunction of the overlying endothelial cells. This allows
increased permeability of the LDL and plasma proteins into the intima triggering the migration and
proliferation of SMC from the medial layer. The accumulation of lipids and formation of
macrophage foam cells along with the dysfunctional endothelial cells trigger an inflammatory
response which re-enforces the recruitment of macrophages. This inflammatory response will
generate oxidants which contribute to the formation of oxLDL. Continual proliferation of the SMC
and accumulation of the macrophage foam cells leads to the formation of the complex plaque.
Response-to-retention’ hypothesis implies that the retention of the LDL within the artery is the
initialisation event to lesion formation (Williams and Tabas, 1995). The retention is mediated by the
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apoB moiety interaction with the arterial extracellular martix, and once bound at these locations
oxidation of the LDL occurs. It is well established that oxLDL is formed within the intimal layer,
absent of the protective mechanism within plasma (Williams and Tabas, 1995). The presence of the
oxLDL and macrophages within the intimal layer contribute to the process of lesion formation.
1.1.4 Localisation of plaques and the role of shear stress
It is well known that atherosclerotic plaques form predominantly at branch points and points of high
blood turbulence (Chatzizisis et al., 2007; Helderman et al., 2007; Libby et al., 2002; Stary et al.,
1995). At these points the flow of blood is non-linear due to the change in the arterial structure.
Endothelial shear stress (ESS) is defined and determined by the blood viscosity and shear rate
(spatial gradient of blood velocity) of the blood across the endothelial cells. Pusatile ESS on the
endothelial cells occurs in relation to cardiac output, where this type of stress occurs before the
branch points. When the artery is non-linear the pulsatile ESS can give rise to low and oscillatory
ESS. Low ESS typically occurs around and upstream of the bifurcation, whereas oscillatory occurs
typically downstream (Chatzizisis et al., 2007). However, low ESS may also occur downstream
(Tricot et al., 2000) and high shear stress may also occur upstream (Helderman et al., 2007).
Shear stress is a mechano-transducer influencing the function of endothelial cells. Normal shear
stress induces the expression of anti-atherogenic, anti-inflammatory and anti-apoptotic genes
including superoxide dismutase and endothelial nitric oxide synthase producing nitric oxide which
can inhibit VCAM-1 expression (Libby, 2002a). When this shear stress is disturbed, different genes
are activated including atherogenic and inflammatory genes (Gimbrone, 1999; Resnick et al., 2003).
This makes these regions prone to inflammation due to the constitutive activation of inflammatory
mediators NF-κβ (Helderman et al., 2007) which activates monocyte chemoattractant protein-1 and
γ-interferon (Chatzizisis et al., 2007). In the downstream area of carotid plaques associated with low
ESS, endothelial cells had an increased rate of cell death via apoptotic mechanisms, relative to the
upstream region (Tricot et al., 2000). One study found that the VCAM-1 receptor, expressed on
endothelial cells is upregulated by low ESS compared to high ESS. A higher proportion of
monocytes were co-localised with the increased level of VCAM-1 under the low ESS. This
indicates that shear stress is involved in the increased permeability of LDL through the endothelial
layer (Walpola et al., 1995). Also the low ESS is associated with an increase in SMC proteoglycans
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synthesis therefore increasing the ability to retain and oxidise LDL (Libby et al., 2002). Other
properties of low ESS include an increase of oxidative stress by increasing the NADPH oxidase
within endothelial cells and downregulating superoxide dismutase and glutathione (Chatzizisis et
al., 2007). In a hypercholesteremic mouse model low shear stress increased the size of the intima
relative to oscillatory shear stress. The low shear stress plaques also had an increased proportion of
lipid, where the oscillatory shear stress plaques had a higher proportion of vascular SMC and
collagen. Furthermore in another mouse model, regions of high shear stress contained more
macrophages, SMC, lipid and metalloproteinase activity. This indicates that the level and type of
shear stress induced by the plaque may influence the plaque composition (Helderman et al. 2007).
1.2 Free radicals and oxidants are mediators of oxidative stress in
biological systems
Free radicals are defined by any species which has one or more unpaired electrons and is able to
independently exist (Halliwell and Gutteridge, 1999). Radicals can either react with each other to
form a non-radical product, or it can ‘steal’ an electron from easily extractable molecules
effectively neutralising the unpaired electron. These reactions are in part dependent on the mobility
and reactivity of the radical. Radicals are not only produced as a metabolic product but also
intentionally under controlled situations and locations (Cheeseman and Slater, 1993). The immune
system is a classic example of this, where activated macrophages and neutrophils release
superoxide which can be processed to the oxidants hydrogen peroxide and hypochlorous acid as an
anti-bacterial and anti-fungal response (Halliwell and Gutteridge, 1999). Oxidative stress occurs
when the rate of clearance of free radicals and oxidants is exceeded by their formation (Aldini et al.,
2007). Oxidative stress and therefore oxidative damage is associated with many diseases including
atherosclerosis and neurodegenerative diseases such as alzheimers and parkinsons disease (Beal,
2002) to name a few. The macrophages and monocytes within the plaque can release oxidants and
oxygen derived radicals contributing to the source of oxidative stress (Jang et al., 1993). Aortic
plaque gruel was shown to stimulate lipid peroxidation in microsomes and deoxyribose degradation
due to the presence of free iron and copper (Smith et al., 1992). This indicates that within the plaque
oxidative damage can occur. Supporting this, numerous studies have identified oxidative damage
associated with radical attack within plaques (Figure 1.3) (Fu et al., 1998; Leeuwenburgh et al.,
1997; Martinet et al., 2002; Prunet et al., 2006; Smith et al., 1992; Stanley et al., 2006). Theses
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oxidative products may contribute to the persistence of plaques due to their cytotoxcity to immune
cells. The gruel of carotid and aortic plaques phagocytosed by macrophage like cells and human
monocyte derived macrophage induced apoptosis attributed to the presence of aldehydes, carbonyls
and hydroperoxides within the gruel (Li et al., 2006).
Superoxide (O2•−) is the primary free radical generated within a biological system (Dean et al.,
1997). It is formed by the reaction between oxygen and an electron (reaction 1). The electron
transport chains within the mitochondria and endoplasmic reticulum are the major source for
superoxide (Halliwell and Gutteridge, 1999). Superoxide can be removed from the system by
dismutation to hydrogen peroxide via the enzyme superoxide dismutase (reaction 2). Because
superoxide is a relatively unreactive radical (Dean et al., 1997), its main fate is the precursor to
hydrogen peroxide and the reduction of transition metals (Cheeseman and Slater, 1993). These
transition metals can cause the formation of hydroxyl, peroxyl and alkoxyl radicals (Dean et al.,
1997). In the presence of the most biologically relevant transition metals, iron and copper, hydrogen
peroxide and superoxide can reduce the ions to a redox active state (reaction 3). The reduced metal
ion can undergo Fenton reactions by reacting with hydrogen peroxide catalysing the formation of
hydroxyl radicals (OH•) (reaction 4). These reactions constitute the main fate of hydrogen peroxide
within the system. Hydroxyl radicals can also be formed by a non-catalysed reaction between
superoxide and hydrogen peroxide, however in vivo this reaction is slow (Cheeseman and Slater,
1993). Reaction 4 is also dependent on the oxidative state and concentration of the iron and copper
present (Berlett and Stadtman, 1997). Using a minimally invasive technique Stadler et al. (2004)
identified high non-ferritin non-heme iron levels concentrated within the intimal layer of plaques,
along with copper ions, that may represent a redox active pool capable of undergoing these
reactions.
(1) O2 + e− →   O2•−
(2) 2O2•− + 2H+ →   H2O2 + O2
(3) Fe3+/Cu2+ + O2•− →  Fe2+/Cu+ + O2
(4) H2O2 + Fe2+/Cu+ → •OH + OH− + Fe3+/Cu2+
The hydroxyl radical is the most reactive radical with a reaction rate of 10-9 seconds at 37ºC,
therefore is considered the most prominent inducer of biomolecular damage (Gebicki, 1997). This
damage can be induced on a range of molecules including protein, lipids and nucleic acids.
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1.2.1 Protein oxidation
The hydroxyl radical is non-discriminative towards biomolecules. Protein is the most abundant
component within the cell therefore the hydroxyl radical will most likely react with and induce
protein damage (Gebicki, 1997). The damage caused to proteins by radicals and oxidants range
from protein carbonyls, protein hydroperoxides, DOPA, dityrosine, 3-chlorotyrosine and 5-hydroxy
leucine (Aldini et al., 2007; Davies et al., 1999; Dean et al., 1997; Gebicki, 1997; Gieseg et al.,
1993) to name a few. Many of these changes can alter the structure at either the primary, secondary,
tertiary and if applicable quaternary structure contributing to full or partial inactivation (Aldini et
al., 2007). Metal-dependent oxidation of proteins is facilitated by the ability of proteins to bind
metals and to their abundance within the system (Gebicki, 1997). This results in a localised level of
damage. Many of the protein oxidation markers mentioned above have previously been identified
within atherosclerotic plaques (Davies et al., 1999).
1.2.1.1 Protein carbonyls formation
Protein carbonyls are the most studied form of protein damage (Dalle-Donne et al., 2003). Protein
carbonyl formation can be induced by numerous radicals (Halliwell and Gutteridge 1998). Because
of this the primary radical that induced the formation of the protein carbonyls within a biological
system cannot be identified therefore protein carbonyls are a general marker of oxidation (Dalle-
Donne et al., 2003; Halliwell and Gutteridge, 1999). Protein carbonylation is irreversible (Aldini et
al., 2007), indicative of large degree of oxidative stress (Dalle-Donne et al., 2003) and associated
with aging and numerous diseases (Berlett and Stadtman, 1997).
There are many pathways for protein carbonyl formation including direct derivatisation of amino
acid residues particularly on lysine, arginine, proline and threonine. More complex mechanisms
include, a secondary reaction involving the lipid oxidation breakdown products, reactive aldehydes
(malondialdehyde and 4-hydroxy-2-nonenal) reacting with nucleophilic residues like lysine,
histidine and cysteine. The reaction of protein with reducing sugars (glyoxal and methylglyoxal)
and their corresponding breakdown products (ketoaldehydes and ketoamines) with lysine residues
via glycation and glycoxidation reactions also leads to carbonyl formation. By oxidative cleavage of
the protein backbone occurring through the α-amidation pathway or the abstract of the γ-carbon on
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Figure 1.3 Overview of the free radicals, oxidants and oxidative damage identified within
atherosclerotic plaques
Within the intima LDL can become oxidised via cell or metal mediated oxidation. The oxLDL
contains protein hydroperoxides (PrOOH) and lipid hydroperoxides (LOOH), where the LOOH can
break down forming oxysterols and reactive aldehydes. The peroxyl radicals (LOO•) and aldehydes
can mediate the formation of protein carbonyls (Pr carbonyls) and PrOOH. The PrOOH can
themselves mediate oxidative damage including the formation of protein carbonyls. The
macrophage releases superoxide (O2•-) which can mediate the formation of hydrogen peroxide
(H2O2), as well as reduce iron and copper maintaining the pool of redox active ions. Electrons from
the trans plasma membrane electron transport (TPMET) within macrophages can also maintain this
pool. Via myeloperoxidase (MPO) the H2O2 is converted to hypochlorous acid (HOCl) which along
with the hydroxyl radical (•OH) can induce PrOOH and LOOH formation contributing to the
oxidative damage on the oxLDL and cellular damage. The tyrosine residues are also prone to
modification to DOPA and dityrosine. Modified from Gieseg et al. (2008b).
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the glutamic residue along with subsequent reactions can result in cleavage of the peptide and a N-
terminus block via a α-ketoacyl derivative forming protein carbonyls (Aldini et al., 2007; Berlett
and Stadtman, 1997; Dalle-Donne et al., 2003). Protein carbonyls are also formed from the
breakdown of protein hydroperoxides by the formation of an alkoxyl radical on the α-carbon
mediated by transition metals. Rearrangement of the one electron results in the cleave of the peptide
bond and the formation of the protein carbonyl (Davies, 1996). It has been proposed that protein
hydroperoxide formation and degradation is the main reaction pathway leading to carbonyl
formation.
1.2.1.2 Protein hydroperoxidation
Protein hydroperoxides (PrOOH) are the most abundant form of protein oxidation (Firth et al.,
2008). In the presence of radicals (R•) a hydrogen can be abstracted from a protein carbon (PrH) to
form a carbon centred radical (Pr•) (reaction 5). This radical is stable enough to remain and react
with oxygen forming the protein peroxyl radical (PrOO•) (reaction 6), which propagates a chain
reaction by abstracting a hydrogen from another carbon forming a second carbon centred radical
(reaction 7). The chain reaction is terminated when either the carbon centred radical or protein
peroxyl radical reacts forming non-radical products (reaction 8).
(5) PrH + R• → Pr• + RH
(6) Pr• + O2 → PrOO•
(7) PrOO• + R'H → PrOOH + R' •
(8) Pr•/ PrOO• + e− + H+ → PrH/PrOOH
There are six amino acids which are highly susceptible to PrOOH formation isoleucine, leucine,
valine, glutamate, proline and lysine. These six amino acids either have a tertiary or secondary
carbon on the side chain providing sufficient stability of the carbon centred radical long enough for
its reaction with oxygen (Gebicki, 1997; Simpson et al., 1992). Not only are the side chains
modified, the α-carbon on residues is also a site for PrOOH formation (Dean et al., 1997). PrOOH
is an oxidising agent capable of oxidising antioxidants like ascorbate and glutathione, thereby
propagating oxidative stress (Simpson et al., 1992). As previously mentioned PrOOH breakdown
products can also induce the formation of protein carbonyls (Firth et al., 2008). PrOOH are further
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involved in oxidative stress as PrOOH can form strong intermolecular bonds with DNA on non-
specific sites at relatively slow rates (Gebicki and Gebicki, 1999) thus inducing DNA damage.
1.2.1.3 DOPA and dityrosine formation
Protein bound 3,4-dihydroxyphenylalanine (DOPA) formation can occur via a radical mechanism
by the addition of hydroxyl radicals onto the ortho-position of the tyrosine aromatic ring (Gieseg et
al., 1993; Rodgers and Dean, 2000). Its formation can also be mediated by HOCl (Sutherland et al.,
2003) and peroxyl radicals (Davies et al., 1999). DOPA is also intentionally formed by enzymatic
activity of tyrosinase as DOPA is a naturally occurring pigment associated with melanin. It has
been found in the active site of some amine oxidases and shown that DOPA can extensively cross
link increasing its resistance to proteolysis. Protein-bound DOPA is also formed by incorporation of
free DOPA into proteins. Whereas degradation by detoxification, tyrosinase, proteolysis and auto-
oxidant to dopaquinone can remove it from the system (Rodgers and Dean, 2000).
DOPA is a strong reducing agent able to reduce metalloprotein and transition metals which can then
undergo Fenton reactions (reaction 4) (Dean et al., 1997; Exner et al., 2003; Fu et al., 1998; Gieseg
et al., 1993). Morin et al. (1998) found that DOPA in the presence of Cu+ and oxygen induces
damage to DNA putatively via a hydroxyl radical intermediate. The effects of DOPA can be far
reached as it is able to diffuse from its point of origin due to is relatively high stability (Gieseg et
al., 1993). Because of this it is hypothesised that DOPA may be involved in the progression of
plaque development (Rodgers and Dean, 2000). Peptide bound-DOPA has also been reported to
inhibit Cu2+ mediated LDL oxidation by the sequestering of the ion preventing its interaction with
apoB on LDL. When the LDL oxidation was already in progress the role of DOPA convert to a pro-
oxidant effect, thus the DOPA was involved in mediating the oxidation of LDL (Exner et al., 2003).
Dityrosine is another prominent stable protein oxidation marker, where the concentration of this
marker is dependent on the radical flux determined by the degree of oxidative stress and radical
formation rate (Davies et al., 1999). Redox active metal mediated hydroxyl radicals (reaction 4) can
abstract the hydrogen from the hydroxyl group of the tyrosine residue. The lone electron can
resonate from the oxygen to the ortho position (Figure 1.3) (Giulivi and Davies, 1994) producing
the long lived tyrosyl radical (Heinecke et al., 1993). The dityrosine is formed by the reaction
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Figure 1.4 Dityrosine formation
A hydrogen from the tyrosine residue is abstract via hydroxyl radicals, forming the tyrosyl radical
where the unpaired electron can resonate around the aromatic ring increasing its stability. Two
tyrosyl radicals can neutralise creating a carbon-carbon bond across the ortho position of the ring
and the production of dityrosine. Adapted from Heinecke (1999)
between two tyrosyl radicals across the ortho position. Dityrosine is also formed via metal-
independent pathways associated with activated phagocyte secreted myeloperoxidase (MPO).
The MPO-H2O2 system mediated by hydrogen peroxide results in the tyrosyl radical (Heinecke et
al., 1993; Leeuwenburgh et al., 1997). Further supporting this system Heinecke et al. (1993) treated
neutrophils and macrophages with heme poisons, knocking out the MPO, which inhibited the
formation of dityrosine. DOPA and dityrosine have both been identified within atherosclerotic
plaques (Fu et al., 1998), acting as a marker of oxidative and free radical damage respectively
(Davies et al., 1999).
1.2.2 Lipid oxidation and the formation of oxidised low density lipoprotein
Lipid oxidation occurs on polyunsaturated fatty acids (PUFAs) which are highly susceptible to free
radical attack. Cellular membranes have a high proportion of PUFAs where alterations can lead to
modification in structure and possibly function making it a destructive component of oxidative
stress. LDL has a high proportion of cholesterol and PUFA substrates for lipid oxidation and the ε-
amino groups of lysine residues are highly susceptible to modified by lipid peroxidation products
(Esterbauer et al., 1993). PUFAs have easily extractable hydrogens which radicals can rapidly
abstract forming carbon centred radicals (L•) (reaction 9). This carbon centred radical readily reacts
with oxygen to form the peroxyl radical (LOO•) (reaction 10), which propagates the radical damage
by abstracting an electron from a hydrogen of another PUFA (reaction 11), effectively creating a
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chain reaction. The products formed are the lipid peroxide (LOOH) and a second carbon centred
radical. This chain reaction will continue until it is neutralised forming a non-radical product
(reaction 12) (Cheeseman and Slater, 1993). The chain reaction can also be terminated by
antioxidants primarily α-tocopherol. In the presence of transition metals LOOH can decompose
forming alkoxyl (LO•) and peroxyl radicals resulting in the formation of a large range of products
including reactive aldehydes, isoprostanes and oxysterols (reaction 13) (Cheeseman and Slater,
1993). The lipid hydroperoxide breakdown products of isoprostanes and reactive aldehydes 4-
hydroxy-2-nonenal and malondialdehyde have been identified within plaques (Gniwotta et al.,
1997).
(9) LH + R• →  L• + R•
(10) L• + O2 → LOO•
(11) LOO• + L'H → LOOH + L' •
(12) LOO• + LOO • → non-radical product
(13) LOOH → LO• or LOO• or aldehydes or oxysterols
It is well established that the lipid peroxides and/or lipid oxidation products can mediate protein
oxidation (see section 1.2.1.1). LDL oxidation is a prime example of this where on LDL’s only
protein, apoB, modification can be mediated by the more complex lipid peroxidation breakdown
products (Gieseg et al., 2003; Steinbrecher et al., 1989). Roubal and Tappel (1966) identified that
lipid peroxyl radicals can mediate protein crosslinking. Furthermore the formation of protein
hydroperoxides on copper and peroxyl radical mediated LDL oxidation was induced by the lipid
peroxyl radicals formed from the lipid hydroperoxides (Gieseg et al., 2003).
1.2.3 Properties of oxidised low density lipoprotein
LDL is the main free and ester cholesterol carrying particle in the blood. It consists of 42%
cholesteryl esters, 22% phospholipids, 22% of the protein, apoB, 10% free cholesterol and 6%
triglycerides (Esterbauer et al., 1992). It is well established that one of the risk factors for
atherosclerosis is high plasma LDL (Steinberg et al., 1989), as it is this LDL that is retained and
oxidised within the arterial wall (Upston et al., 2002a). The high content of PUFA within the LDL
makes it highly susceptible to lipid oxidation and indeed when the composition of LDL was
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compared to LDL collected from plaques the fatty acid content was greatly decreased (Esterbauer et
al., 1992).
There are three phases to LDL oxidation, the lag phase where all the antioxidants predominantly α-
tocopherol are consumed. The propagation phase, where cholesterol dienes and lipid peroxide
concentrations rapidly increase along with a slower rate of TBARS formation. Followed by the
decomposition stage where the level of lipid hydroperoxide breakdown products such as
malondialdehyde, 4-hydroxynonenal increase. As discussed above the apoB can be modified by the
lipid peroxyl and alkoxyl radicals produced by the propagation phase (Esterbauer et al., 1992).
Additionally the apoB protein can be oxidised via reaction of reactive aldehydes to the є-amino
groups on lysine (Esterbauer et al., 1992). This leads to fragmentation of the apoB and increased
substrate for the scavenger receptors (Steinberg et al., 1989) scavenger receptor A and CD36
presented by the macrophages (Goldstein et al., 1979; Libby, 2002a).
LDL modified into a state which is recognisable by the scavenger receptor has been reported to be
mediated by the main cells types within the vascular wall (Steinberg et al., 1989); monocytes,
macrophages (Hiramatsu et al., 1987), SMC (Heinecke et al., 1986) and endothelial cells
(Steinbrecher, 1988). The mechanism of cell mediated LDL oxidation requires redox active metal
ions (Garner and Jessup, 1996; Kritharides et al., 1995). Copper is able to strongly bind to specific
binding sites on the apoB protein, and in the presence of preformed lipid peroxides the redox active
ions can initiate further lipid oxidation chain events (reaction 14 and 15) (Esterbauer et al., 1992;
Patterson et al., 2003).
(14) LOOH + Cu+ →   LO• + OH− + Cu2+
(15) LOOH + Cu2+ →   LOO• + H+ + Cu+
Even though many cells may mediate the oxidation of LDL, the oxLDL is itself cytotoxic towards
the cells. Studies have identified that it induces apoptosis in SMC (Nishio et al., 1996), endothelial
cells, macrophages (Dayuan et al., 1998) and T cells (Alcouffe et al., 1999). In terms of the
macrophage when the oxLDL is taken up it causes the loss of pH homeostasis within the lysosome,
affecting the activity of lysosomal lipase, an enzyme responsible for the hydrolysis of the
cholesterol esters. By loss of its activity the lipids cannot be processed and therefore accumulate
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within the macrophage (Cox et al., 2007). Also lysosomal leakage results in macrophage foam cell
death (Yuan et al., 2000), contributing to the formation of the acellular lipid core. Another toxicity
property of oxLDL is that it is a chemoattractant for circulating monocytes (Quinn et al., 1987). It is
also chemotactic to SMC and T-cells (Williams and Tabas, 1995), cells all involved in the
inflammatory component of atherosclerosis. There are numerous other properties including
encouraging adhesion of monocytes to endothelial cells, the formation of the macrophage foam
cells, migration and proliferation of SMC, and inducement of necrosis as well as apoptosis of
various cells (Chisolm and Steinberg, 2000; Esterbauer et al., 1992).
1.2.4 Oxysterols
Oxidation of cholesterol produces oxysterol by either enzymatic (sterol 27-hydroxylase, cholesterol
7 α-hydroxylase) or non-enzymatic auto-oxidation (Jessup and Brown, 2005; van Reyk et al.,
2006). Oxysterols levels are maintained at low concentrations, however in disease states they can
accumulate. They have been identified within plaques, where 27-hydroxylcholesterol, 7-
ketocholesterol (7-KC) (Jessup and Brown, 2005) and 7-β-hydroxylcholesterol are the most
abundant oxysterols (Larsson et al., 2006). Within macrophage foam cells 7-KC accounted for 0.1-
9.9% of oxysterol as a percentage of cholesterol (van Reyk et al., 2006). Cholesterol oxidation
most likely begins from the radicals produced by PUFA oxidation. An increase in α/β-expoide, 7-
α/β-hydroxylcholesterol and 7-KC, with a concomitant decrease in α-tocopherol was observed
within LDL after copper oxidation (Chang et al., 1997).
Chang et al. (1997) propose that the non-enzymatic formation of 7-KC begins by the auto-oxidation
of cholesterol in the presence of lipid alkoxyl or peroxyl radicals and a redox active metal. The
reactive allylic hydrogen at the 7 position is abstracted (Figure 1.5 (2)), creating a carbon centred
radical which reacts with oxygen to form a peroxyl radical (Figure 1.5 (3)). The abstraction of
hydrogen from a lipid results in a peroxide on the 7-position (Figure 1.5 (4)). Thermal or transition
metal induction of homolysis of the peroxide bond yields an alkoxyl radical (Figure 1.5 (5)) and the
formation of the 7-KC (Figure 1.5 (6)). Alternatively the rearrangement of the peroxyl radical
(Figure 1.5 (4)) to the keto functionality may also produce 7-KC (Figure 1.5 (6)).
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Figure 1.5 Putative reaction scheme for the formation of 7-ketocholesterol
In the presence of redox active metal lipid peroxyl or alkoxyl radicals can abstract the hydrogen
from the 7 position on cholesterol (1), forming 3β-hydroxycholes-5-en-7-yl a carbon centred radical
(2). In the presence of oxygen forms 3β-hydroxycholes-5-en-7-peroxyl (3) radical and can
propergate by abstraction of hydrogen from lipid to form 3β-hydroxycholes-5-ene-7-hydroperoxide
(4), and dervises 3β-hydroxycholes-5-en 7-oxyl (5) radical before forming 7-ketocholesterol (6).
Alternatively 7-ketocholesterol can be directly produced from 3β-hydroxycholes-5-en-7-peroxyl
(3). Adapted from Chang et al. (1997).
Oxysterols may contribute to plaque growth. It is hypothesised the plaques are able to maintain and
grow because this material cannot be detoxified and removed due to the cytotoxic effects towards
various cells including macrophages (Larsson et al., 2007). In a study which exposed 7-β-
hydroxycholesterol and 7-KC in proportions reported within lesions to the human monocyte line U-
937, the oxysterols induced apoptosis and necrosis along with increased lysosome and mitochondria
membrane permeability, a decrease in cellular thiol content and increased in oxidants. The 25- and
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27-hydroxylcholesterol displayed protective effects towards the 7-β-hydroxycholesterol and 7-KC
induced cytotoxicity towards the cells. However when all four oxysterols where present in atheroma
relevant proportions the cytotoxic effect prevailed (Larsson et al., 2006). When HUVEC and human
artery SMC where exposed to 7-KC and 7-β-hydroxycholesterol, apoptotic like features were
observed and with fibroblast cells the oxysterols induced necrosis like features, further supporting
the cytotoxic role of these oxysterols on vascular cells (Lizard et al., 1999). One of the cytotoxic
components of death inducing oxLDL towards porcine aortic SMC was identified as 7-KC (Hughes
et al., 1994). Furthermore, within copper mediated oxidation of LDL the concentration of 7-KC
increased with exposure of copper and it was the high 7-KC containing oxLDL which showed the
most toxicity towards human retinal pigment epithelial cells. Exposure of these cells to 7-KC alone
had the most pronounced effect compared to other 7-modified cholesterols supporting its cytotoxic
role towards the cells (Rodriguez et al., 2004). Steffen et al. (2006) argued that 7-β-
hydroxycholesterol exerts the proapototic effect on endothelial cells and the 7-KC counteracts this.
That the proportion of 7-ketocholesterol and 7-β-hydroxycholesterol present within the site and not
the total concentration of oxysterols will dictate the pro-apopototic effects on the cells (Steffen et
al., 2006).
1.3 Inflammation and atherosclerosis
Inflammation is closely associated and plays a crucial role in atherosclerosis (Libby, 2002a). The
migration and presence of inflammatory cells within the plaque such as macrophages and T cells
(Chatzizisis et al., 2007), and a large array of inflammatory mediators supports this (Lassila, 1993).
For example cytokines released within the plaque include growth factor-β and γ-interferon which
stimulate and inhibit collagen synthesis by the SMC respectively (Libby, 2002a; Stocker and
Keaney, 2004), platelet-derived growth factor released from endothelial cells, macrophages, SMC
and platelets induces the proliferation and migration of SMC (Lassila, 1993). Furthermore, low
shear stress can upregulate the expression of γ-interferon along with VCAM-1 and ICAM-1
(Chatzizisis et al., 2007). Interleukins and tumour necrosis factor-α released by macrophages can
further recruit monocytes into the intima (Jang et al., 1993), and regulate metalloproteinase (Lassila,
1993), where interleukins and lymphokines from activated T cells are involved in lipid uptake of
macrophages. SMC migration and proliferation may be mediated by the macrophage-derived
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growth factor (Jang et al., 1993). Thus the inflammatory components within the plaque qualitatively
and quantitatively can alter the extracellular matrix within plaques (Lassila, 1993). Further
supporting the role of inflammation with atherosclerosis is the presence of the inflammatory marker
neopterin (Firth et al., 2008; Gieseg et al., 2008a).
1.3.1 Neopterin and 7,8-dihydroneopterin
Activated T cells release γ-interferon stimulating the synthesis and secretion of 7,8-
dihydroneopterin (7,8-NP) by macrophages. Based on literature it is suggested that 7,8-NP may act
to protect macrophages and other cells from oxidants released during inflammation, including the
macrophages own oxidants (Gieseg et al., 2008a). The concentration of neopterin, the oxidation
product of 7,8-NP, within plasma of cardiovascular diseased patients are elevated (Tatzber et al.,
1991), and correlate to the severity of the disease (Weiss et al., 1994). Because neopterin is
relatively stable and highly fluorescent it is a marker of immune cell activation (Widner et al.,
2000). Hence it has been used in numerous clinical settings to monitor HIV (Wirleitner et al.,
2005), bacterial and viral infections (Denz et al., 1990), predictor of long term renal graft outcome
(Grebe et al., 2004), and cancer (Reibnegger et al., 1991). Neopterin has been identified within
plaques and is most likely the source of the high levels of neopterin in the plasma of the
cardiovascular diseased patients (Gieseg et al., 2008a).
The synthesis of 7,8-NP and neopterin begins with an enzyme unregulated by γ-interferon,
guanosine triphosphate (GTP)-cyclohydrolase which converts GTP to dihydroneopterin
triphosphate. In the presence of 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase the
dihydroneopterin triphosphate is converted to 5,6,7,8-tetrahydrobiopterin. 5,6,7,8-
Tetrahydrobiopterin is a co-factor for many enzymes like the aromatic acid hydroxylases and
inducible nitric oxide synthase. However, within primate macrophages there is little to no
significant 6-pyruvoyl tetrahydropterin synthase activity allowing the buildup of dihydroneopterin
triphosphate. Via unspecific intracellular proteases the phosphates are cleaved to yield 7,8-
dihydroneopterin (Figure 1.6) (Hoffmann et al., 2003; Schoedon et al., 1987).
7,8-NP has been reported to have antioxidant (Firth et al., 2008; Gieseg et al., 1995; Herpfer et al.,
2002; Weiss et al., 1993) and pro-oxidant activity (Herpfer et al., 2002; Wirleitner et al., 2003).
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Figure 1.6 Overview of the synthesis of 7,8-dihydroneopterin and neopterin
T cell released γ-interferon stimulates the synthesis and secretion of 7,8-dihydroneopterin from
macrophages. In the presence of hypochlorous acid (HOCl), 7,8-dihyroneopterin is oxidised to
neopterin, and in the presence of hydroxyl (HO•) or peroxyl radicals (ROO•) 7,8-
dihydroxanthopterin is formed. Adapted from Gieseg et al. (2008b).
Evidence suggests 7,8-NP is an effective peroxyl radical scavenger (Baird et al., 2005; Firth et al.,
2008; Gieseg et al., 2003). Measurement of spin trapping of superoxide and peroxyl radicals in the
presence of 7,8-NP indicated that it was a potent scavenger of these radical with rate constants of
103 and 107 moles per second respectively. This scavenging ability was not seen with neopterin
(Oettl et al., 1997). THP-1 and human monocyte derived macrophages have been reported to
mediate LDL oxidation by the formation of lipid and protein hydroperoxides. As a result of the
lipid peroxyl radical scavenging ability of 7,8-NP, micromolar concentrations inhibited the protein
and lipid hydroperoxidation formation on the LDL (Firth et al., 2008). 7,8-NP also protected the
viability of U937 cells from Fe2+ and hypochlorous acid mediated oxidation (Gieseg et al., 2001), as
well as protein hydroperoxidation formation and peroxyl radical mediated thiol cell loss (Duggan et
al., 2002). 7,8-NP was able to protect U937 cells from oxLDL mediated cell death. It was also able
to protect both THP-1 and U937 cells from AAPH derived peroxyl radicals (Baird et al., 2005).
However, 7,8-NP failed to protect THP-1 from oxLDL mediated death (Baird et al. 2005) and
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human monocyte derived macrophages from peroxyl mediated death (Firth et al., 2007). Thus the
mechanism of 7,8-NP antioxidant activity is not fully understood.
7,8-NP is a reducing agent and thereby under specific conditions can help maintain a pool of redox
active copper (Herpfer et al., 2002) and iron (Oettl et al., 1999). At high concentrations 7,8-NP may
induce apoptosis within Jurkat T cells by an interruption to the balance of the redox status of the
cells (Baier-Bitterlich et al., 1996). In conjugation with tumour necrosis factor-α, higher
concentrations can induce oxidative stress mediated death of U-937 cells (Baier-Bitterlich et al.,
1995). Within peripheral T cells 7,8-NP induced apoptosis at concentrations as low as 200
micromolar. When co-incubated with superoxide dismutase, catalase and a metal chelator the
cytotoxic effect of 7,8-NP was significantly reduced putatively due to the removal of the hydrogen
peroxide supporting the oxidative stress mediated mechanism of 7,8-NP (Wirleitner et al., 2003).
In vivo the only know pathway to neopterin is the oxidation of 7,8-NP by hypohalous acids such as
hypochlorous acid (HOCl) sourced from the MPO/H2O2 system (Gieseg et al., 2000; Widner et al.,
2000). The expression of MPO which has been identified within plaques associated with
macrophages rich regions (Daugherty et al., 1994), is also secreted from activated neutrophils
providing a source for HOCl within the plaque (Chisolm et al., 1999; Libby, 2002a). Further
evidence for the activation of MPO and subsequent HOCl production within plaques is the presence
of the HOCl mediated protein oxidation product chlorotyrosine (Upston et al., 2002a).
As with 7,8-NP, the in vivo function if any of neopterin is not fully understood (Gieseg et al.,
2008a), Neopterin has been reported as pro-oxidant (Hoffmann et al., 1998), which suggests that
one of the main functions of neopterin is to enhance the cytotoxic effect of oxidants during
inflammation (Hoffmann et al., 2003). Neopterin in the presence of hydrogen peroxide or
chloramines enhanced the killing effect of the oxidants towards E.coli compared to 7,8-NP which
displayed the opposite effect via a scavenging mechanism. This relationship towards hydrogen
peroxide supports the balancing role between neopterin and 7,8-NP, by either a protective effect or
a enhanced oxidative stress effect (Weiss et al., 1993). Neopterin, tumour necrosis factor-α and γ-
interferon exposed to vascular SMC in vitro induced apoptosis potentially mediated by the
interruption of nitric oxide synthesis and inducible nitric oxide synthase gene expression (Hoffmann
et al., 1998). Nanomolar concentrations of neopterin and 7,8-NP transiently increase the calcium
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concentration within THP-1 cells via an extracellular source. This increase in calcium may have a
role in activation of the macrophages (Woll et al., 1993). In the presence of phorbol myristate
acetate stimulated macrophages, neopterin decreased the release of superoxide thus thought to be
exerting a scavenging effect. However, neopterin failed to reduce the concentration of superoxide in
a xanthine/xanthine oxidase system therefore its mode of action against the reduction of
superoxides produced by the macrophages was thought to be due to interaction within the cells
itself (Kojima et al., 1992).
1.3.2 Antioxidants in biological systems
Antioxidants are capable of removing or converting free radicals and/or oxidants into a less reactive
state. The mechanism of antioxidant activity includes enzymatic removal for example the enzymes
superoxide dismutase and catalase which remove superoxide and hydrogen peroxide respectively.
Also compounds which scavenge free radicals for example α-tocopherol and ascorbic acid and
proteins which sequester redox active metals (Halliwell and Gutteridge, 1999). Plasma contains a
number of antioxidants including ascorbic acid, uric acid, α-tocopherol, albumin and bilirubin (Frei
et al., 1988), making blood a highly protected environment against oxidative stresses. Within
atherosclerotic plaques α/γ-tocopherol, ascorbic acid, ubiquinol-10, uric acid, glutahione peroxidise,
glutahione reductase and the three isoforms of superoxide dismutase have been identified (Stocker
and Keaney, 2004). However, despite this extensive list, oxidative damage still occurs within
plaques.
1.3.2.1 α-Tocopherol and ascorbic acid
α-Tocopherol, the biologically active form of vitamin E, is an important lipid soluble antioxidant in
blood and tissue. It is localised within membranes and lipoproteins (Stocker and Keaney, 2004;
Upston et al., 2002b) and is present at approximately 6-7 molecules per LDL particle (Esterbauer et
al., 1992). α-Tocopherol is an effective scavenger of peroxyl radicals by donation of an electron
forming a relatively nonreactive intermediate, the α-tocopheroxyl radical (α-Toc•) (reaction 16) at a
rate of ~106 moles per second. Under a high radical flux the α-tocopheroxyl radical can neutralise
another lipid peroxide radical to a non radical product (reaction 17), thereby breaking the chain
reaction. Therefore α-tocopherol potentially removes two radicals from the system (Bowry and
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Stocker, 1993; Stocker and Keaney, 2004). In the presence of endogenous co-antioxidants, aqueous
ascorbic acid or lipid soluble ubiqinol-10, the α-tocopheroxyl radical can be scavenged recycling it
back to α-tocopherol (reaction 18) and in the case of ascorbic acid effectively exporting the radical
into the aqueous media (Bowry and Stocker, 1993; Neuzil et al., 1996).
(16) α-TocH + LOO• →   α-Toc• + LOOH
(17) α-Toc• + LOO• →   non radical product + LOOH
(18) α-Toc• + ascorbic acid →   α-TocH + ascorbyl radical
(19) α-Toc• + LH →   L• + α-TocH
Despite the presence of α-tocopherol within the atherosclerotic plaque (Niu et al., 1999; Suarna et
al., 1995), lipid oxidation still occurs evident by the high level of lipid oxidation products identified
within plaques (Upston et al., 2002b). Via a temporal factor, transitory depletion of α-tocopherol
may allow the occurrence of lipid peroxidation with subsequent recycling of the α-tocopherol pool
via co-antioxidants (Upston et al., 2002b). This may give explanation to how α-tocopherol and lipid
oxidation products both exist at relatively high proportions within the plaque. Alternatively of α-
tocopherol maybe involved in the oxidation of lipids by a mechanism of tocopherol mediated
peroxidation (TMP).
Under a low radical flux, the α-tocopheroxyl radical can mediate radical formation by abstracting a
hydrogen from a susceptible site on the lipid forming a carbon centred radical (reaction 19) (Neuzil
et al., 1996). The rate of reaction of TMP is relatively slow at a rate of ~10-1 - 10-2 moles per second
(Bowry and Stocker, 1993; Halliwell and Gutteridge, 1999). Therefore, for TMP to occur the
radical flux is low which increases the probability of interacting with a lipid rather than a radical.
Suarna et al. (1995) reported relatively high concentrations of α-tocopherol and its co-antioxidant
ascorbic acid within human plaques, in coexistence with oxidised cholesterol esters, indicating that
the ascorbic acid may also have a temporal depletion and restoration. Another pro-oxidant feature
of α-tocopherol is its ability to reduce free Cu 2+ to Cu+ potentially contributing to a pool of redox
active metals within the system (Yoshida et al., 1994).
Ascorbic acid is the main water soluble antioxidant within the system (Halliwell and Gutteridge,
1999), and predominantly occurs in its redox active state (Suarna et al., 1995). As a reducing agent
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it is able to reduce metals, hydroxyl radical and superoxide, thus can exert both anti- and pro-
oxidant properties. Upon the addition of an electron it forms ascorbyl radical which like the α-
tocopheroxyl radical is relatively inert. This antioxidant is effectively recycled via the
disproportional reaction between two ascorbyl radicals (Halliwell and Gutteridge, 1999). Ascorbic
acid has been localised within femoral and carotid plaques at concentrations higher that that
detected within normal arterial tissue and similar to that within healthy plasma (Suarna et al., 1995).
1.4 Objective of this study
Many studies have identified antioxidant and oxidative products within atherosclerotic plaques
(Davies et al., 1999; Fu et al., 1998; Leeuwenburgh et al., 1997; Stanley et al., 2006; Suarna et al.,
1995), but none have investigated the spatial localisation of these markers within the plaques in
relation to one another. Within the published literature only studies from our laboratory have
measured the concentration of neopterin within carotid and femoral plaques (Firth et al., 2008;
Gieseg et al., 2008a). By identifying relationships within and between the markers within the
plaques in a spatial context, mechanisms driving the process of advance plaque formation maybe
hypothesised on. By understanding these processes and the potential relationships between the
markers, the important and more informative conclusions may provide a base for elucidating the
mechanisms of plaque growth. Knowledge of these processes is vital for providing preventative
measures towards this disease.
Within our laboratory, to date, eight plaques have been fully analysed, however due to the
complexity and differences of these plaques at the advance disease stage, it is difficult to obtain
significant trends or correlations between the plaques due to the small sample size. Therefore I have
analysed a further six plaques. In addition the mechanism of plasma protein oxidation was
examined to gain further understanding of the processes likely to be occurring within the plaques.
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Materials and Methods
2.1 Materials
2.1.1 Chemicals
All solutions were prepared using de-ionised and ultrafiltrated water from a NANOpure ultra-
filtration system supplied by Barnstead/Thermolyne (IA, USA). All reagents used are of analytical
grade or better, unless otherwise stated.
Acetic acid (glacial) JT Baker, Mallinckrodt Baker Inc.
Acetone Merck
Acetonitrile JT Baker, Mallinckrodt Baker Inc.
Riedel-de Haen, Honeywell International Inc.
BDH Chemicals Ltd
Argon gas BOC gasses, N.Z.
4-Aminobenzoic acid (ABA) Sigma Chemical Co.
Ammonium phosphate dibasic minimum 98% Sigma Chemical Co.
Ammonium ferrous sulphate Hopkins and Williams Ltd
2,2-azobis (2-aminopropane) dihydrochloride (AAPH) Arcos, N.J., U.S.A.
Bicinchoninic acid (BCA) protein determination kit Pierce, U.S.A.
Bovine serum albumin (BSA) Sigma Chemical Co.
Bromophenol blue
Butylated hydroxytoulene (BHT) Sigma Chemical Co.
Chelex 100 resin Bio-Rad Laboratories, USA
Cholesterol reagent Roche Diagnostics, USA
Chloroform Merck
Coumassie brilliant blue Scharlau Chemie S.A.
Deferoxamin methansulfonic (Desferal) Ciba-Gergy Ltd, Switzerland
Diethyl ether Merck
Diethylenetriaminepentaacetic acid (DTPA) Sigma Chemical Co.
7,8-Dihydroneopterin (7,8-NP) Schiricks Laboratory
2,4-Dinitrophenylhydrazine (DNPH) Aldrich
Ethanol Scharlau Chemie S.A.
BDH Chemical Ltd
Ethyl acetate BDH Chemical Ltd
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Ethylenediaminetetraacetic acid (EDTA) BDH Chemical Ltd
Guanidine hydrochloride Sigma Chemical Co.
Glycerol Sigma Chemical Co.
n-Hexane Unichrom, ARS
Hydrochloric acid (HCl) Merck
Iodine BDH Chemicals Ltd
L-3,4-Dihydroxyphenylalanine Sigma Chemical Co.
L-Ascorbic acid Sigma Chemical Co.
BDH Chemicals Ltd
Mercaptoacetic acid Sigma Chemical Ltd
2-Mercaptoethanol Sigma Chemical Co.
Methanol Scharlau Chemie S.A.
Merck
2-(N-Morpholino)ethanesulfonic acid (MES) Sigma Chemical Co.
3-(N-Morpholino)propanesulfonic acid (MOPS) Sigma Chemical Co.
Neopterin Schiricks Laboratory
Nitrogen gas Boc Gasses, N.Z.
Nitrogen liquid Cryogenics, Department of Chemistry, University of
Canterbury
Orthophosphoric acid (85%) BDH Chemicals Ltd
Phenol Sigma-Aldrich
Potassium Bromide Merck
Potassium Iodide Merck
Prestained Protein Molecular Weight Marker Fermentas, Life Sciences
2-Propanol (isopropanol) Merck
Sigma Marker Wide Range Sigma Chemical Co.
Sodium acetate Merck
Sodium chloride Merck
Sodium carbonate (NaHCO3) BDH Chemicals Ltd
Sodium cyanoborohydride (NaCNBH3) Fluka
Sodium dihydrogen phosphate monohydrate Scharlau Chemie S.A.
Sodium dodecyl sulphate (SDS) Sigma-Aldrich
Sulfuric acid BDH Chemicals Ltd
1,1,3,3-Tetramethoxypropane Sigma Chemical Co.
2-Thiobarbituric acid, minimum 98% (TBA) Sigma Chemical Co.
α-Tocopherol Sigma Chemical Co.
Trichloricacetic acid (TCA) Merck
Trifluroacetic acid (TFA) anahydrous Sigma Chemical Co.
Xylenol orange Riedel-de Haen, Honeywell International Inc.
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2.1.2 HPLC system
The HPLC system (Shimadzu Corporation, Japan) consists of the controller SCL-10Avp, a
fluorescence detector RF-10AXL, UV-Vis detector SPD-10A, SIL-10A autosamplier and on-line
degasser. Peak areas were determined using Class-VP software.
2.1.3 General solutions and buffers
A) HPLC mobile phases
Salt based HPLC mobile phases were filtered through a 45 μm filter and all mobile phases were
sonicated for 10 minutes before loading onto the HPLC.
B) Phosphate buffered saline (PBS)
Phosphate buffered saline with a final concentration of 150 mM sodium chloride and 10 mM
sodium dihydrogen orthophosphate pH 7.4 was stirred with water washed chelex 100 for at least 12
hours prior to use.
C) Reagents for the FOX assay
5 mM xylenol orange (MW 760.59 g/mol) and 5 mM ammonium ferrous sulphate (MW 392.16
g/mol) were freshly prepared daily in 25 mM sulphuric acid for both the sulphuric acid and acetic
acid FOX assays.
D) Gel electrophoresis solutions
Cracker buffer
A solution 0.5M Tris-HCl was adjusted to a pH of 6.8 with concentrated HCl. To obtain the correct
conductivity care was taken not to overshoot the pH value. A cracker buffer stock was then
prepared consisting of 0.125 M Tris-HCl pH 6.8, 10% SDS, 20% glycerol and 0.1% bromophenol
blue in water and stored at room temperature. The final cracker buffer solution was freshly prepared
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by mixing 1 mL of stock cracker buffer with 20 μL of mercaptoethanol and 2 μL of 100 mg/mL
EDTA.
MOPS transfer buffer
A 10 times concentrated stock was prepared and stored at 4ºC. When required it was diluted with
water to give a final concentration of 50 mM MOPS, 50 mM Tris base, 0.1% SDS and 1 mM
EDTA at pH 7.7.
Cousmassie Brilliant Blue Stain
0.1% cousmassie brilliant blue, 10% v/v acetic acid and 50% v/v methanol in water.
Destain
10% v/v glacial acetic acid and 5% v/v methanol in water.
2.2 Methods
2.2.1 Plaque Homogenisation
Plaques were surgically removed at the Christchurch Hospital and immediately transported to the
Free Radical Biochemistry Laboratory on ice before storing at -80ºC. When ready the plaques were
sectioned into 3-5 mm segments down their longitudinal axis while still frozen. Numbering of the
sections began at the end prior to the bifurcation and were photographed before homogenising
under liquid nitrogen. To each homogenised plaque section 4 mL of water, 50 μL of 100 mg/mL
EDTA and 50 μL of 20mg/mL BHT (in methanol) was added and further homogenised by the
Tissumizer 3000 (Takmar Company, USA). The Tissumizer was rinsed with 1 mL of water and
added to the homogenate to minimise loss of sample. Total mass and final volume of each section
was noted.
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2.2.2 Cholesterol Determination
This spectrophotometric assay is based on a series of reactions involving the enzymes cholesterol
esterase, cholesterol oxidase and peroxidase ultimately resulting in the development of a red dye.
The intensity of the dye is directly proportional to the concentration of total cholesterol within the
sample. To 10 μL of plaque homogenate, 1 mL of cholesterol reagent (CHOL, Roche Chemicals)
was added and incubated in the dark for 10 minutes at room temperature. The absorbance was read
at 500 nm against a cholesterol reagent blank.
2.2.3 Protein determination
In the presence of bicinchoninic acid (BCA), the concentration of protein dictates the intensity of a
purple dye development forming the basis of the BCA protein determination kit (Pierce, Illinois,
USA). Optimally, the protein concentration within the sample is required to be between 25 and 250
μg/mL therefore plaque homogenate was diluted with water by a factor of 10, and plasma diluted by
a factor between 100 and 500. 1 mL of the freshly prepared working reagent (Reagent A sodium
carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.1 M sodium hydroxide and reagent B
4% hydrated copper sulphate in a 50:1 ratio of reagent A:B) was added to 50 μL of diluted sample
and placed on a heated block at 60ºC with gentle shaking for 30 minutes. The reaction was stopped
by incubating the samples on ice before reading the absorbance at 562 nm against a water blank.
Concentrations were determined from a BSA standard curve analysed by Prism (version 4.0;
GraphPad Software, USA).
2.2.4 Antioxidant detection
2.2.4.1 Pterin Assay
The pterin assay takes advantage of neopterin’s natural fluorescence allowing the detection and
determination of neopterin and 7,8-dihydroneopterin (7,8-NP). To determined the 7,8NP
concentration it is oxidised to neopterin giving a total neopterin value, therefore subtracting the
neopterin from the total neopterin gives the 7,8NP concentration. Using reverse phase HPLC the
accuracy of the assay is dependent on the removal of protein from the sample, as it has been shown
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to interact with proteins leading to an underestimation of its concentration (Flavall et al., 2008).
Due to the lability of 7,8-NP the pterin assay was performed on the same day as the homogenisation
of the plaque.
For neopterin quantification the protein precipitation was induced by mixing 100 μL of ACN with
100 μL of plaque homogenate/plasma followed by vortexing and centrifugation at 10,300 g for 10
minutes at 4ºC. For the total neopterin samples 100 μL of ACN was added to 100 μL plaque
homogenate/plasma, vortexed and centrifuged as described above for 5 minutes. For the oxidation
of 7,8-NP to neopterin 10 μL of acidic iodide (5.4% I2/10.8% KI in 1 M HCl) was added, vortexed
and incubated in the dark for 15 minutes. This was followed by 10 μL of 0.6 M ascorbic acid to
neutralise excess acidic iodide, and centrifuged as before for 10 minutes.
From the neopterin and total neopterin supernatants, 10 μL was injected onto a reverse phase
Develosil C18, 250 x 4.6 mm, 5 μm column (Phenomenex) maintained at 35ºC. The 20 mM
ammonium phosphate pH 6.0 with 5% methanol mobile phase was pumped at a flow rate of 1
mL/minute and the neopterin detected at an excitation of 353 nm and emission 438 nm.
A standard neopterin stock stored at -20ºC was prepared in 10 mM phosphoric acid and sonicated
for 2 minutes. When required an aliquot was thawed and diluted to 1 μM with mobile phase. The
7,8-NP standard was prepared fresh in mobile phase and kept on ice and in the dark to minimise
loss. Where spiking of 7,8-NP was required a known concentration was added to samples and
allowed to equilibrate on ice for 5 minutes before beginning sample preparation.
2.2.4.2 α-Tocopherol assay
α-Tocopherol is a lipid soluble antioxidant due to its long hydrocarbon chain and efficient peroxyl
radical scavenging properties. It has a cyclic structure which is important for its antioxidant activity
and also allows its detection at 292 nm.
Within a 10 mL glass culture tube with screw top 100 μL of plaque homogenate was diluted with
400 μL of water. To prevent additional oxidation occurring 10 μL of 100 mg/mL EDTA and 25 μL
of 20 mg/mL BHT (in methanol) was added. Protein precipitation was induced with 500 μL of ice
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cold ethanol and vortexed for 10 seconds. The α-tocopherol was extracted by adding 2 mL of ice
cold hexane and further vortexing for 30 seconds. At this point the samples can be stored at -80ºC.
Once thawed the samples are re-vortexed for 60 seconds before centrifuging at 1,600 g for 5
minutes at 4ºC to maximise phase separation. Into glass tapered 10 mL centrifuge tubes 70% of the
hexane layer was transferred before it was evaporated in a hot water bath under nitrogen gas. The
remaining residue was dissolved in 100 μL ice cold methanol and transferred to the HPLC.
With a mobile phase of 100% methanol, 20 μL of the sample was injected onto a reverse phase
Econosphere C18, 4 x 125 mm, 5 μm column (Alltech Associates Inc.) maintained at 35ºC, and
detected at an extinction and emission of 292 and 353 nm respectively. The α-tocopherol standard
was prepared by diluting approximately 1 mg/mL α-tocopherol in methanol and the concentration
determined spectrophotometrically using an extinction coefficient of 3086 cm-1M-1 at a wavelength
of 294 nm. The α-tocopherol standard stock was stored at -20ºC under argon gas and when required
was diluted to 3 μM concentration with 100% methanol.
2.2.5 Lipid oxidation detection
2.2.5.1 TBARS assay
The TBARS assay provides a general measurement of fatty acid oxidation occurring within
biological systems. One of the breakdown products of lipid oxidation is malondialdehyde (MDA).
The well established 2-thiobarbitutic (TBA) reaction with MDA yields a pink colour that is
detectable around 553 nm.
After combining 100 μL of plaque homogenate, 50 μL of 150 mM of phosphoric acid to increase
the acidity and precipitate the protein and 10 μL of 20 mg/mL BHT (in methanol) to prevent further
oxidation, the samples are stored at -80ºC. When ready for analysis 50 μL of freshly prepared 42
mM TBA was added to the thawed samples and placed on a heated block at 95ºC with gently
shaking for 30 minutes allowing the formation of the TBA-MDA adduct. The samples were
immediately cooled on ice and centrifuged at 10,300 g at 4ºC for 10 minutes. In the original method
(Plaques A-C,F) 100 μL of the supernatant was combined with 300 μL of ice cold methanol,
vortexed and left on ice for 5 minutes. The samples were re-spun at 21,000 g for 5 minutes before
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loading onto the HPLC. Modifications were made to the original method to improve within and
between run measurements. The new method (Plaques D-E) involved adding 800 μL of ice cold
methanol to the cooled sample immediately after the incubation step. Samples were then left on ice
for 5 minutes followed by centrifugation at 21,000 g for 10 minutes at 4ºC. To equilibrate the
sample to the mobile phase 100 μL of the supernatant was added to 100 μL of 50 mM NaH2PO4 pH
6.8 and injected onto the HPLC.
The HPLC pumped 50 mM NaH2PO4 pH 6.8 with 45% methanol at a flow rate of 1 mL/min
through a reverse phase Phenosphere C-18, 4.6 x 150 mm, 5 μm column (Phenomenex) heated to
35ºC. The TBA-MDA was detected at an excitation of 525 nm and emission of 550 nm. Both blank
and 1 μM TBA-MDA standards are required to determine the concentration of TBARS within the
samples.
MDA is very labile, therefore the standard was prepared fresh with every sample block by
incubating a known concentration of the MDA precursor 1,1,3,3-tetramethoxypropane with TBA.
1,1,3,3-Tetramethoxypropane hydrolyses to MDA during the heated incubation step forming a
known concentration of TBA-MDA. During preparation of the standard the first dilution step of
1,1,3,3-tetramethoxypropane was in a solution of ethanol:water at 2:3, where further dilutions were
made in water.
2.2.5.2 7-ketocholesterol and α-tocopherol assay
The LDL and oxLDL was diluted with PBS to a concentration of 1 mg/mL in 500 μL and with
plaque 100 μL of homogenate was added to 400 uL of water. To prevent additional oxidation 10 μL
of 20 mg/mL BHT (in methanol) and 20 μL of 100 mg/mL EDTA were added. Protein precipitation
was induced by 1 mL ice cold methanol and vortexed briefly. The 7-ketocholesterol and α-
tocopherol was extracted by the addition of 5 mL of ice cold hexane and a 60 second vortex. To
ensure phase separation the samples were centrifuged at 200 g for 5 minutes at 4ºC. Of the top
hexane layer 80% was transferred to glass tapered 10 mL centrifuge tubes and dried under nitrogen
gas, before re-solubilising in 100 μL of mobile phase.
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Onto an Phenosphere-NEXT C18, 250 x 4.6 mm, 5μm (Phenomenex, NZ) maintained at 35ºC
pumping a mobile phase of 54 isopropanol:44 acetonitrile:2 water at 1 mL/min, 20 μL of the sample
was injected. The sample first runs through the UV-Vis detector set at a wavelength of 234 nm for
the detection of 7-ketocholesterol, and continues through to the fluorescence detector set at an
excitation of 292 nm and emission of 335 nm for the detection of α-tocopherol.
The 7-ketocholesterol standard was freshly prepared in and diluted with mobile phase, and the α-
tocopherol stock stored in the -20ºC under argon gas was diluted with mobile phase. (Preparation of
the α-tocopherol stock is described in section 2.2.4B.)
2.2.6 Protein oxidation detection
2.2.6.1 DOPA and dityrosine assay
DOPA and dityrosine are oxidative products derived from the tyrosine residue. Because HPLC
analysis is able to separate the products after release from the protein this allows the detection of
both protein oxidative products within the one assay.
To 7.5 mm glass durham tubes 10 μL of 100 mg/mL EDTA and 10 μL 20 mg/mL BHT was added
to 10 μL of plaque homogenate. The protein was precipitated by the addition of 900 μL acetone
(stored at -20ºC) and incubated on ice for 10 minutes followed by centrifugation at 7000 g at 4ºC
for 15 minutes. The supernatant was removed and the pellet washed with 500 μL of ice cold diethyl
ether and centrifuged as before. After removal of the supernatant the pellets were dried under
vacuum for 1 hour and then placed into Pico-Tag vials (Millipore, USA) with 1 mL of 6 M HCl
with 1% (w/v) phenol and 50 μL mercaptoacetic acid in each vial. Argon gas was flushed through
the Pico-Tag vials for 5 minutes and the vials were evacuated by connecting to the vacuum line of a
solvent Speed Vac for 2 seconds (ensuring that the Vac. gauge pressure was below 200 mm Torr)
creating an anaerobic environment. For the acid hydrolysis of the proteins the vials were incubated
in a 110ºC oven for 16 hours. After cooling, the samples were centrifuged under vacuum (Speed
Vac) for 2 hours before re-solubilising the pellet with 200 μL of 0.1% TFA. To enable the samples
to be spun at 21,000 g for 5 minutes at 4ºC, the samples were transferred to eppendorf tubes before
loading onto the HPLC.
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Onto a reverse phase Aqua C18, 250 x 4.6 mm, 5 μm column (Phenomenex) 10 μL of supernatant
was injected with a gradient mobile phase pumping at 1 mL/minute. The gradient began at 100%
0.1% TFA pH 2.5 with 1% ACN where the ACN linearly increased to 5% by the 10th minute, 10%
by the 14th minute and 50% by the 16th minute. This was maintained for 5 minutes to clean the
column, after which the ACN concentration was returned and maintain at 1% until the 30th minute.
Because DOPA elutes first the fluorescence detector began at an excitation of 280 nm and an
emission of 320 nm. At the 11th minute the emission was changed to 410 nm for the detection of
dityrosine. The DOPA standard was prepared fresh and a dityrosine stock stored at -20ºC were
diluted to 1 μM with mobile phase.
2.2.6.2 Protein carbonyls spectrophotometric assay
Protein carbonyls are a general protein oxidation marker that detects the formation of carbonyls on
amino acid side chains. The dye reagent dinitrophenylhydrazine (DNPH) interacts with these
moieties allowing the quantification of the protein carbonyls.
Within the black top glass tubes 1 mL of DNPH in 2 M HCl was added to 200 μL of plaque
homogenate alongside blanks prepared by mixing 1 mL 2 M HCl to 200 μL of plaque homogenate,
and then stored at -80ºC. After the samples were thawed in the dark they were incubated at 37ºC for
90 minutes with shaking at 80 rpm permitting the reaction between the carbonyls and DNPH. The
samples were cooled on ice and the protein precipitated with of 1 mL of 28% TCA and left on ice
for 10 minutes followed by centrifugation at 4,100 g at 4ºC for 10 minutes. The supernatant was
decanted and the pellet re-suspended in 5 mL of 1:1 ethanol:ethyl acetate to remove excess DNPH.
After the samples were vortexed and centrifuged as before, the ethanol:ethyl acetate wash was
repeated followed by a third centrifugation. The remaining protein pellet was dissolved in 1 mL of 6
M guandine hydrochloride (in 2 M HCl), incubated in the dark for 30 minutes and the absorbance
read at 560 nm against a water blank. To calculate the concentration within the sample the average
absorbance of the blank was subtracted from each DNPH treated sample and the concentration
determined using the extinction coefficient of 21,000 cm-1M-1 (Quinlan et al., 1994).
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2.2.6.3 Protein carbonyls AAS and GGS HPLC assay
This method detects the two main protein carbonyl products α-aminoadipic semialdehyde (AAS)
and γ-glutamic semialdehyde (GGS). AAS and GGS accounts for 23% of the total carbonyls within
native BSA (Akagawa et al., 2006).
The samples were prepared in glass durham tubes with either 200 μL of BSA, 40 μL of plasma or
plaque homogenate made up to 200 μL with water. For the prevention of further oxidative events 50
μL of 20 mM DTPA and 50 μL of 20 mg/mL BHT (in methanol) was added followed by protein
precipitation with 200 μL of 72% TCA. The samples were kept on ice for 10 minutes then
centrifuged at 1,500 g at 4ºC for 10 minutes. The supernatant was removed and using a sealed
pasteur pipette the protein pellet re-suspended in 250 μL of MES buffer pH 6.5 with 0.5% SDS. To
the mixture 500 μL of 150 mM aminobenzoic acid (in MES buffer pH 6.5) and 125 μL of 250 mM
sodium cyanoborohydride (in MES buffer pH 6.5) was added and the tubes inverted before
incubating at 37ºC at 80 rpm for 90 minutes, allowing the condensation of ABA to AAS and GGS.
After the samples were cooled on ice the protein was precipitated with 500 μL of ACN and
centrifuged at 1,500 g at 4ºC for 15 minutes. To ensure the protein was precipitated the protein
pellet was washed with 200 μL of 28% of TCA and centrifuged as before. Once the supernatant was
removed the pellets were re-suspended using a sealed pasteur pipette in 500 μL ice cold ethanol and
spun as before. For the final time the supernatant was removed and residual ethanol drained off by
inverting the tubes for 5 minutes. The pellets were dried under vacuum for 1 hour before placing
them into Pico-Tag vials with 1.5 mL 6 M HCl for acid hydrolysis. Air was flushed out using argon
gas for 5 minutes before the vials were evacuated by connecting to the vacuum line of a solvent
Speed Vac for 2 seconds (ensuring that the Vac. gauge pressure was below 200 mm Torr). Acid
hydrolysis began once the vials were placed into the 110ºC oven and left for 24 hours. After the
vials had cooled the vacuum was released from the Pico-Tag vials and the durham tubes were spun
under vacuum for 2 hours (Speed Vac, Solvant) before re-solubilsing in 200 μL of 50 mM sodium
acetate pH 5.4. For the samples to be centrifuged at a high g force the samples were transferred to
an eppendorf tube and centrifuged for 5 minutes at 21,000g.
Onto a reverse phase Synergi Fusion 250 x 4.6 mm, 4 μm column (Phenomenex) with a gradient
mobile phase pumping at 1 mL/minute, 20 μL of the sample was injected. The mobile phase began
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at 95% of 50 mM sodium acetate pH 5.4 and 5% ACN and was maintained until the 30th minute.
The ACN concentration linearly increased reaching 50% by the 35th minute. This was maintained
for 5 minutes to clean the column, after which the ACN concentration returned to and was
maintained at 5% until the end of the run (50 minutes). The AAS-ABA and GGS-ABA compounds
were detected at an excitation of 283 nm and an emission of 350 nm. For the standard, ABA was
prepared in mobile phase, sonicated for 2 minutes and injected at a concentration of 1 μM.
2.2.7 Plasma oxidation methods
2.2.7.1 Blood collection and plasma preparation
Blood was collected from healthy volunteers by venipuncture and approximately 50 mL
immediately added to 500 μL of 100 mg/mL EDTA to prevent clotting. The blood was separated by
centrifugation at 4,100 g at 4ºC for 20 minutes with slow stop. The plasma was transferred and
centrifuged on a fixed angled rotor at 12,400 g for 20 minutes at 4ºC with soft start and stop to
further remove remaining red blood cells. The resulting plasma was stored at -80ºC until use.
2.2.7.2 Oxidation of BSA and plasma
All BSA solutions were prepared using PBS. Immediately after the addition of 10 mM AAPH the
plasma or BSA solutions were incubated at 37ºC at 80 rpm for the required time period.
2.2.7.3 Dialysis of human plasma
The 14 kDal dialysis tubing (Medicell International Ltd) was prepared by boiling in 5% (w/v)
NaHCO3 and 1 mM EDTA, washed with water before boiling in water and stored at 4ºC in 50%
ethanol. Immediately before use the dialysis tube was extensively washed with double distilled
water. Pre-cooled PBS in 1 litre bottles was degassed with nitrogen for 10 minutes. Plasma was
transferred into the dialysis tube and flushed with argon gas for 5 minutes, before placing into PBS,
overlaying the PBS with argon gas for a further 5 minutes and sealing the bottle. The plasma was
dialysed with constant stirring in the dark at 4ºC, with a PBS change every 3 hours. The third
change of PBS was left to stir overnight.
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2.2.7.4 Protein hydroperoxide determination via the FOX assay
The FOX assay determines the concentration of protein hydroperoxides by the hydroperoxides
reacting with ferrous ions oxidising them to ferric ions. The ferric ions react with xylenol orange
providing a colour intensity that is detected spectrophotometrically.
a) Sulphuric Acid FOX assay
This version optimally determines the protein hydroperoxide concentrations within a pure protein
system and therefore was used on BSA samples. The protein was precipitated on ice with the
addition of 40 μL of 72% TCA to 1 mL of BSA, followed by a 5 minute incubation and a 7 minute
centrifugation at 10,300 g and 4ºC. After the supernatant was decanted the pellet was washed twice
by re-solublising in 1 mL of 5% TCA using a sealed pasteur pipette and centrifuged as before,
effectively removing the AAPH. The supernatant was removed and the pellet was re-dissolved in
900 μL of 25 mM sulphuric acid using a sealed pasteur pipette, before the addition of 50 μL of 5
mM xylenol orange (in 25 mM sulphuric acid) and 50 μL 5 mM ammonium ferrous sulphate (in 25
mM sulphuric acid). Blanks were prepared alongside consisting of 900 μL of 25 mM sulphuric acid,
50 μL 5 mM xylenol orange (in 25 mM H2SO4) and 50 μL 5 mM ammonium ferrous sulphate (in
25 mM H2SO4). The colour was allowed to develop by a 30 minute incubation in the dark at room
temperature followed by an absorbance reading at 560 nm against a water blank. The protein
hydroperoxide concentration was calculated using the extinction coefficient of 32,500 cm-1M-1 (Gay
et al., 1999).
b) Acetic Acid FOX assay
This FOX assay version modified by Pearson (2002) is used for plasma because plasma requires the
removal of lipid hydroperoxides as it interferes with the detection of protein hydroperoxides. The
resulting plasma pellets also have an increased solubility in the 50% acetic acid compared to the 25
mM H2SO4 therefore increasing the accuracy of the assay.
To 200 μL of plasma, 800 μL of water was added and the protein precipitated with 140 μL of 72%
TCA. The samples were incubated on ice for 5 minutes before centrifugation at 10,300 g at 4ºC for
7 minutes. After the supernatant was decanted 1 mL of 1:1 chloroform:ethanol was added for the
removal of lipid peroxides and centrifuged as before. The pellet was dissolved in 900 μL of 50%
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acetic acid before the addition of 50 μL 5 mM xylenol orange (in 25 mM H2SO4) and 50 μL 5 mM
ammonium ferrous sulphate (in 25 mM H2SO4). Blanks were prepared alongside consisting of 900
μL of 50% acetic acid, 50 μL 5 mM xylenol orange (in 25 mM H2SO4) and 50 μL 5 mM
ammonium ferrous sulphate (in 25 mM H2SO4). The colour was allowed to develop by incubating
the blanks and samples in the dark at room temperature for 30 minutes. The absorbance was read at
560 nm and concentration calculated using the extinction coefficient of 32,500 cm-1M-1 (Gay et al.,
1999).
2.2.7.5 Gel electrophoresis
This technique allows the accurate separation of proteins due to their mass. To be able to compare
band intensity between lanes the protein loading per well needs to be equivalent. Protein
concentration was determined by the BCA method (section 2.2.3). To the required volume of
sample 100 μL of cracker buffer was added before placing on a heated block at 95ºC for 3 minutes
with rigorous shaking inducing the denaturation of the proteins. The samples are spun at 23,100 g
for 5 minutes at 4ºC. Onto a NuPAGE 4-12% Bis-Tris Gel (Invitrogen), 10 μL of sample was
loaded per well and 5 to 10 μL of protein marker in either the first or last well. The gel was run in
MOPS transfer buffer and a voltage applied at 50 volts until the front line had entered the gel before
increasing the voltage to 120 volts until the end of the run. The gel was stained with coumassie
brilliant blue stain for 30 minutes with gentle rocking, and excess stain removed by washing in
destain. The destain was changed three times every 15 minutes, where the last change was left
overnight. The gel was photographed on Syngene Chemigenius-2 bioimaging system using
Genesnap software (Global, NZ).
2.2.8 LDL preparation and oxidation
2.2.8.1 LDL preparation
After defrosting a tube of plasma (section 2.2.7A), it was centrifuged at 4700 rpm for 10 minutes at
4ºC to remove precipitated fibrinogen. The plasma was transferred to a beaker placed on ice and
0.3816 grams of potassium bromide (KBr) was added per mL of plasma creating a plasma density
of 1.24. The mixture was gently stirred to avoid denaturation of LDL which can interfere with later
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separation techniques. A solution of 1 mg/mL EDTA pH 7.4 was deoxygenated with nitrogen gas
for 15 minutes before adding 8 mL into an OptiSealTM centrifuge tube (Beckman, USA). This was
underlayed with 4 mL of the plasma containing KBr using a long luer-fitting needle attached to a 5
mL syringe. Ensuring there are no bubbles the tubes were capped, placed into the NVT-65 rotor
(Beckman, USA) and centrifuge at 60,000 rpm for 120 minutes at 10ºC allowing the lipoproteins to
migrate along their density gradient.
The LDL was isolated by first discarding the top colourless layer by pipette, followed by the
removal of the yellow LDL band using a right angled needle attached to a 20 mL syringe. The LDL
was transferred into treated dialysis tubing (section 2.2.7C) and layered with argon gas. To remove
the EDTA the LDL was dialysed at 4ºC in nitrogen degassed PBS. Every four hours the PBS was
changed for up three times with the last change left overnight.
2.2.8.2 Determination of the LDL concentration
The cholesterol concentration of the LDL was measured as before (section 2.2.2). Based on an
estimate of the mass of cholesterol in LDL particle as 31.69% and using the molecular weight of 2.5
MDa LDL (Gieseg and Esterbauer, 1994) the concentration of LDL was calculated.
Calculations
Ab500nm x 14.9 (extinction coefficient) = Cholesterol concentration (mole/L)
Cholesterol concentration (mole/L) x cholesterol molecular weight (386.64 g/mol) = Cholesterol
concentration (g/L)
Cholesterol concentration (g/L) x 100/31.69 = LDL concentration (g/L)
LDL concentration (g/L) / LDL molecular weight (2.5 x 10-6 g/mol) = LDL concentration (mole/L)
2.2.8.3 Copper mediated oxidation of LDL
To produce oxidised LDL (oxLDL) the LDL at a concentration of 3-4 mg/mL was incubated with
copper chloride (CuCl2) at 37ºC for 24 hours. The CuCl2 was added from a 50 mM stock solution to
a final concentration of 300-400 μM. The Cu2+ ions were removed by mixing the oxLDL with
chelex-100 for two hours at 4ºC on a rotating turntable at 8 rpm. For the removal of the chelex the
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oxLDL was centrifuge at 500 g for 2 minutes. The LDL and oxLDL were concentrated using a
Vivapore membrane concentrator (Millipore, U.S.A.) and stored under argon gas at 4ºC for up to 2
weeks.
2.3 Statistical Analysis
Unless otherwise stated, data shown represents the mean ± standard error of the mean (SEM) of
triplicates for each section/treatment. The SEM is represented on each bar or data point within the
graphs. Except for the combined plaque analysis (section 3.1.7), comparison between treatments
were analysed by the Tukey’s test, performed on Prism (version 4.0, GraphPad Software, USA).
The combined plaque analysis involving the Cochran C, Hartley and Bartlett test, Tukey’s test, one
way- ANOVA, factorial-ANOVA and correlations were performed using Statistica (version 7.1,
StatSoft, Inc. USA). Statistical significance are represented by * (P<0.05), ** (P<0.01) and ***
(P<0.001).
The purpose of the combined plaque analysis (section 3.1.8) was to determine if any significant
variation in the marker concentrations existed between the different zones of the plaque, different
overall composition and overall morphology of the plaque along with the external factors,
medication and symptoms presented by the patient. To do this analysis the plaques were
independent and assumed to be homogenous. For the zoning analysis (section 3.1.8.2) the data from
the sections classified as a pre-bifurcation zone from all 12 plaques (excludes plaque B and F) was
pooled. The data for the bifurcation and post-bifurcation zones were also prepared in the same way.
One way-ANOVA and Tukey’s test were performed to determine if any significant variation
occurred between the zones. This provided information on the general trends that occur across all
plaques, to identify, if any, common trends and mechanism that may occur across all the plaques.
For the remaining analysis (sections 3.1.8.3-3.1.8.6) the plaques were classified into categories and
if applicable subcategories associated with the factor investigated. For example thrombosed,
calcified or neither categories and further subcategorised into Y shaped, small secondary branch or
linear morphology. The data across all sections of the plaques for each subcategory were pooled
and differences between the categories assessed via factorial-ANOVA and Tukey’s test. This
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provided information on the general trends associated with the marker concentrations between the
plaques and the factors that maybe contributing to the variation.
2.4 Ethics Approval
Ethics approval for access to patient information and analysis of atherosclerotic plaques was
granted from the Upper South A Regional Ethics Committee, ethics number CTY/01/04/036. Under
this agreement consent from the donor was obtained and the plaques remained anonymous from the
donor labelled by a laboratory based code.
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Results
3.1 Atherosclerotic Plaques
All atherosclerotic plaques were received from patients undergoing carotid or femoral
endarterectomy and were in an advanced stage of the disease. The plaques were cut into 3-5 mm
sections beginning at the proximal end in relation to the direction of blood flow and the bifurcation
point (section 2.2.1). During homogenisation, the plaques were qualitatively assessed on their
morphology and overall composition, including the degree of calcification and the presence of an
obvious thrombus. Sections described as ‘gruelly’ refers to the sections with a relatively high
proportion of the lipid core.
Because the level of shear stress may play a role in the formation, progression and rupture of these
plaques (Chatzizisis et al., 2007; Helderman et al., 2007; Tricot et al., 2000), each plaque section
was classified into zones based on its location along the plaque. These zones represent the pre-
bifurcation, bifurcation and post-bifurcation regions. The zones may be under different levels of
shear stress and therefore represent potentially different oxidative environments. The zoning also
allows for standardisation of each plaque for a combined plaque analysis.
Within each plaque the inflammatory marker neopterin, lipid soluble antioxidant α-tocopherol, the
general lipid oxidation marker TBARS, general protein oxidation markers DOPA and protein
carbonyls, a specific protein oxidation marker dityrosine along with protein and total cholesterol
were measured within each section of six atherosclerotic plaques. Within the plaque graphs the
dotted filled bars represent the section/s from the pre-bifurcation zone, solid filled the bifurcation
zone and the stripped bars represent the section/s from the post-bifurcation zone.
Common medication for CAD patients are aspirin, a known anti-thrombotic and anti-inflammatory
drug (Cyrus et al., 2002), primarily involved in the attenuation of platelet aggregation by the
inhibition of cyclo-oxygenase-1 (Chapman, 2007), and statins a lipid lowering drug which also has
anti-atherosclerotic properties (Chapman, 2007; Danilevicius et al., 2007). The main mechanism
attributed to statins is associated with the increased uptake of LDL by the liver via the up-regulation
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of LDL receptor leading to a decrease in cholesterol accumulation within the plaque which may
contribute to increased plaque stability. Both aspirin and statins also have anti-inflammatory
properties (Chapman, 2007). Within the six plaques analysed two were exposed to statins alone, one
to aspirin alone, two to both statins and aspirin and one exposed to neither. All but one of the
patients was being treated for hypertension and all were on additional medication for other aliments
and/or conditions.
3.1.1 Plaque A (RB040407a)
Plaque A was removed from the right femoral artery. It was characterised with over 75% stenosis,
33 mm in length and a total mass of 1.156 grams. In overall composition, this plaque had a high
degree of calcification occurring predominantly around the bifurcation region (Figure 3.1.1). Plaque
A was cut into 8 sections where section 1 was the pre-bifurcation section, 2-4 were the bifurcation
and sections 5-8 were the post-bifurcation. The plaque lacked a definitive secondary branch but the
opening was clearly seen in sections 2-4 corresponding to the bifurcation region.
Table 3.1.1. Plaque A patient and clinical information
Location Stenosis
Symptoms Gender
Smoking status
Left femoral artery
Not stated
Non-smoker Age
>75%
M
75
Purpose/FunctionMedication - Generic Name
Simvastatin
Frusemide
Prednisolone
Digoxin
Reduction cholesterol and lipids
Hypertension
Steroid anti-inflammatory drug
Congestive heart failure
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Figure 3.1.1 Sectioning and zones of plaque A
Plaque A was removed from the left femoral artery and homogenised into 8 sections. Section 1 was
the pre-bifurcation zone, sections 2-4 were the bifurcation zone and sections 5-8 were the post-
bifurcation zone. Top right hand insert not to scale.
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Figure 3.1.2 Protein, cholesterol, neopterin and α-tocopherol content within plaque A
Protein (a) and cholesterol (b) concentrations were determined spectrophotometrically where the
neopterin (c) and α-tocopherol were quantified by reverse phase HPLC. Dotted filled bar represents
the pre-bifurcation zone, solid filled bars the bifurcation and stripped filled bars the post-
bifurcation. Each bar represents the mean ± SEM of triplicate samples.
The protein content within plaque A had statistically high levels in the two peripheral sections,
section 1 and section 8, and a low in section 6. Therefore the protein in the pre-bifurcation zone was
significantly high compared to the subsequent zones (P<0.001) (Figure 3.1.2a). The cholesterol
concentration was the highest in the most distal section; section 8 (P<0.05) along with section 1 and
7 and due to these high levels, sections 2 and 6 were significantly low (Figure 3.1.2b). Like protein,
the concentration of neopterin was the highest in the most proximal and distal sections of plaque A
with 6.65 ± 0.16 and 3.76 ± 0.05 nmole/g of plaque respectively (Figure 3.1.2c). Consequently the
bifurcation zone had significantly low neopterin levels compared to the pre- and post-bifurcation
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Figure 3.1.3 Lipid and protein oxidative product markers within plaque A
TBARS (a), protein carbonyls (b), DOPA (c) and dityrosine (d) were either quantified via reverse
phase HPLC or spectrophotometry. Dotted filled bar represents the pre-bifurcation zone, solid filled
bars the bifurcation and stripped filled bars the post-bifurcation zone. Each bar represents the mean
± SEM of triplicate samples.
zones (P<0.001). The average concentration of α-tocopherol was 21.84 ± 1.66 nmole/g plaque with
no significant variation occurring across the length of plaque A (Figure 3.1.2d). Both TBARS and
protein carbonyl concentrations were at maximum levels within the pre-bifurcation zone with
concentrations of 64.48 ± 10.0 and 954.57 ± 97.8 nmole/g of plaque respectively (P<0.01) (Figure
3.1.3a,b). As with α-tocopherol, DOPA had no significant variation across the plaque while
dityrosine was only detected within the post-bifurcation section 4 at a concentration of 0.267 ±
0.015 nmole/g of plaque (Figure 3.1.3c,d).
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Overall, neopterin, α-tocopherol and protein concentrations had a significant positive correlation
towards each other across the length of plaque A (Table 3.1.17), correlations not seen within any
other plaque. With the oxidative markers, neopterin levels had a positive correlation with TBARS
levels (P<0.05), and α-tocopherol with protein carbonyl concentrations (P<0.01). In turn TBARS
and protein carbonyl levels had a positive correlation (P<0.01). Compared to the pre- and post-
bifurcation zones neopterin levels were significantly low in the bifurcation which is where the
dityrosine was detected.
3.1.2 Plaque B (RB040407b)
Plaque B was removed from the right femoral artery from the same patient as plaque A. In
comparison to plaque A this plaque was considerably smaller at a length of 13 mm and mass of
0.474 grams making the directionality of the plaque difficult to determine based on its morphology.
Therefore the plaque sections can only be classified as a bifurcation section flanked by two
peripheral sections. Plaque B had two distinct openings on either end and like plaque A was highly
calcified.
Table 3.1.2 Plaque B patient and clinical information
Location Stenosis
Symptoms Gender
Smoking status
Right femoral artery
Not stated
Non-smoker Age
Not stated
M
75
Purpose/FunctionMedication - Generic Name
Simvastatin
Frusemide
Prednisolone
Digoxin
Reduction of cholesterol and lipids
Hypertension
Steroid anti-inflammatory drug
Congestive heart failure
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Figure 3.1.4 Sectioning and zones of plaque B
Plaque B was removed from the right femoral artery from the same patient as plaque A and
homogenised into three sections. Sections 1 and 3 represent the peripheral sections and section 2 the
bifurcation region. Top right hand insert not to scale.
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Figure 3.1.5 Protein, cholesterol, neopterin and α-tocopherol content within plaque B
The protein (a) and cholesterol (b) content were determined spectrophotometrically and the
neopterin (c) and α-tocopherol (d) concentration via reverse phase HPLC. The chequered bars
represent the peripheral sections and the solid bar the bifurcation section. Each bar represents the
mean ± SEM of triplicate samples.
The concentration of protein differs within all three sections across plaque B with a maximum
concentration in section 2, the bifurcation zone (p<0.001) (Figure 3.1.5a). Like that of protein, the
cholesterol concentration was also significantly lower within the first peripheral section (P<0.01)
(Figure 3.1.5b). The neopterin levels significantly decreased along the plaque with a maximum
concentration of 2.08 ± 0.05 nmole/g of plaque in section 1 (Figure 3.1.5c). The α-tocopherol
concentration mirrored this by increasing along the length of the plaque with a significant
difference between the two peripheral sections (P<0.05) (Figure 3.1.6d). Opposite of α-tocopherol
and like neopterin, the TBARS concentration was maximum within the peripheral section 1
(P<0.05) (Figure 3.1.6a). Along with protein, the DOPA and protein carbonyl concentration had
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Figure 3.1.6 Lipid and protein oxidative product markers in plaque B
TBARS (a), protein carbonyls (b) DOPA (c) were measure via either reverse phase HPLC or
spectrophotometry. The chequered bars represent the peripheral sections and the solid bar the
bifurcation section. Each bar represents the mean ± SEM of triplicate samples.
significantly high levels in the bifurcation section. This is reflected in the positive correlation
between protein carbonyls and DOPA (P<0.05) (Table 3.1.7). No dityrosine was detected within
this plaque.
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3.1.3 Plaque C (MD260407)
Plaque C was removed from the left common carotid artery and was 28-29 mm long with a total
mass of 0.834 grams. Morphologically it had the characteristic Y shape with the primary branch
from the internal carotid artery and the smaller secondary branch from the external carotid artery.
The lipid core was located predominately in the bifurcation sections and along the primary branch.
Qualitatively the solid mass was a red white marble colour with relatively little calcification and no
visible thrombus.
Table 3.1.3 Plaque C patient and clinical information
Location Stenosis
Symptoms Gender
Smoking status
Left common carotid artery
Transient ischemic attack
Non-smoker Age
85%
F
84
Purpose/FunctionMedication - Generic Name
Aspirin
Tenoxicam
Omeprazole
Alendronate
Calcium
Calciferol
Anti-inflammatory and anti-thrombotic
Non-steroid anti-inflammatory drug
Reduction of gastric acid
Osteoporosis
Osteoporosis
Vitamin D/Osteoporosis
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Figure 3.1.7 Sectioning and zones of plaque C
Plaque C was removed from the right carotid artery and homogenised into seven sections. Sections
1, 2 and 3 represent the pre-bifurcation zone, sections 4 and 5 the bifurcation zone, section 6 the
post-bifurcation zone and section 7 was classified as the secondary branch and a sub-region of the
bifurcation zone. Top right hand insert not to scale.
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Figure 3.1.8 Protein, cholesterol, neopterin and α-tocopherol content within plaque C
Protein (a) and cholesterol (b) were measured by spectrophotometry and neopterin (c) and α-
tocopherol (d) were measured by reverse phase HPLC. The dotted bars represent the pre-bifurcation
sections, black solid bars the bifurcation sections, the stripped bar the post-bifurcation section and
the grey solid bar represents the secondary branch a sub-region of the bifurcation zone. Each bar
represents the mean ± SEM of triplicate samples.
The protein concentration was significantly low in section 4 compared to all but the two peripheral
sections 1 and 6 (Figure 3.1.8a). The majority of the cholesterol concentration was within sections
3, 4 and 5 with a maximum level within section 5 (Figure 3.1.8b). There was significantly high
neopterin (maximum concentration of 2.86 ± 0.13 nmole/g of plaque in section 1) in the peripheral
sections compared to the ‘gruelly’ sections 3, 4 and 6 (P<0.001). This was reflected in the
significantly low concentration of neopterin in the bifurcation zone compared to the pre-bifurcation
and secondary branch (P<0.01) (Figure 3.1.8c). The α-tocopherol had the opposite trend to
neopterin with high levels in the ‘grueller’ sections 3, 4 and 5 (P<0.001), with a maximum
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concentration of 298.77 ± 12.18 nmole/g of plaque in the pre-bifurcation section 3 (Figure 3.1.8d).
The TBARS concentration was maximum in the proximal section 1 and lowered in the distal
section 6, therefore the pre-bifurcation had significantly high levels (P<0.05) compared to the post-
bifurcation zone (Figure 3.1.9a). Protein carbonyl levels were maximum within the pre-bifurcation
section 2 with 603.08 ± 94.81 nmole/g of plaque and were significantly high within the ‘non-
gruelly’ sections compared to the ‘gruelly’ central sections (P<0.01) (Figure 3.1.9b). The dityrosine
concentration was significantly high within the bifurcation sections 4 and 6 (P<0.001) (Figure
3.1.9d), therefore the ‘gruelly’ sections also contained the maximum dityrosine concentration
within the plaque. DOPA had the opposite trend with high concentrations within the ‘non-gruelly’
sections (P<0.001) (Figure 3.1.9c).
Figure 3.1.9 Lipid and protein oxidative product markers in plaque C
TBARS (a), protein carbonyls (b), DOPA (c) and dityrosine (d) were measured by either reverse
phase HPLC or spectrophotometry. The dotted bars represent the pre-bifurcation sections, solid bars
the bifurcation sections and the stripped bar the post-bifurcation section. The solid grey bar
represents the secondary branch a sub-region of the bifurcation section. Each bar represents the
mean ± SEM of triplicate samples.
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Cholesterol and α-tocopherol concentrations displayed a significant positive correlation (P<0.05)
towards each other and both also showed a negative correlation towards DOPA (Table 3.1.17). The
dityrosine concentration across the plaque mirrored that of DOPA levels therefore the dityrosine
had a positive correlation towards cholesterol concentrations (P<0.05). Neopterin the inflammatory
marker had the negative relationship towards the dityrosine levels (P<0.05). As for the ‘gruelly’
sections there were higher concentrations of α-tocopherol and dityrosine compared to the low levels
of DOPA, neopterin and protein carbonyls within these sections.
3.1.4 Plaque D (MLA130607)
Plaque D was removed from the right carotid artery. It was 30 mm in length with a total mass of
1.238 grams. It had a relatively small degree of calcification observed predominantly within the
first two sections identified within the outer rings (Figure 3.1.10). The ‘gruel’ was primarily a red
and white solid mass. Plaque D was cut into 7 sections where the pre-bifurcation zone was
represented by section 1, the bifurcation zone by section 2 and includes the small secondary branch
from the external carotid artery, and sections 4-7 the post-bifurcation zone. Unlike previous plaques
much of the mass was located in the post-bifurcation region.
Table 3.1.4 Plaque D patient and clinical information
Location Stenosis
Symptoms Gender
Smoking status
Right carotid artery
Stroke
Non-smoker Age
98%
M
82
Purpose/FunctionMedication - Generic Name
Aspirin
Simvastatin
Doxazosin
Cilazapril
Metaprolol
Paracetamol
Anti-inflammatory and anti-thrombotic
Reduction cholesterol and lipids
Hypertension
Hypertension
Hypertension
Analgesic
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Figure 3.1.10 Sectioning and zones of plaque D
Plaque D was removed from the right carotid artery and homogenised into seven sections. Section 1
represents the pre-bifurcation zone, section 2 the bifurcation zone, and sections 3-7 the post-
bifurcation zone. Top right hand insert not to scale.
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Figure 3.1.11 Protein, cholesterol, neopterin and α-tocopherol content in Plaque D
Protein (a) and cholesterol (b) were determined by spectrophotometric analysis and neopterin (c)
and α-tocopherol (d) via reverse phase HPLC. The dotted filled bar represents the pre-bifurcation
section, solid bar the bifurcation section and the stripped bars the post-bifurcation sections. Each
bar represents the mean ± SEM of triplicate samples.
The pre-bifurcation and bifurcation zones were significantly low in protein content compared to the
post-bifurcation zone (P<0.01) (Figure 3.1.11a). The cholesterol concentration was maximum in the
first post-bifurcation section, significantly dropping (P<0.001) in section 4 before returning to the
high concentration at the distal end of the plaque (Figure 3.1.11b). Like plaques A, B and C the
neopterin levels had a significant high within the proximal section 1, the pre-bifurcation zone, with
a concentration of 3.01 ± 0.01 nmole/g of plaque. Similarly to plaque A the neopterin also had a
high concentration in the 2nd to last section within the post-bifurcation zone (Figure 3.1.11c). The α-
tocopherol content was consistent along the plaque before decreasing significantly within the last
two sections (P<0.05) (Figure 3.1.11d). TBARS had a maximum concentration within the first
section with a concentration of 14.89 ± 0.52 nmole/g of plaque therefore the pre-bifurcation zone
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was significantly high compared to the post-bifurcation region (P<0.01) (Figure 3.1.12a). Because
the DOPA concentration increased along the length of the plaque from the proximal to the distal
end (Figure 3.1.12c), the post-bifurcation zone had significantly more DOPA levels than the pre-
bifurcation (P<0.05). The dityrosine concentration was similar in that it had a high level in the post-
bifurcation section 6 (20.11 ± 0.03 nmole/g of plaque), and the majority of this protein oxidative
product were in the latter three sections (Figure 3.1.12d). The protein carbonyls displayed no
variation across the length of the plaque (Figure 3.1.12b).
Figure 3.1.12 Lipid and protein oxidative product markers in plaque D
TBARS (a), protein carbonyls (b), DOPA (c) and dityrosine (d) were measured by either reverse
phase HPLC or spectrophotometry. The dotted filled bar represent the pre-bifurcation section, solid
bar the bifurcation section and the stripped bars the post-bifurcation sections. All bars were the
mean ± SEM of triplicate samples.
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Both DOPA and dityrosine concentrations were positively correlated with protein across the plaque
(P<0.01) and (P<0.05) respectively, however not towards each other (Table 3.1.7). Within the
oxidative markers, DOPA levels were negatively correlated towards TBARS concentrations
(P<0.05), whereas the dityrosine levels had a negative correlation with α-tocopherol concentrations
(P<0.05).
3.1.5 Plaque E (BB050507)
Plaque E had a stenosis of 80-95% and was taken from the right internal carotid artery. It was 30
mm in length with a total mass of 0.943 grams. Plaque E had a relatively small level of calcification
compared to the previous plaques and was characterised with a thrombus observed within sections
3-5. For the majority of plaques there were associated symptoms induced within the patient. The
presence of the disease within this patient was recently discovered and subsequently the patient was
asymptomatic. Because of this the patient had only just begun taking the classic CAD medications;
statins and aspirin. Therefore in the combined plaque analysis the patient was considered to be on
neither of the medications.
Table 3.1.5 Clinical information of plaque E
Location Stenosis
Symptoms Gender
Smoking status
Right carotid artery
Asymptomatic
Smoker Age
80-95%
M
60
Purpose/FunctionMedication - Generic Name
Aspirin
Simivastatin
Metaprolol
Allopurinol
Alluretic
Anti-inflammatory and anti-thrombotic
Reduction in cholesterol and lipids
Hypertension
Gout
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Figure 3.1.13 Sectioning and zones of plaque E
Plaque E was removed from the right carotid artery and homogenised into eight sections. Section 1
represents the pre-bifurcation zone, sections 2 and 3 the bifurcation zone, and sections 4-8 the post-
bifurcation zone. Top right hand insert not to scale.
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Figure 3.1.14 Protein, cholesterol, neopterin and α-tocopherol content within plaque E
Protein (a) and cholesterol (b) were measured by spectrophotometry and neopterin (c) and α-
tocopherol (d) concentrations were determined by reverse phase HPLC. The dotted filled bar
represents the pre-bifurcation zone, solid bars the bifurcation zone and the stripped bars the post-
bifurcation zones. Each bar represents the mean ± SEM of triplicate samples.
The last section, section 8, contained the maximum concentrations of protein, cholesterol, neopterin
and α-tocopherol detected within the plaque (Figure 3.1.14). The protein levels were also high
within the first two post-bifurcation sections 4 and 5, whereas the neopterin also had high levels
within the pre-bifurcation section. For α-tocopherol the majority of this antioxidant was found
within the last two sections of the plaque. TBARS maximised in section 8, and along with
dityrosine had high levels within the red ‘gruel’ sections 3, 4 and 5 (Figure 3.1.15a,d). Protein
carbonyl and DOPA concentrations displayed no variation across this plaque. However when
protein carbonyls was expressed as per gram of protein a zoning effect emerges with both the pre-
bifurcation and bifurcation regions having higher levels than the post-bifurcation (data not shown).
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Figure 3.1.15 Lipid and protein oxidative product markers in plaque E
TBARS (a), DOPA (c) and dityrosine (d) were measured by reverse phase HPLC and protein
carbonyls (b) via spectrophotometry. The dotted bar represents the pre-bifurcation section, solid
bars the bifurcation sections and the stripped bars the post-bifurcation sections. Ear bar represents
the mean ± SEM of triplicate samples.
The two lipid based analytes α-tocopherol and TBARS positively correlated (P<0.05) (Table
3.1.17) and both also correlated to cholesterol (P<0.01) and (P<0.01) respectively. This plaque was
the only plaque to display correlations between all three lipid related components. Positive
correlations between protein levels and two unrelated markers, cholesterol and TBARS were also
observed.
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3.1.6 Plaque F (TE120704)
Plaque F was characterised with 80-90% stenosis, 31 mm in length and a total mass of 0.692 grams.
It was homogenised as a whole plaque because it was not suitable for sectioning. Therefore the
marker concentrations are comparable to the average overall levels of previous plaques (Table I/II).
Plaque F homogenate was also used for investigating the pterin, 7-ketocholesterol/α-tocopherol and
AAS/GGS assays (section 3.2).
Table 3.1.6 Plaque F patient and clinical information
Figure 3.1.16 Plaque F morphology
Plaque F was homogenised whole under liquid nitrogen
Location Stenosis
Symptoms Gender
Smoking status
Right common carotid artery
Transient ischemic attack
Non smoker Age
80-90%
M
76
Purpose/FunctionMedication - Generic Name
Aspirin
Simvastatin
Atenolol
Bendrofluazide
Prazosin
Dipyridamole
Anti-inflammatory and anti-thrombosis
Reduction cholesterol and lipids
Hypertension
Hypertension
Hypertension
Anti-thrombosis1 cm
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Plaque F had a protein content of 91.76 ± 4.04 mg/g of plaque, very similar to the overall average
of the plaques (Table I). The cholesterol and α-tocopherol concentrations were the highest recorded
thus far in the study and the neopterin concentration was the lowest at 0.72 ± 0.01 nmole/g plaque.
The TBARS, protein carbonyl, DOPA and dityrosine concentrations were all close to the overall
average concentration of all the plaques with concentrations of 9.84 ± 0.68, 256.10 ± 56.94, 16.24 ±
1.63 and 3.94 ± 0.12 nmole/g of plaque respectively (Table II).
3.1.7 Individual plaque summary
In general the femoral plaques had overall lower concentrations of protein, cholesterol, α-
tocopherol, DOPA and dityrosine but higher levels of lipid oxidation. Besides dityrosine, the
overall α-tocopherol concentrations were the most variable between the plaques with a 37 fold
difference between the plaque with the highest concentration in plaque F and lowest in plaque B.
The overall neopterin concentration within each plaque ranged from 0.72-2.34 nmole/g of plaque
between the six plaques. Within and between the first five plaques only one correlation occurred
twice, a positive correlation between α-tocopherol and cholesterol (plaque C and E) (Table 3.1.17).
However many of expected correlations did occur at least once within the five plaques, highlighting
the differences between and within the plaque.
The lipid soluble antioxidant, α-tocopherol had a significant correlation with every marker within
plaques A-E. The relationship was positive towards neopterin, cholesterol, TBARS, protein and
protein carbonyl concentrations, but negative to both DOPA and dityrosine concentrations within
different plaques (Table 3.1.17). Neopterin concentrations displayed a correlation towards TBARS
and dityrosine, but not protein carbonyl or DOPA levels. Within plaques C and D the ‘gruelly’
sections generally had higher concentrations of the oxidative markers. Of the oxidative markers
TBARS, DOPA and protein carbonyl levels all had a correlation with each other within one of the
five plaques. All correlations where positive except between DOPA and TBARS. When relating to
the appropriate compound of origin, TBARS and cholesterol concentrations positively correlated
(Plaque E) and DOPA and dityrosine positively correlated with protein levels however this occurred
within the same plaque (Plaque D).
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Table 3.1.7 Correlations of inflammatory and oxidative markers within plaques A-E and
between plaques A-N
Significant correlations were determined based on the average of each section (n=3) within plaques
A-E. N is the number of sections within each plaque. Combined plaque analysis was preformed on
plaques A, C-E, G-N, where N is the collated number of sections of the plaques. For neopterin
correlations plaques G-J were excluded. Protein was expressed in mg/g plaque, cholesterol μmole/g
plaque and neopterin, α-tocopherol, TBARS, protein carbonyl, DOPA and dityrosine as nmole/g
plaque. Where stated, per cholesterol, the α-tocopherol and TBARS were expressed μmole/mole of
cholesterol, and per protein, the DOPA, dityrosine and protein carbonyls were expressed per
nmole/gram of protein. Statistical significance represented by P<0.05 * P<0.01 ** P<0.001 ***
Markers r(Pearson) P value N
Plaque A
protein vs. α-tocopherol 0.8027 0.016 * 8
neopterin vs. protein 0.9827 0.000 *** 8
neopterin vs. α-tocopherol 0.7741 0.024 * 8
neopterin vs. TBARS 0.7200 0.044 * 8
α-tocopherol vs. protein carbonyls 0.8693 0.005 ** 8
TBARS vs. protein carbonyls 0.8465 0.008 ** 8
α-tocopherol (per cholesterol) vs.
protein carbonyls (per protein)
0.7807 0.022 * 8
Plaque B
DOPA vs. protein carbonyls 1.0000 0.040 * 3
α-tocopherol vs. TBARS (per cholesterol) -0.9974 0.046 * 3
α-tocopherol vs. DOPA (per protein) -0.9984 0.036 * 3
Plaque C
α-tocopherol vs. cholesterol 0.7982 0.031 * 7
α-tocopherol vs. DOPA -0.8694 0.011 * 7
DOPA vs. cholesterol -0.9267 0.003 ** 7
dityrosine vs. cholesterol 0.7546 0.050 * 7
dityrosine vs. neopterin -0.8092 0.027 * 7
α-tocopherol vs. dityrosine (per protein) -0.7909 0.034 * 7
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DOPA (per protein) vs.
protein carbonyls (per protein) 0.8157 0.025 * 7
Plaque D
protein vs. DOPA 0.9122 0.004 ** 7
protein vs. dityrosine 0.8540 0.014 * 7
α-tocopherol vs. dityrosine -0.8328 0.020 * 7
TBARS vs. DOPA -0.8432 0.017 * 7
tocopherol (per cholesterol) vs.
TBARS (per cholesterol)
0.8969 0.006 ** 7
Plaque E
protein vs. cholesterol 0.7316 0.039 * 8
protein vs. TBARS 0.8898 0.003 ** 8
cholesterol vs. α-tocopherol 0.9875 0.000 *** 8
cholesterol vs. TBARS 0.8348 0.010 ** 8
α-tocopherol vs. TBARS 0.7702 0.025 * 8
α-tocopherol (per cholesterol) vs.
DOPA (per protein)
0.7742 0.024 * 8
Combined data analysis
TBARS vs. cholesterol -0.2983 0.005 ** 87
α-tocopherol vs. cholesterol 0.2604 0.015 * 87
α-tocopherol vs. protein 0.5132 0.000 *** 87
α-tocopherol vs. protein carbonyls 0.2804 0.009 ** 87
neopterin vs. protein carbonyls 0.3807 0.003 ** 59
protein carbonyls vs. protein 0.3025 0.004 ** 87
neopterin vs. protein 0.3615 0.005 ** 59
dityrosine vs. cholesterol 0.4313 0.000 *** 87
dityrosine vs. DOPA 0.3294 0.002 ** 87
α-tocopherol vs. DOPA (per protein) -0.2800 0.009 ** 87
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3.1.8 Combined plaque analysis
Due to the small sample set (n=5) and the apparent complexity of the plaques, correlations within
the individual plaques (plaques A-E) did not occur more than once with one exception (section
3.1.7). With a higher number of plaque samples the more likely common factors and correlations
will emerge. This research was a continuation from a PhD (Firth, 2006) and Masters (Flavall, 2008)
research which had collectively analysed the same markers within eight plaques. Thus to better
understand the processes occurring within these plaques, the entire database of 13 plaques (excludes
plaque F) was statistically analysed to identify any underlying trends within the inflammatory and
oxidative markers along with other influential factors (Table 3.1.8).
All 13 plaques were in an advanced state of the disease displaying from 60-90% stenosis. The
patients presented with a range and combination of symptoms including stroke, transient ischemic
attacks (temporary blockage of blood flow), amaurosis fugax (temporary loss of vision) and
dysphemia (temporary loss of speech). The morphology of the 13 plaques was classified by the
overall shape of the plaque. The difference between morphological shapes were very distinctive as
each plaque was either in the form of a Y shape where both branches were similar in size, had a
smaller secondary branch, or was linear with no side protrusions. Another qualitative characteristic
noted was overall composition assessed during homogenisation and classified as being either
heavily calcified, contained an obvious thrombus or did not strongly have either of these features.
The location of the plaque either in the carotid or femoral artery may play a role in the
concentration and/or localisation of the markers within the plaques. However, only plaques A and B
were removed from the femoral arteries and were also from the same patient (Table 3.1.8).
Therefore any differences observed between the locations may be due to patient variations, thus
location was not considered in the analysis. Like plaques A-E the effects of zoning were assessed to
see if variation existed between these regions in relation to the inflammatory and oxidative markers.
Long term medication is another possible influential factor affecting plaque growth. Except for the
femoral plaque patient all patients were on aspirin, however not all patients where on statins
therefore this effect on plaque morphology and patients symptoms where also analysed (Table
3.1.8).
Results 70
To assess the correlations between these plaques one way- and factorial-analysis of variance
(ANOVA) were preformed. Where required data was logarithmically transformed. For the
combined plaque analysis plaques G-J were excluded from the neopterin correlations because their
concentrations were determined by the trichloricacetic acid method (section 3.2.1). This method has
since been replaced with the more accurate acetonitrile method (section 2.2.4A).
Table 3.1.8 Summary of clinical and patient information of plaques A-N
Location
Plaque Total
mass (g) Morp. Composition
Section
N LC RC LF RF
Symptoms Meds
A 1.156 linear calcified 8 Unknown S
B 0.474 linear calcified 3 Unknown S
C 0.814 Y neither 7 TIA A
D 1.238 small thrombosis 7 stroke SA
E 0.943 linear thrombosis 8 asymptomatic N
F 0.692 linear unknown whole TIA SA
G 0.909 linear neither 6 TIA A
H 2.857 small calcified 7 Stroke SA
I 1.500 small neither 8 TIA SA
J 0.763 small thrombosis 7 Stroke SA
K 1.306 Y calcified 7 TIA SA
L 0.822 Y thrombosis 6 AF SA
M 0.507 small calcified 6 Stroke A
N 0.377 Y thrombosis 6 AF A
Overall morphology (Morp.) Y - Y shaped, small - small secondary branch and linear
Overall composition (Composition) thrombosed, calcified and neither
Section – number of sections each plaque was homogenised in to
Arterial location of plaque: LC– left carotid, RC – right carotid, LF – left femoral and RF – right femoral
Patient Symptoms (Symptoms) TIA – transient ischemic attack, AF – amaurosis fugax
Patient Medication (Meds) S – statins alone, A – aspirin alone, SA – statins and aspirin, N – neither
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3.1.8.1 Combined plaque correlations
Between the 13 plaques cholesterol positively correlated to α-tocopherol (P<0.05) supported by the
fact that LDL is the main source of α-tocopherol and possibly cholesterol (Table 3.1.17). The
negative relationship between cholesterol and TBARS concentrations (P<0.001) indicates that at
higher cholesterol content there is less lipid peroxides present. The positive correlation between
neopterin and protein levels (P<0.01) (Table 3.1.17) was also observed in plaque A.
Even though protein carbonyl levels show little if any variation across individual plaques overall it
displayed a positive correlation towards α-tocopherol (P<0.01), neopterin (P<0.01) and protein
levels (P<0.01) (Table 3.1.17). This is the only oxidation marker that positively correlated to both
α-tocopherol and neopterin.
Significant correlations observed in the combined plaque analysis, but not within any individual
plaques, included the above mentioned correlations between protein carbonyl concentration with
protein (P<0.01) and neopterin levels (P<0.01). This indicates that protein carbonyls do have
relevant relationships with some markers but this was only observed when all plaques were
included in the analysis. Within the protein oxidative markers, dityrosine and DOPA concentrations
positively correlated (P<0.01) but protein carbonyls did not to either. This was another correlation
observed in the combined plaque analysis that was not seen within individual plaques along with
the positive correlation between dityrosine and cholesterol (P<0.001). This further supports the
diversity among atherosclerotic plaques.
3.1.8.2 Variation in marker concentration associated with zones
Across the 13 plaques the post-bifurcation section had significantly high protein and cholesterol
levels compared to the bifurcation (P<0.05) and pre-bifurcation (P<0.01) zones respectively (Figure
3.1.17 a,b). As was observed with plaques A-E in the individual plaque analysis the neopterin had
significantly high levels within the pre- and post-bifurcation sections (P<0.01) (Figure 3.1.17 c).
This is opposite of the lipid peroxidation marker TBARS which has a lower concentration in the
pre- and post-bifurcation sections (P<0.01) (Figure 3.1.17 c,e). The free radical specific protein
Results 72
Figure 3.1.17 Effects of zoning on the concentration of the inflammatory and oxidative
markers within plaques A-N
Data from each section from plaques A-N (N=13) were classified into either pre-bifurcation (pre-),
bifurcation or post-bifurcation (post-) zones (as described in section 2.3). The variation between the
concentrations of protein (a), cholesterol (b), neopterin (c), α-tocopherol (d), TBARS (e), protein
carbonyl (f), DOPA (g) and dityrosine (h) within each zone was assessed by one way-ANOVA and
Tukey’s test. Displayed are the LS means and vertical bars represent 95 % confidence intervals. For
the neopterin data only plaques A-E and K-N were included (N=9). Significant differences
represent P<0.05*, P<0.01** and P<0.001*** to the other zones.
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oxidation product dityrosine had higher levels in the bifurcation and post-bifurcation zones (Figure
3.1.17 h), suggesting that more free radical damage is occurring at these locations. Low shear stress
occurs within these zones therefore increased oxidative stress (Chatzizisis et al., 2007) providing a
site for the production of dityrosine inducible free radicals. Concentrations of the lipid soluble
antioxidant α-tocopherol and protein oxidation products DOPA and protein carbonyls display no
variation between the zones (Figure 3.1.17 d,f,g).
3.1.8.3 Variation in marker concentration associated with overall plaque
composition
The plaques with a thrombus have higher protein content (Figure 3.1.18 a) presumably due to the
increased presence of blood proteins. These plaques also had high levels of α-tocopherol and
dityrosine (Figure 3.1.18 d,h). For the calcified plaques there were significantly low levels of
protein, cholesterol, α-tocopherol, DOPA and dityrosine (Figure 3.1.18 a,b,d,h). However there is
no variation between the categories for neopterin, TBARS and protein carbonyls (Figure 3.1.18
c,e,f). For the plaques that are not in either category (neither) the concentration of protein, α-
tocopherol and dityrosine was between that of the thrombosed and calcified plaques.
When the thrombosed, calcified and neither plaques were analysed for variation between the zones,
the trend was similar to that of analysing the whole plaque in each overall compositional state. This
suggests that the zoning had little effect on the concentration of the markers when the compositional
state was taken into consideration (Figure 3.1.18). Notable differences in the trends identified were
higher levels of cholesterol, α-tocopherol and dityrosine in the bifurcation of neither plaques and
higher protein carbonyls in the pre-bifurcation zone compared to the bifurcation zone of calcified
plaques (data not shown).
3.1.8.4 Interaction between overall composition and overall morphology
As seen before, the thrombosed plaques had high protein content compared to both calcified and
neither plaques which was true regardless of plaque shape (Figure 3.1.19 a). The calcified plaques
generally had lower concentrations of protein, neopterin, DOPA and dityrosine however plaque
morphology was influential with the concentration of cholesterol, α-tocopherol and TBARS (Figure
3.1.19).
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Figure 3.1.18 Influence of the overall plaque composition on the variation of inflammatory
and oxidative markers between plaques A-N
Plaques A-N were qualitatively classified as being either thrombosed (thromb) (n=5), calcified
(n=5) or neither (n=3). The data from the plaques were analysed as described in section 2.3. The
variation in the concentrations of protein (a), cholesterol (b), neopterin (c), α-tocopherol (d),
TBARS (e), protein carbonyls (f), DOPA (g) and dityrosine (h) were assessed by performing one
way-ANOVA and Tukey’s test. Displayed are the LS means and vertical bars represent 95 %
confidence intervals. For the neopterin data only plaques A-E and K-N were included (thrombosed
(n=4), calcified (n=4) and neither (n=1)). Significant differences represent P<0.05*, P<0.01** and
P<0.001 to the other compositional states.
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Within the linear plaques the protein, cholesterol and DOPA concentrations were lower in the
calcified linear plaques but had higher TBARS concentrations (Figure 3.1.19). The thrombosed
linear plaques were high in protein carbonyls compared to a lower level in the linear neither which
may be due the presence of blood proteins and the thrombotic cascade event introducing an increase
in oxidative stress. The Y shaped plaques had higher α-tocopherol levels regardless of
compositional state compared to the other morphological shaped plaques (Figure 3.1.19d).
Similarly, the cholesterol was statistically the same between the different compositional states and
the concentration was also the same across the different morphologies (Figure 3.1.19b). Along with
dityrosine, the DOPA and TBARS levels were lower in the Y shaped calcified plaques. This
compares to the higher DOPA and TBARS content in the neither calcified plaques. Regardless of
compositional state the α-tocopherol was low and cholesterol high in the small branched plaques
(Figure 3.1.19b,d), indicating a lower proportion of α-tocopherol per cholesterol in the small
branched plaques. Like the linear and Y shaped plaques the thrombosed small branched plaques had
higher protein than the calcified or neither plaques. Along with this the dityrosine was higher in the
thrombosed compared to the calcified and neither plaques. Neopterin showed no difference between
either of the morphologies or compositional state.
Overall the DOPA concentration was generally higher in the neither plaques, the morphology of the
plaque may play a role in the concentration of protein carbonyls in the neither and thrombosed
plaques, TBARS concentration only differed across the Y shaped plaques, dityrosine was higher in
the Y shaped plaques and the morphological shape may be influential on α-tocopherol
concentration.
3.1.8.5 Interaction between symptom presented and overall morphology
Of the 11 patients (femoral plaque patient was excluded), four had strokes, four had transient
ischemic attacks (TIA), two had amaurosis fugax (AF), and one patient was asymptomatic. The
morphology of the plaque may have an influence on the symptoms suffered because the AF
inducing plaques were both Y shaped and the stroke inducing plaques all had a small secondary
branch. TIA inducing plaques were represented by all three different morphological shapes. In
terms of the markers it was found that the Y shaped plaques generally had higher concentrations.
Protein, α-tocopherol and protein carbonyl levels were statistically the same within the plaques
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Figure 3.1.19 Interactions of overall composition and overall morphology of plaques in the
concentration of the inflammatory and oxidative markers between plaques A-N
Plaques A-N were classified by composition as either calcified (n=5), thrombosed (thromb) (n=5)
or neither (n=3) as well overall morphology as either Y shaped ( ) (n=4), small secondary branch
(■) (n=5) or linear (○) (n=4). Factorial-ANOVA was performed on the data (as described in section
2.3) to identify any interactions towards protein (a), cholesterol (b), neopterin (c), α-tocopherol (d),
TBARS (e), protein carbonyls (f), DOPA (g) and dityrosine (g) concentrations. Displayed are the
LS means and vertical bars represent 95% confidence intervals. For neopterin only plaques A-E and
K-N were analysed. Significant differences represented P<0.05*, P<0.01**, P<0.001*** to all other
points, except dityrosine top three points significant to all but each other.
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associated with stroke and TIA events and again within the AF and asymptomatic plaques where
the AF and asymptomatic groups had significantly higher levels than the stroke and AF groups.
This was not the case for the other markers.
Following the above mentioned trend the protein concentration was higher in the plaques that
induced AF and asymptomatic events (Figure 3.1.20a). The cholesterol appeared to be influenced
by the morphology of the plaque where the small branched plaques had the highest level of
cholesterol, the linear plaques the lowest and the Y shaped plaques in between (Figure 3.1.20b).
Due to the smaller sample size for neopterin analysis (N=9) the neopterin only differed between the
plaques that induced TIA and AF events which are both Y shaped plaques. Otherwise the neopterin
was consistent between the symptoms (Figure 3.1.20c). The antioxidant α-tocopherol followed the
same trend as protein with high levels in the TIA and asymptomatic plaques (Figure 3.1.20d). To
some extent the protein carbonyl concentrations also followed this trend where the highest levels of
protein carbonyls occurred in the AF and asymptomatic plaques (Figure 3.1.20f). The dityrosine
had the highest levels in the AF plaques compared to the linear and small branched inducing TIA
plaques (Figure 3.1.20h). TBARS and DOPA showed no variation within the markers when the
morphology and symptoms suffered were taken into consideration (Figure 3.1.20e,g).
The small branched plaques showed no difference when categorised as either stroke or TIA
inducing plauques, except with dityrosine (Figure 3.1.20h). The Y shaped plaques again showed no
difference in the concentration of markers between the TIA and AF inducing plaques. This was true
except for neopterin and dityrosine, where the TIA inducing plaques had higher neopterin and the
AF inducing had higher dityrosine. The linear plaques differed only in the protein, α-tocopherol and
protein carbonyls concentrations which were higher in the asymptomatic plaque compared to the
plaques that induced TIA events.
Overall, the trends observed indicate that the concentration of the protein, α-tocopherol and protein
carbonyls had a correlation with the symptoms suffered. When the plaques were further categorised
to the morphology of the plaque the symptoms suffered did not have a role in the concentration of
the markers. The major exception to that was dityrosine and protein (Figure 3.1.20a,h).
Results 78
Figure 3.1.20 Interactions between symptoms presented and plaque morphology to the
variation of inflammatory and oxidative marker concentrations between plaques C-N
Plaques A-N induced either stroke (n=4), transient ischemic attack (TIA) (n=4), amaurosis fugax
(AF) (n=2) events or were asymptomatic (asym) (n=1). Plaques were either Y shaped ( ) (n=4),
small secondary branch (■) (n=5) or linear (○) (n=2) in morphology. Factorial-ANOVA was
performed on data (as described in section 2.3) to identify any interactions in terms of protein (a),
cholesterol (b), neopterin (c) α-tocopherol (d), TBARS (e), protein carbonyls (f), DOPA (g), and
dityrosine (h) concentrations. Displayed are the LS means and vertical bars represent 95%
confidence intervals. For neopterin only plaques A-E and K-N were analysed. Significant
differences represented by P<0.05*, P<0.01** and P<0.001***
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3.1.8.6 Interaction between patient medication and symptom presented
All patients have been on medication for a relatively long period (excluding the asymptomatic
patient). Aspirin is taken as an anti-inflammatory and statin as a lipid lowering drug (Chapman et
al. 2007). Therefore the combination of these drugs may influence the processes occurring within
the plaque feeding on the plaque morphology and possibly the symptoms the patient may later
present. Therefore a factorial-ANOVA was performed to see if the drug combination and symptoms
presented by the patient could explain some of the variations between these plaques.
In the four patients on aspirin alone, the AF plaques had higher protein, α-tocopherol and TBARS
content (Figure 3.1.21). The TIA plaques had lower cholesterol and higher neopterin, and the stroke
suffers had lower cholesterol, neopterin and dityrosine. This was similar for the six patients on both
aspirin and statins, the AF suffers have higher α-tocopherol and protein carbonyls. The TIA suffers
had lower TBARS and dityrosine and the stroke suffers had no significant variation between the
markers.
In other words, the stroke inducing plaques exposed to both aspirin and statins have higher
cholesterol, dityrosine and DOPA, than the aspirin alone exposed plaques. The TIA plaques had no
significant difference between medication treatments. The AF plaques differ in that the statin and
aspirin exposed plaques had higher neopterin and lower TBARS compared to the aspirin alone
exposed plaque which had the opposite relationship.
3.1.8.7 Combined plaque analysis summary
In this analysis the zoning and overall composition of the plaques were the strongest predictors of
the variation in marker concentration across and between the plaques respectively. When two
factors were considered in combination the trends, if any, were weak possibly due to the small
sample size. In the overall composition and morphology analysis both factors only appeared to
affect the concentration of cholesterol in the linear calcified plaques, dityrosine within the neither Y
shaped and linear thrombosed plaques, the protein carbonyls in the small branched thrombosed
plaques and the α-tocopherol in the linear thrombosed plaques. In the symptoms and morphology
analysis there were no distinct variations between the plaques. In the symptoms and medication
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Figure 3.1.21 Interactions of symptoms presented and medication in the variation of the
inflammatory and oxidative marker concentrations between plaques C-N
Symptoms induced by plaques A-N were either stroke (n=4), transient ischemic attack (TIA) (n=4),
amaurosis fugax (AF) (n=2) or asymptomatic (n=1). Medication included aspirins only (▲) (n=4) 
statins and aspirin (○) (n=6) or neither () (n=1). Factorial-ANOVA was performed data (as
described in section 2.3) to identify any interactions based on the concentration of protein (a),
cholesterol (b), neopterin (c) α-tocopherol (d), TBARS (e), protein carbonyls (f), DOPA (g), and
dityrosine (h). Display are the LS means and vertical bars represent 95 % confidence intervals. For
neopterin analysis only plaques A-E and K-N were included. Significant differences represented by
P<0.05*, P<0.01** and P<0.001***
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analysis these factors combined only affected the concentration of protein within the aspirin alone
AF plaque, the neopterin aspirin alone TIA plaques and the DOPA and dityrosine in the aspirin
alone stroke plaque. Many of these categories represent one to two plaques therefore other factors
that influence each particular plaque may influence the variation observed and not observed within
these analyses.
3.2 Investigating assays and additional markers for detection within
atherosclerotic plaques
3.2.1 Neopterin and 7,8-dihydroneopterin assay
The pterin assay was recently improved by using acetonitrile for the induction of protein precipitate
within samples compared to trichloroacetic acid (Flavall et al., 2008). The change in solvent allows
a greater detection of neopterin within both plasma and plaque. The pterin assay is able to quantify
both neopterin and 7,8-dihydroneopterin (7,8-NP). 7,8-NP itself has little to no fluorescence
therefore it is quantified by it’s oxidation to neopterin (section 2.2.4 A), creating a total neopterin
concentration. The 7,8-NP is calculated by subtracting the neopterin concentration from the total
neopterin level. Within plaque samples there was no significant difference between the
concentration of neopterin compared to total neopterin, indicating there is no 7,8-NP present in the
plaques. 7,8-NP is quite labile therefore to ensure this was an accurate result and not due to loss of
7,8-NP during preparation, the acidic iodide, pH levels and presence of endogenous free iron were
investigated. It was already established within our laboratory that the ascorbate was not interfering
with the detection of the total neopterin.
The oxidation of 7,8-NP to neopterin is induced by the IO3- in the acidic iodide solution (5.4% I2,
10.8% KI in 1 M HCl). To determine if the molarity of the HCl in the acidic iodide solution was
affecting the ability to detect 7,8-NP, the concentration of HCl in the acidic iodide was altered to
non-acidic (no HCl) and 0.5 M. The concentration of neopterin in healthy plasma was 25.4 ± 2.1
nM and using the non-acidic iodide the total neopterin was significantly high (P<0.05) detecting
7,8-NP at a concentration of 10.1 ± 2.3 nM (Figure 3.2.1 a). The concentrations and ratio of
neopterin to 7,8-NP agrees with previously reported levels in healthy plasma (Flavall et al. 2008)
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Figure 3.2.1 Effect of HCl molarity in acidic iodide solutions on the detection of 7,8-
dihydroneopterin within plasma and plaque
The concentration of neopterin (NP) and total neopterin (TN) in plasma (a) and plaque (b) treated
with different acidic iodide solution. Each bar represents the mean ± SEM of duplicate samples.
Figure 3.2.2 Effect acidic iodide pH on the ability to detect 7,8-dihydroneopterin spikes in
plasma and plaque
Neopterin (NP), total neopterin (TN) and 7,8-dihydroneopterin (7,8-NP) concentrations were
measured in plasma and plaque E. Spiked samples contained an additional 20 nM 7,8-NP. Each bar
represents mean ± SEM of duplicate samples.
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The total neopterin values from the 0.5 M and 1 M HCl acidic iodide solutions were statistically the
same as neopterin, detecting 7,8-NP concentrations at 3.4 ± 2.3 nM and 4.4 ± 2.6 nM respectively.
Plaque F neopterin levels were the same as previously determined (Figure 3.2.1 b) (section 3.1.6),
and the neopterin versus total neopterin concentrations for all acidic iodide treatments were
statistically the same. This suggests that the molarity of HCl in the acidic iodide solutions tested
were not responsible for the lack of 7,8-NP detected within the plaques.
The molarity of HCl had an effect on the plasma measurements, but not on the plaque, therefore the
pH of the acidic iodide was investigated. The pH values were adjusted to an alkaline pH range ~8,
slightly acidic pH range ~4 and acidic iodide pH<1. To ensure there was 7,8-NP present within the
plasma and plaque to detect the samples were spiked with 20 nM 7,8-NP. Within plasma 91.1% and
82.7% of the 20 nM 7,8-NP spike was returned after treatment with the pH~8 and pH~4 iodide
solutions respectively (Figure 3.2.2a). The pH<1 acidic iodide solution only returned 16.5% of the
20 nM 7,8-NP spike from plasma. Within the plaque all three acidic iodides failed to detect the 7,8-
NP spike.
Plaques are considered a highly oxidative environment (Smith et al., 1992), and a component within
the plaque that maybe facilitate this is the presence of free iron at high concentrations. The iron
maybe able to convert the 7,8-NP to 7,8-dihydroxanthopterin via Fenton reactions (section 1.2).
This would underestimate the true concentration of 7,8-NP within the sample. To remove the iron
an iron chelator, deferoxamine was added to 7,8-NP spiked plaque samples above a concentration
reported to almost completely inhibit deoxyribose degradation in the presence of plaque gruel
(Smith et al., 1992).
The concentration of neopterin and total neopterin in plaque F was the same in the absence and
presence of 200 μM DFO, indicating that the DFO was not interfering with the neopterin detection
or concentration (Figure 3.2.3). To ensure there was sufficient 7,8-NP present within the plaque to
detect, the samples were spiked with 11 μM 7,8-NP. Because 1-2 μM was detected with plaques
this was considered a more physiologically relevant concentration compared to the 20 nM 7,8-NP
spike in the previous experiment. The neopterin concentration within the 7,8-NP spike samples was
double that of neopterin in the control samples because 7,8-NP has a low level of fluorescence
(Figure 3.2.3). Within the 7,8-NP spiked samples the acidic iodide (1 M HCl), returned 51% of the
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Figure 3.2.3 Effect of deferoxamine on the ability to detect neopterin and 7,8-dihyroneopterin
in plaque samples
Neopterin (NP) and total neopterin (TN) concentrations were measured in plaque F samples in the
presence or absence of 200 μM deferoxamine and/or 11 μM 7,8-NP. Each bar represents mean ±
SEM of triplicate samples.
added 7,8-NP. Within the DFO and spiked treated samples 69.2% of the 7,8-NP was detected. This
was a significant increase however it is still underestimating the concentration of 7,8-NP spiked
within the plaque homogenate.
3.2.2 Simultaneous quantification of 7-ketocholesterol and α-tocopherol
The oxysterol 7-ketocholesterol (7-KC) is one of the three oxysterols detected in oxLDL and plaque
that is known to exert cytotoxic properties, along with 25- and 27-hydroxyl cholesterols (Stocker
and Keaney, 2004). OxLDL is cytotoxic to cells and our laboratory has found that different batches
of oxLDL induce variable LD50 towards U-937 cells and human monocyte derived macrophages.
The concentration of 7-KC in oxLDL may have an influential role in determining the potency and
therefore the toxicity towards these cells. Because 7-KC is cytotoxic to vascular cells (Larsson et
al., 2006) it may play a role in the death of macrophages, SMC and endothelial cells within the
plaque. Future work on plaques will include the measurement of 7-KC within the sections. This will
provide information on its quantity and spatial localisation across the plaques therefore possible
interactions with lipid hydroperoxides, protein oxidation, α-tocopherol and neopterin.
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The original method (Kritharides et al., 1993) was modified within our laboratory for the
determination of conjugated ester dienes in combination with α-tocopherol in human plasma
exposed to peroxyl radicals (Osborn, 2006). Here the same method was applied for the detection of
7-KC and α-tocopherol. An advantage to this assay is it simultaneously determines the
concentration of 7-KC and α-tocopherol (section 2.2.5B) therefore may replace the original α-
tocopherol assay for plaque analysis (section 2.2.4B), and at the same time provide additional
information on the occurrence of lipid oxidation therefore reducing the amount of sample required
for analysis.
The 7-ketocholesterol (7-KC) content measured within LDL (Figure 3.2.4) is in agreement with
concentrations reported by Steffen et al. (2006) and Chang et al. (1997) (Table 3.2.1). The 7-KC
Figure 3.2.4 7-Ketocholesterol and α-tocopherol content in LDL and oxLDL
The 7-ketocholesterol (a) and α-tocopherol (b) were measured by the 7-KC method in 1 mg/mL of
LDL and oxLDL prepared from the same batch. Each bar represents the mean ± SEM of triplicate
samples.
Table 3.2.1 7-Ketocholesterol content in LDL and copper mediated oxidised LDL
LDL
(μmole/g LDL)
Cu2+ incubation
time (hours)
oxLDL
(μmole/g LDL) Reference
2.68 ± 1.01 24 18.00 ± 1.02 This study
2.37 ± 1.26* 3.33 35.14 ± 5.29* Steffen et al. (2006)
2.93 ± 0.59§ 3.33 15.4 ± 2.20§ Chang et al. (1997)
* Values calculated based on 31.64% of LDL is cholesterol (Esterbauer et al., 1992)
§ Values calculated based on 22% of LDL is protein (Esterbauer et al., 1992) and oxLDL measurement read off graph
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Figure 3.2.5 7-Ketocholesterol content within plaque E determined by the 7-ketocholesterol/α-
tocopherol assay
The 7-ketocholesterol concentration per gram of plaque (a) and per mole of cholesterol (b) were
measured by reverse phase-HPLC with a mobile phase of 54 isopropanol: 44 acetonitrile: 2 water.
The dotted bar represents the pre-bifurcation zone, the solid bars represent the bifurcation zone and
the stripped bars represents the pos-bifurcation zone. Each bar represents the mean ± SEM of
triplicate samples.
concentration increased 7-fold after 24 hours incubation with copper ions (Figure 3.2.4a). The 7-
KC concentration was in the same magnitude as reported by Steffen et al. (2006) and Chang et al.
(1997). As was expected and previously reported (Esterbauer et al. 1992) the α-tocopherol content
declined from 11.2 ± 0.047 μmole/g of LDL to almost zero within the oxLDL after incubation with
copper (Figure 3.2.4b). The 7-KC concentration within plaque F was 136.7 ± 11.5 nmole/g of
plaque. Within plaque E the average 7-KC concentration was 138.4 ± 54.8 nmole/g of plaque, with
the maximum level detected within section 5, a post bifurcation section (P<0.01) (Figure 3.2.5).
Comparing the α-tocopherol concentration in plaque E detected by the original α-tocopherol and the
7-KC/α-tocopherol method (Figure 3.2.6), the concentrations in each corresponding section were on
average 53% lower using the 7-KC/α-tocopherol method. Correlation between the two methods
produced a linear regression value of r2=0.9183 (Figure 3.2.6c) therefore the trend across the plaque
for both methods is highly similar. This suggests a problem with the α-tocopherol solubility in the
7-KC/α-tocopherol mobile phase.
The 7-KC/α-tocopherol mobile phase consisted of 54 isopropanol: 44 acetonitrile: 2 water therefore
had a polar solvent component compared to methanol, a non-polar mobile phase used for the
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Figure 3.2.6 Comparison between the original α-tocopherol and the 7-ketocholesterol/α-
tocopherol assay in the determination of α-tocopherol content within plaque E
The α-tocopherol content determined by the original α-tocopherol (a) and the 7-ketocholesterol/α-
tocopherol (b) methods within plaque E, and the correlation between the two methods (c). The
dotted filled bar represents the bifurcation, solid filled the bifurcation and the stripped bars the post-
bifurcation zone. Each bar represents the mean ± SEM of triplicate samples.
original α-tocopherol assay. To investigate this further the mobile phase was modified to a ratio of
50 isopropanol: 50 acetonitrile. For the sample preparation the original α- tocopherol method was
followed up to the point of re-solubilising the residue in the appropriate mobile phase. The α-
tocopherol concentration across the plaque was significantly higher with the 7-KC/α-tocopherol
method using the 50 isopropanol: 50 acetonitrile mobile phase compared to the original α-
tocopherol method (Figure 3.2.7a). The correlation between the two methods gave a linear
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Figure 3.2.7 7-Ketocholesterol and α-tocopherol content within plaque E analysed using the
50 isopropanol: 50 acetonitrile mobile phase
7-Ketocholesterol (a) and α-tocopherol (b) content was determined using the modified 7-KC
method. The mobile phase consisted of 50 isopropanol: 50 acetonitrile. The dotted bar represents
the pre-bifurcation zone, the solid bars represent the bifurcation zone and the stripped bars
represents the pos-bifurcation zone. Each bar represents the mean ± SEM of triplicate samples.
regression of r2=0.8909 (graph not shown), again indicating the trend across the plaque was highly
similar to the concentration detected with the original α-tocopherol method (Figure 3.2.6a).
Opposite to α-tocopherol, the 7-KC levels detected using the 54 isopropanol: 44 acetonitrile: 2
water mobile phase compared to the 50 isopropanol: 50 acetonitrile mobile phase was significantly
higher in the former mobile phase (Figure 3.2.7b). Furthermore, the error bars for the 7-
ketocholesterol in both mobile phases were large (Figure 3.2.5a and 3.2.7b). This suggests a
solubility issue for both α-tocopherol and 7-KC in the mobile phases.
3.2.3 Investigating the detection of AAS and GGS; a candidate for the
replacement of the protein carbonyl assay
Currently our laboratory uses the well established 4-dinitrophenylhydrazine (DNPH) method for the
detection of protein carbonyls (section 2.2.6 B). Using the DNPH method on plaque homogenate, a
complex biological fluid, the standard errors within the triplicates are large, which may be masking
any statistical differences in plaque sections within and between the plaques. For this reason a more
accurate and reliable assay for protein carbonyls was investigated.
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Figure 3.2.8 Derivatisation of the two main carbonyl oxidation products AAS and GGS
AAS and GGS putatively formed from free radical damage are reduced by sodium
cyanoborohydride (NaCNBH3) and conjugated to ABA. The derviatised protein undergoes acid
hydrolysis to release the conjugates from the protein backbone and detected by reverse phase
HPLC. Figure from Akagawa et al. (2006).
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Figure 3.2.9 HPLC chromatagrams of AAS and GGS from BSA incubated with AAPH
2 mg/mL of BSA was incubated with 10 mM AAPH at 37º C and analysed using the modified
HPLC method for the detection of AAS and GGS after zero hours (a) and 24 hours (b) incubation
with AAPH. Peak one elutes within the 4th minute, peak two at the end of the 5th minute, peak three
at the beginning of the 7th minute and peak four at the 10th minute.
a) b)
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Recently Akagawa et al. (2006) have developed a method which measures the two main oxidative
products formed from protein carbonylation reactions via a highly sensitive HPLC method. This
method detects the two main carbonyls derivatives α-aminoadipic semialdehyde (AAS) derived
from lysine residues and γ-glutamic semialdehyde (GGS) derived from proline and arginine
residues (Figure 3.2.8). To quantifiably detect AAS and GGS they are first converted to their
corresponding hydroxyl amino acid using the mildly reducing agent sodium cyanoborohydride,
before conjugating to the highly fluorescent aminobenzoic acid (ABA). Because ABA will react
with any carbonyl moiety the oxidative products are retained within the protein backbone to avoid
the derivatisation of the peptide skeletal carbonyls. The samples then undergo acid hydrolysis
allowing the release of the AAS-ABA and GGS-ABA conjugates from the protein backbone. AAS-
ABA and GGS-ABA are then separated via reverse phase HPLC and detected at an extinction and
emission wavelengths of 283 and 350 nm respectively. Because these carbonyl moieties react with
ABA in a one to one ratio the concentration of the AAS and GGS are quantified against a known
concentration of ABA.
The assay was first investigated on a pure protein system, bovine serum albumin (BSA), and the
AAS and GGS formation induced by the free radical initiator 2,2-azobis (2-aminopropane)
dihydrochloride (AAPH). The chromatograms constantly produced four peaks with relatively
consistent retention times of 4.5, 5.8-5.9, 7.0-7.1 and 10.1-10.6 minutes (Figure 3.2.9). Residual
ABA elutes around the 7th minute, confirmed by injecting a pure sample of ABA onto the HPLC
system.
Taking into consideration the physical properties of AAS and GGS and as well as the properties of
the HPLC column, the GGS-ABA is expected to elute first. It is highly unlikely that the first peak is
either AAS-ABA or GGS-ABA, because even though the peak areas do vary across treatments they
do not increase in relation to increased exposure time to AAPH nor with increased BSA
concentration (data not shown). This leaves the second peak to be the GGS-ABA compound and the
fourth peak to be AAS-ABA.
In BSA exposed to peroxyl radicals, the concentration of AAS and GGS increased 208 fold and 38
fold respectively over the 24 hour incubation period (Figure 3.2.10). The AAS concentration had
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Figure 3.2.10 Concentration of AAS, GGS, protein carbonyls and protein hydroperoxides in
BSA incubated with AAPH
2 mg/mL BSA was incubated with 10 mM AAPH at 37C and aliquots taken at the specified times
and analysed for protein carbonyls ( ) by the DNPH method, the protein hydroperoxides (*) via the
FOX assay and AAS (■) and GGS (●) by the modified HPLC method. Data was corrected against 
its corresponding zero time point and each time point represents mean ± SEM of triplicate samples.
significantly increased from the basal level by three hours (P<0.001) and the GGS had significantly
increased after six hours (P<0.01) (Figure 3.2.10).
The modified HPLC carbonyl assay was compared to other protein oxidation methods including the
FOX and the DNPH protein carbonyls assay on BSA (Figure 3.2.10). The FOX assay determines
the concentration of PrOOH a protein modification similar to protein carbonyls (see section 3.3). In
agreement with a previous study the basal levels of GGS were higher than AAS in BSA (Requena
et al., 2001) with a concentration of 71.0 ± 6.8 and 54.7 ± 5.7 nmole/g protein respectively. The
concentration of AAS, GGS and protein carbonyls had increased linearly after 24 hours incubation
with AAPH (Figure 3.2.10). Initially the PrOOH had a faster rate of formation before slowing down
after six hours. At time zero the AAS and GGS accounted for 6% of the protein carbonyls. This
basal level was lower than Akagawa et al. (2006) reported at 23% and even lower than the 88%
detected by Requena et al. (2001). With iron catalysed oxidation of BSA the AAS and GGS
concentration increased, however the proportion of AAS and GGS to total protein carbonyls
decreased from 88% to 51% (Requena et al. 2001). In this study after 24 hours exposure to peroxyl
radicals 86% of the protein carbonyls was attributed to AAS and GGS. Between the protein
carbonyls and AAS and GGS the linear regression was r2=0.9822 and 0.9841 respectively. This
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indicates that the rate of formation of AAS and GGS has a high agreement to the formation of the
total protein carbonyls formed on BSA supporting that AAS and GGS are the two main protein
carbonyl products. The linear regression between AAS and GGS was r2=0.9990 also supporting that
these two carbonyl derivatives form via similar kinetics.
The assay was also investigated on a biological system, human plasma. Small endogenous
antioxidants were removed from the plasma by dialysis to increase the AAPH induced oxidation of
the proteins (see section 3.3). After 12 hours both AAS and GGS increased by 126 nmole/g of
protein a 9 and 4 fold increase of AAS and GGS respectively relative to the basal levels (Figure
3.2.11a,b).
Within plasma the rates of formation of AAS, GGS and PrOOH (Figure 3.2.11) were similar to that
of BSA. The PrOOH concentration increased over the time period but displayed different rates of
formation compared to AAS and GGS. The PrOOH concentration increased at a faster rate than
AAS and GGS before starting to plateau after eight hours (Figure 3.2.11c). Opposite to this the
AAS and GGS initially formed at a slower rate until the eight hour time point before increasing the
rate of formation between eight and ten hours (Figure 3.2.11a,b).
Further comparisons were made between the DNPH method and the modified HPLC method on the
whole plaque homogenate of plaque F (section 3.1.6). The AAS and GGS attributed to 42% of the
protein carbonyls detected by the DNPH method (Table 3.2.2). This indicates that a large
proportion of protein carbonyls are not one of these two semialdehydes. The standard error of the
mean for protein carbonyls was 25 % of the mean value and for AAS and GGS it was 4 and 3%
respectively. This is a considerable improvement to the error rate for the measurement of protein
oxidation within this plaque.
Table 3.2.2 Protein carbonyl, AAS and GGS content in plaque F
nmole/g protein*
Protein carbonyls 2791 ± 713
AAS 950 ± 41
GGS 225 ± 6
* mean ± SEM of triplicate samples
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Figure 3.2.11 AAS, GGS and protein hydroperoxide formation in dialysed plasma incubated
with AAPH
Dialysed plasma was incubated with AAPH at 37ºC (filled symbols) and without AAPH (open
symbols) and aliquots were removed at specified time points and analysed for AAS (a) and GGS (b)
by the modified HPLC method and protein hydroperoxide (PrOOH) (c) by the acetic acid FOX
assay. Each data point was corrected against its corresponding zero time point. For AAS and GGS
each point represents the mean ± SEM of duplicate samples and PrOOH triplicate samples.
3.2.4 Investigation of protein oxidation in human plasma
Protein oxidation is a key oxidative process within plaques and is linked to the oxidation of lipids
and cell mediated death. To better understand the process and components involved in protein
oxidation within the plaque, oxidation of plasma was investigated. Many of the antioxidants within
plasma have been reported within plaque (Frei et al., 1988; Stocker and Keaney, 2004). Therefore,
by investigating the mechanism and kinetics of protein hydroperoxidation formation within plasma
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and the relationship of antioxidants to protein oxidation may provide a platform to elucidating the
mechanisms involved in protein oxidation occurring within plaques.
Human plasma contains many antioxidants providing a defence against oxidative stress. These
antioxidants include ascorbic acid, α-tocopherol, uric acid, bilirubin, albumin and protein thiols
which are capable of scavenging the oxidants or breaking the chain to oxidative damage formation
(Frei et al., 1988).
Under thermal decomposition AAPH forms peroxyl radicals and in the presence of BSA, a pure
protein system, induces the formation of protein hydroperoxides (PrOOH) at an immediate and
rapid rate (Figure 3.2.12). Human plasma exposed to peroxyl radicals produced a lag phase period
before any significant protein hydroxide formation began (Figure 3.2.13a). A previous study (Yang,
2005) hypothesised that was due to protein thiol protective mechanism as the concentration of
protein thiols reduced to almost zero before any significant PrOOH formation began. When plasma
was dialysed it removed small molecular weight antioxidants and consequently when dialysed
plasma was incubated with peroxyl radicals the lag phase was abolished (Figure 3.2.13b). In the
Figure 3.2.12 Protein hydroperoxide formation in BSA incubated with AAPH
2 mg/mL BSA was incubated with (▲) and without (□) 10 mM AAPH at 37ºC. Aliquots were
taken at specified time points and PrOOH measured via the acetic acid FOX assay. Data was
corrected against its corresponding zero time points and represents the mean ± SEM of triplicate
samples.
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Figure 3.2.13 Protein hydroperoxide formation in plasma incubated with AAPH
Whole plasma (a) and dialysed plasma (b) where incubated with (▲) and without (□) 10 mM 
AAPH at 37ºC. Aliquots were taken at specified time points and analysed for PrOOH concentration
using the acetic acid FOX assay. Data was corrected against its corresponding zero time point and
represents the mean ± SEM of triplicate samples.
Figure 3.2.14 Protein hydroperoxide formation within dialysed plasma incubated with AAPH
Dialysed plasma was incubated with 10 mM AAPH at 37º C for 24 hours. Aliquots were taken at
specified time points and PrOOH concentration determined by acetic acid FOX assay. Data was
collated from two experiments, experiment a (solid black line) and experiment b (dashed black
line). The grey solids line were times of rapid PrOOH formation and dashed grey stationary PrOOH
concentration. Data was corrected against its corresponding zero time point and represents the mean
± SEM of triplicate samples.
a) b)
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dialysed plasma the protein thiol concentration and rate of loss was similar to the whole plasma
indicating that the protein thiols are not responsible for this lag phase. The previous studies (Ling,
2003; Osborn, 2006; Yang, 2005) have found that a combination of uric acid, ascorbic acid and α-
tocopherol are responsible for the initial lag phase (as seen in Figure 3.2.13a), as dialysed plasma
supplement with physiological concentrations of uric and ascorbic acid re-establishes the lag phase
observed within whole plasma.
Yang (2005) also identified a second lag phase occurring within dialysed plasma after 10-12 hours
incubation with AAPH. Measuring the accumulation of PrOOH in dialysed plasma in two hour
increments over 24 hours the initial lag phase was abolished as before and a second lag phase
occurred beginning at eight hours and continuing until 16 hours (Figure 3.2.14), confirming the
presence of the latter lag phase. The PrOOH formation began at a rate of 6.1 μmole/hour between
zero and eight hours, plateauing between eight and 16 hours with a rate of 0.9 μmole/hour before
increasing to a rate of 4.8 μmole/hour. Because the plasma was dialysed it suggested the latter lag
phase was due to the scavenging of high molecular weight protein/s, hypothesised to be either
albumin or apolipoprotein. If these proteins were providing a protective effect then on a gel
electrophoresis the intensity and/or position of the corresponding band would change with
increasing exposure to AAPH. In plasma incubated without AAPH and at the zero time points of
the plasma with AAPH, two bands are evident between the 45 and 36 kDa markers (Figure 3.2.15)
After four hours incubation the low sharper band of the two had disappeared or merged with the
other higher molecular weight band (Figure 3.2.15). This indicates that the alteration to this protein
was occurred early before the second lag phase and therefore most likely not associated with the
second lag phase. Apolipoprotein B has a molecular weight of ~515 kDa larger than the gel can
separate. There was no change to the level of human serum albumin (~71 kDa).
Results 97
Figur
Dialys
taken
with a
hours
hours
hours
top to
top to
a) b)
Lanes 1 2 3 4 5 6 7 8 9 10
Time
point
1 2 3 4 5 6 7 8 9e 3.2.15 Gel electrophoresis of dialysed plasma i
ed plasma was incubated with (a) and without (b
at specified time points and applied to gel electro
high range marker, lane 2 after zero hours incubat
(experiment b), lane 4 four hours (experiment a),
(experiment a), lane 7 12 hours (experiment b),
(experiment b) and in the gel (a) lane 10 was a lo
bottom 205, 116, 97, 84, 66, 55, 45, 36, 29, 24 and
bottom 117, 85, 49, 34, 25 and 19 kDa.
0 0 4 8 12 12 18 24nc
) 1
ph
io
lan
la
w
2ubated with and without AAPH
0 mM AAPH at 37ºC and aliquots were
oresis. For both gels, lane 1 was loaded
n with AAPH (experiment a), lane 3 zero
e 5 eight hours (experiment a), lane 6 12
ne 8 18 hours (experiment b), lane 9 24
range ladder. High range band sizes from
0 kDa bands. Low range band sizes from
0 0 4 8 12 12 18 24
Discussion 98
Discussion
Cardiovascular disease, including atherosclerosis, is the major cause of morbidity and mortality
within the developed world (Danilevicius et al., 2007; Helderman et al., 2007). There is no doubt
that atherosclerotic plaque formation is a complex process involving multiple mechanisms. In the
beginning of the plaque project it was hypothesised these plaques would have similar overall
concentration of the markers as well as a similar spatial variation across the plaques. However, this
is not the case. Evident through this study advanced atherosclerotic plaques are diverse in their
biochemical composition. The plaques analysed have conclusively shown a lack of consistent
correlations across the plaques (Table 3.1.7). For example only a significant correlation between α-
tocopherol and cholesterol occurred twice within individual plaques (Plaques C and E). A variation
in oxidative and inflammatory marker concentration was also observed in the overall concentrations
between the plaques (Table I,II). For example the average overall cholesterol content within plaque
F was 14 fold higher than within plaque B and the average overall dityrosine content within plaque
J was 232 fold higher than in plaque A. Therefore the factors responsible for the concentration and
spatial localisation of the markers measured within these plaques may be influenced by different
mechanisms and/or combination of these mechanisms. If this holds true then these different factors
which maybe influencing the initiation and progression of these plaques may also be driving
different degrees and type of this disease as seen within the advanced state atherosclerotic plaques
in this study.
Yet several significant correlations emerged between the markers within the combined plaque
analysis that was not observed within individual plaques (Table 3.1.7). Furthermore the analysis
between plaques zones (Figure 3.1.17) and between different overall plaque compositions (Figure
3.1.18) shows the concentration of the oxidative and inflammatory markers across and between the
plaques have significant trends. These significant trends and correlations may exist because of the
occurrence of common mechanism and/or influences on the concentration of the oxidative and
inflammatory markers within the plaques. This suggests that even though the plaques individually
are all different in their biochemical composition, there are potentially common features like that of
zoning associated with shear stress and the overall plaque composition that have an influential role
in the concentration of these markers within and across the plaques.
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4.1 Comparison of the marker concentrations within atherosclerotic
plaques to published literature
Except for neopterin, all of the markers quantified within this study have previously been quantified
within atherosclerotic plaques (Adachi et al., 2007; Carpenter et al., 1995; Fu et al., 1998; Li et al.,
2006; Nishi et al., 2002; Suarna et al., 1995). Despite the plaques having varied average
concentrations of oxidative and inflammatory markers between the plaques, the majority of the
overall average concentration of these markers within the plaques (Table I,II) agree with
concentrations that have previously been measured.
This laboratory was the first to quantify the level of neopterin within both carotid and femoral
plaques via HPLC (Firth et al., 2008; Gieseg et al., 2008a). At the same time neopterin was detected
in coronary plaques via immunohistochemical staining in conjunction with SMC, macrophages, T
cells and neutrophils, but its concentration was not quantified (Adachi et al., 2007). Our study
showed the highest average concentration of neopterin detected within a plaque was 2.34 μM
(Table I). Within this study the overall average concentration of α-tocopherol within 14 plaques was
112.41 ± 10.09 nmole/g plaque. In agreement with this, Carpenter et al. (1995) determined an
average (± SD) α-tocopherol concentration of 156 ± 118 nmole/g tissue within 19 plaques. The α-
tocopherol level in this study, expressed as α-tocopherol per cholesterol, had an average
concentration of 2.49 ± 0.19 mmole/mole of total cholesterol. Suarna et al. (1995) detected an
average (± SD) concentration of 6.4 ± 4.8 mmole/mole of free cholesterol within 11 femoral and
carotid plaques. The α-tocopherol within this study was adjusted against the total cholesterol of the
plaques whereas Suarna et al., (1995) adjusted against the free cholesterol content of the intima.
Thus the α-tocopherol measurements within plaques determined by both Suarna et al. (1995) and
Carpenter et al. (1995) agree with this study.
In our study the overall average concentration of DOPA and dityrosine was 13.75 ± 1.43 and 4.41 ±
0.81 nmole/g plaque respectively. These measurements agree with previous DOPA and dityrosine
average values (± SD) measured in carotid plaques of 14.26 ± 3.80 and 4.75 ± 5.17 nmole/g of
plaque respectively (Fu et al., 1998). In conjunction with the highly oxidative environment of
plaques, the overall average protein carbonyl content (3.77 ± 0.47 μmole/g protein) was
considerably high compared to normal tissue (approximately 1 nmole/g protein) (Davies et al.,
1999). Via an ELISA method a protein carbonyl concentration of 21.1 μmole/g protein within the
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gruel of aortic and carotid plaques was detected (Li et al., 2006). Furthermore, within carotid
plaques a noticeably higher TBARS average (± SD) of 36.4 ± 4.2 nmole/g tissue has been reported
(Nishi et al., 2002), compared to the overall average TBARS concentration within this study at
14.32 ± 2.26 nmole/g plaque. Like that of the protein carbonyl measurements (Li et al., 2006), Nishi
et al. (2002) quantified the oxidative marker via a different method to this laboratory possibly
accounting for the discrepancies between the studies. The solvents within the butanol/absorption
method employed to quantify the lipid peroxides include highly volatile solvents which can cause
the overestimation of lipid peroxide content within the sample. However the femoral plaques A and
B had TBARS values within and above the range (Table II) published by Nishi et al. (2002).
4.2 Correlations between the marker concentrations across the
atherosclerotic plaques
Correlations between neopterin, α-tocopherol and the lipid and protein oxidative markers across the
plaques may provide insight into the interactions and influences the oxidative marker have on one
another, whether α-tocopherol exerts a anti- or pro- oxidant effect towards protein and lipid
oxidation and if the macrophage associated neopterin relates to the oxidative damage observed in
the plaques.
Protein and Cholesterol
It may be hypothesised that the variation of the spatial concentration of protein and cholesterol may
have a major influence of the concentration of the resulting oxidative product. Across the individual
and combined analysis this is not conclusively seen. The strongest trend occurs between α-
tocopherol and cholesterol concentration within individual plaques and combined data, as LDL is
the major source of α-tocopherol (Esterbauer et al., 1992). LDL may also be a major contributor to
the cholesterol content within plaques as LDL cholesterol is thought to be the main source of
cholesterol within macrophage foam cells (Kruth et al., 2002). In terms of TBARS formed from
PUFAs located predominantly within the LDL, the cholesterol level only significantly correlated to
TBARS content within one plaque where it also correlated with α-tocopherol concentration. Protein
is the substrate for protein carbonyls, DOPA and dityrosine yet the concentration of DOPA and
dityrosine only significantly correlated with protein content within one plaque. In the combined
plaque analysis, protein positively correlated to protein carbonyl content, the formation of which is
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non-specific. The specificity of DOPA and dityrosine may explain why correlations with protein
levels were only observed once within an individual plaque. This indicates that even though the
concentration of protein and cholesterol will play some role in the degree of oxidative damage,
other major influences are occurring. This includes the degree and nature of oxidative stress as well
as the availability of protein and cholesterol particles. Remodelling may also alter the location of
the protein, cholesterol and/or markers through the formation and degradation of the extracellular
matrix, the migration and proliferation of SMC, as well as cycles of thrombi formation and
subsequent healing. Another factor to consider is DOPA is not an end product as it can be involved
in further oxidation reactions (Dean et al., 1997; Fu et al., 1998) Therefore its formation and
detoxification will be dependent on these factors in combination with the protein concentration.
This is why caution is required when interrupting DOPA results.
Neopterin
Within the combined data, neopterin and protein concentrations have a strong positive relationship.
This correlation was seen within one of the two individual heavily calcified plaques (Plaque A), but
not the other possibly due to its size (Plaque B). Flavall (2008) also reported this significant
correlation within heavily calcified plaques. A possible reason why this relationship was not seen
within the thrombosed plaques is because the higher concentrations of protein introduced by the
presence of a thrombus may alter the spatial variation of protein across the plaques. The presence of
the calcified deposits predominantly within the middle sections of plaques will have a pronounced
effect on the mass of the section. This will decrease the concentration of the neopterin and protein
per gram of tissue within these sections. Within a type II-like alveolar epithelial cell line neopterin
at physiologically relevant plaque concentrations inhibited ATP mediated increase in intracellular
calcium (Hoffmann et al., 2002). Alternatively neopterin and 7,8-NP both increased the intracellular
calcium in human monocyte line cells putatively for the activation of the monocytes (Woll et al.,
1993). Therefore along with oxLDL and lipid accumulation (Tang et al., 2006) neopterin may have
a role in the process of cellular mineralisation.
7,8-NP could not be detected within these plaques, yet as 7,8-NP is the only known precursor to
neopterin, 7,8-NP must have been present within the plaques at some point. Subsequent loss of 7,8-
NP appears to occur by its conversion to either neopterin or its other byproduct 7,8-
dihydroxanthopterin (Figure 1.6). The micromolar concentration of neopterin suggests that 7,8-NP
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present within particular microlocations across the plaque could reach low to mid micromolar
concentrations of 7,8-NP, especially within the peripheral regions of the plaque. This is plausible
because within coronary plaques the majority of neopterin was associated with macrophages and
these cells were significantly correlated towards MPO associated neutrophils (Adachi et al., 2007).
Therefore the hypochlorous acid produced from the MPO could convert 7,8-NP to neopterin within
the macrophage rich regions increasing the proportion of neopterin to 7,8-dihydroxanthopterin.
Thus neopterin may represent the greater proportion of 7,8-NP in these regions. Besides the
possibility that 7,8-NP may act as an antioxidant by reaching sufficient concentrations in vivo, the
formation of oxLDL, TBARS and protein oxidation still occurs. Taking into consideration the
properties of neopterin and 7,8-NP described within literature, the ratio and therefore the
antioxidant and pro-oxidant balance between the 7,8-NP and neopterin may play an influential role
in modulating oxidative stress within the plaque and therefore plaque processes and development
(Gieseg et al., 2008a).
The co-localisation of high levels of neopterin with TBARS (plaque A) and neopterin with protein
carbonyls (combined data) suggests that the 7,8-NP may have failed to protect the lipids and protein
from oxidation. Alternatively, the majority of 7,8-NP was already oxidised to neopterin/7,8-
dihyroxanthopterin therefore the lipids and protein lacked this protective mechanism allowing the
formation of the protein carbonyls and lipid peroxidation. Within plaque A the neopterin and
protein concentrations had a significant positive correlation (Table 3.1.7). At sites of high protein
and neopterin, lower DOPA and dityrosine concentrations were found, suggesting that the 7,8-NP
may be protecting the tyrosine residue from oxidation. This is supported by the DOPA and
dityrosine content occurring within the middle sections of plaque A whereas the majority of
neopterin and protein levels occurred within the peripheral sections (Figures 3.1.2, 3.1.3). Within
plaque C, which had a relatively high degree of protein oxidation levels (Table II), the neopterin
had a similar relationship to dityrosine that is high neopterin to low dityrosine levels. Also observed
within this plaque was a significant negative correlation between α-tocopherol and DOPA
concentrations. The protective effect of α-tocopherol indicates a high radical flux was occurring
within this plaque which may also explain how 7,8-NP may be protecting against dityrosine
formation. Because neopterin is not the only byproduct of 7,8-NP the interactions between 7,8-NP
and protein and lipids speculated above can only be confirmed by directly measuring the 7,8-NP
and possibly the 7,8-dihydroxanthopterin concentrations within and across the plaques.
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α-Tocopherol
With the exception of plaque B, the individual plaques all displayed a relationship between α-
tocopherol and at least one marker. α-Tocopherol had a negative correlation towards DOPA and
dityrosine observed within different plaques. This indicates α-tocopherol is acting as an antioxidant.
The formation of DOPA and dityrosine on the tyrosine residue can be mediated by the hydroxyl or
peroxyl radical (Davies et al., 1999). α-Tocopherol is able to scavenge hydroxyl radicals but
because of its rapid rate of reaction the opportunity to scavenge it will depend on the location of the
hydroxyl radical formation. It is more likely the α-tocopherol is scavenging the peroxyl radicals that
can mediate DOPA and dityrosine formation. Because α-tocopherol appears to protect one plaque
from DOPA and another from dityrosine formation indicates that again other factors and
mechanisms maybe involved in tyrosine oxidation. Within the combined plaque data the TBARS
and cholesterol concentrations negatively correlated as well as a positive correlation between α-
tocopherol and cholesterol levels. Therefore at sites of high cholesterol there were high levels of α-
tocopherol and low levels of TBARS indicating that overall the α-tocopherol maybe protecting the
lipids from lipid peroxidation. Along with the antioxidant properties of α-tocopherol, the positive
correlations towards TBARS (Plaque E) and protein carbonyl concentrations (combined data)
reveal α-tocopherol undergoing pro-oxidant activity involving tocopherol mediated peroxidation
(TMP). Under a low radical flux the α-tocopherol via a much slower rate of reaction can initiate the
lipid hydroperoxide chain reaction leading to malondialdehyde formation suggested by the positive
relationship between α-tocopherol and TBARS within plaque E. However, this may be a minority
relationship as the opposite relationship is inferred in the combined plaque data as discussed above.
The TMP action may occur within the majority of plaques at some point because within the
combined analysis α-tocopherol positively correlated to the protein carbonyls which both in turn
positively correlated to protein the substrate for protein carbonyls (Table 3.1.7). In the presence of
native and mildly oxLDL a human serum ultrafiltrate containing compounds with a molecular
weight below 500 inhibited and accelerated oxidation respectively. The pro-oxidative properties
were associated with uric acid, α-tocopherol and copper towards the preformed lipid
hydroperoxides on the mildly oxLDL (Patterson et al., 2003). This demonstrates that the
environment in which these antioxidants are in dictates the properties it will exert on the
biomolecular components. Studies have shown that plaque supports an oxidative environment
which can mediate cellular death and oxidation of molecules (Li et al., 2006; Smith et al., 1992).
This study has shown that the spatial organisation of the oxidative products and therefore this
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oxidative environment varies. Therefore it can not be surprising that α-tocopherol can undertake
both antioxidant and TMP action within atherosclerotic plaques.
Oxidative markers
Within plaque A TBARS and proteins carbonyl levels correlated. It is known that lipid breakdown
products like malondialdehyde can mediated the formation of protein carbonyls (Berlett and
Stadtman, 1997). In plaque D the opposite relationship was observed with a negative correlation
between DOPA and TBARS concentrations. Within the combined data the only oxidative markers
to relate to one another was the positive correlation between DOPA and dityrosine levels. This was
also observed by Flavall et al. (2008) indicating that overall these two markers appear to be formed
by the same process within the artery wall. DOPA and dityrosine can be induced by similar
oxidants (Davies et al., 1999), notably through hypochlorous acid and hydroxyl radical mediated
damage (Gieseg et al., 1993; Sutherland et al., 2003), whereas many different mechanisms and
oxidants can induce the formation of protein carbonyls (section 1.2.1.1). In all plaques the
concentration of DOPA was higher than dityrosine, but not every plaque or section contained
detectable levels of dityrosine. Considering dityrosine is only formed through free radical mediated
mechanisms and within these dityrosine free plaques the concentration of DOPA was within the
lower range, suggests that the hydroxyl radical/HOCl/peroxyl radicals involved in DOPA and
dityrosine formation was reduced. In combination, the tyrosine residues may be protected via
antioxidants like α-tocopherol, ascorbic acid, uric acid and 7,8-NP among others. Protein carbonyl
concentration positively correlated to TBARS and DOPA levels within two different individual
plaques. Because TBARS and DOPA can further mediate oxidative reactions they may contribute
to the formation of the protein carbonyls. Therefore, along with the radicals and oxidants, the
oxidation markers themselves may play a role in inducing further oxidative damage.
Femoral plaques
Plaques A and B formed within the left and right common femoral branches respectively. These
femoral plaques had higher TBARS, lower cholesterol and α-tocopherol, a DOPA and dityrosine
concentration within the lower range and neopterin content within the higher range of the 12 carotid
plaques (Tables I/II). As both the femoral plaques have this relationship towards the carotids this
could indicate that external factors could influence the plaque biochemical composition. However
both the femoral samples were taken from the same patient so it is difficult to gauge from this data
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alone whether these differences between the femoral and carotid plaques are a patient or location
effect.
4.3 External factors influencing the concentration and/or spatial
localisation of the markers in atherosclerotic plaques
Although the biochemical components within the plaques play a substantial role in the localisation
and occurrence of oxidative, antioxidants and inflammatory markers across and within the plaques
external factors cannot be ruled out. The importance of shear stress in the locality of plaque
formation is well established (Chatzizisis et al., 2007; Helderman et al., 2007), along with the risk
factors including hyperlipidemia, diabetes and obesity (Abedin et al., 2004; Libby et al., 2002). The
effects of aspirin and statins on human plaque biochemical composition have not been investigated
either. Therefore it is essential to examine these factors since they may participate in either the
initiation or progression of the plaque or the clinical outcome of the patient.
4.3.1 The influence of zoning on the variation of the marker concentrations
across the plaques
The level of shear stress differs across the length of the plaque and is known to disrupt the function
of the endothelial cells. Since the endothelial cells are the barrier between the circulating blood and
tissue, the shear stress may also influence processes like the ability of the LDL to accumulate and
therefore affect the concentration of cholesterol and α-tocopherol across the plaque (Chapman,
2007). The cholesterol content was higher within the post-bifurcation zone which may be explained
by the occurrence of low and/or oscillatory endothelial shear stress (ESS) (Figure 3.1.17b). Low
ESS is reported to increase the ability of lipids to accumulate (Chatzizisis et al. 2007). This is not
reflected within the α-tocopherol content as it does not significantly vary across the pre-, post- and
bifurcation regions (Figure 3.1.17d). However, α-tocopherol can have a temporal variation due to
its antioxidant and pro-oxidant effects. Ascorbic acid, a co-antioxidant towards α-tocopherol has
been identified within plaques (Suarna et al., 1995), therefore the temporal and spatial concentration
of ascorbic acid could have a considerable effect of the temporal and spatial concentration of α-
tocopherol.
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Neopterin was significantly higher in the pre- and post-bifurcation regions (Figure 3.1.17a). The
bifurcation was predominantly the location where the plaque begins to significantly narrow the
arterial passage potentially altering the level of ESS. The level of neopterin was lower within the
bifurcation region possibly due to this change in shear stress. Low ESS which can occur before the
point of stenosis activates NF-κβ which in turn induces the expression of γ-interferon (Chatzizisis et
al., 2007). In the presence of macrophages the γ-interferon stimulates the synthesis and secretion of
7,8-NP. Thus a higher synthesis of 7,8-NP could explain the higher neopterin located within the
pre-bifurcation. Plaque gruel was generally located predominantly within the bifurcation and the
proximal end of the post-bifucation region. Gruel from carotid plaques has been shown to be highly
cytotoxic to human monocyte derived macrophages inducing apoptosis due to the phagocytosis of
aldehydes and hydroperoxide products (Li et al., 2006). Therefore the macrophages present within
these sites are most likely dead hence the lack of neopterin present. In combination with this the
significantly high neopterin levels in the pre- and post-bifurcations may also be due to macrophages
concentrated within the shoulder regions of the plaques (Stary et al., 1995) making these sites
metabolically active. As previously mentioned the majority of neopterin associated macrophages
significantly correlated towards MPO associated neutrophils (Adachi et al., 2007). Therefore the
MPO produced hypochlorous acid could convert 7,8-NP to neopterin producing the high neopterin
levels observed in the pre- and post-bifurcation regions. The association between the macrophages
and neutrophils also supports the role of neopterin acting to enhance oxidative species and 7,8-NP
protecting its cell of origin. Another possible cause to the low level of neopterin within the
bifurcation might be the low conversion ratio of 7,8-NP to neopterin. Peroxyl radicals can convert
7,8-NP to 7,8-dihydroxanthopterin rather than neopterin (Figure 1.6). Within the bifurcation zone a
significantly high level of TBARS was observed (Figure 3.1.17). Thus the more peroxyl radicals
present for the 7,8-NP to react with the less neopterin formed. Also 7,8-NP is a known peroxyl
radical scavenger (Gieseg et al., 2003; Ottel et al., 1997) therefore a low concentration of 7,8-NP
may allow a high occurrence of lipid oxidation mediated by the peroxyl radicals.
The peroxyl radicals from the lipid peroxide decay may also contribute to the significant dityrosine
content within the bifurcation region of the plaques (Figure 3.1.17h). Alternatively the tyrosyl
radicals may induce lipid peroxidation. The occurrence of MPO induced tyrosyl radicals during
lipid peroxidation in LDL has been reported supporting an influential relationship between the two
oxidative product pathways (Savenkova et al., 1994). However, this does not explain the high
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concentrations of dityrosine within the post-bifurcation region where the TBARS levels are
significantly low. Because macrophage associated neopterin within plaques had a strong correlation
to MPO associated neutrophils (Alachi et al., 2007) and MPO activity can generate the tyrosyl
radical (Leeuwenburgh et al., 1997), the high neopterin levels within the post-bifurcation region
associated with high MPO maybe responsible for the high dityrosine observed within the post-
bifurcation region. Why this is not seen within the pre-bifurcation where there are also high levels
of neopterin may be because there is a significantly low concentration of protein present therefore
less substrate for the HOCl to act upon. This trend is not observed with DOPA and protein carbonyl
concentrations possibility because DOPA and protein carbonyls are formed from various
mechanisms that include non free radical and oxidant pathways (sections 1.2.1.1 and 1.2.1.3). The
contributions from these paths may obscure the contributions of the free radical/oxidant
mechanisms masking possible trends DOPA or protein carbonyls may have towards neopterin and
TBARS.
4.3.2 The influence of the overall plaque composition on the variation of the
marker concentrations between the plaques
The protein concentration in the thrombosed plaques was significantly high compared to the neither
plaques and the calcified plaques. Thrombosed plaques have a considerable amount of blood
components associated internally within the plaque. The increased blood components may explain
the higher protein content of these plaques. The high dityrosine levels observed within the
thrombosed plaques may also be the result of the high protein levels present. The concentrations of
α-tocopherol, dityrosine and protein associated with the calcified plaques were significantly low
and associated with the thrombosed plaques the concentration of these markers were significantly
high. Within the neither plaques the concentration of α-tocopherol, dityrosine and protein were
between the levels detected within the thrombosed and calcified plaques (Figure 3.1.18a,d,h),
therefore the neither plaques may represent an intermediate state between heavily calcified plaques
and plaques that have formed significant thrombi.
As discussed (section 4.1) the highly calcified plaques had significantly low protein levels. This
was associated with a high level of calcium deposits increasing the mass of the sections and
decreasing the concentration of protein per gram of tissue. This high proportion of the plaque mass
attributed to the calcium deposits within the sections of highly calcified plaque might also extend in
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relation to the low concentrations of cholesterol, α-tocopherol, DOPA and dityrosine observed in
the calcified plaques. However, this effect is not observed with neopterin, TBARS and protein
carbonyl levels therefore will not be the only factors involved in the spatial localisation of these
markers within the calcified plaques. In fact these three markers show a lack of effect across all
three difference plaque composition types. Despite this the overall composition of the plaque had a
significant influential role in the overall concentration of the LDL associated components and the
tyrosine oxidation markers.
4.3.3 The influence of patient medication and symptoms presented on the
variation of the marker concentrations between the plaques
Medications
A study on the effect of statins on the cellular and lipid composition of carotid plaques concluded
that the statin treated groups contained lower cholesterol than the controls (Crisby et al., 2001).
Furthermore, coronary lesions exposed to statins had a significant decrease in the total and LDL
cholesterol content (Burgstahler et al., 2007). Within the statin alone treated patients the
concentration of cholesterol, α-tocopherol, protein, DOPA and dityrosine was low in the plaques
when examined. These plaques were the two femoral plaques therefore any differences associated
with taking statins alone will also be influenced by the highly calcified state of these plaques and an
individual patient effect. Between the seven plaques from statins and aspirin treated patients and the
four plaques from aspirin alone treated patients there was low cholesterol within the aspirin alone
group where the α-tocopherol content in the plaques remained unaltered. This indicates that within
this small sample size the statins were not reducing the total cholesterol content within the advanced
plaques studied. In patients undergoing elective coronary angiography the serum neopterin levels
were lower in the patients that were on a statin (Walter et al., 2003). This was opposite to what was
found in this study. In the plaques of statins and aspirin treated patients, the neopterin concentration
was higher than the plaques from aspirin alone treated patients. With the low cholesterol and
neopterin levels in the plaques of aspirin alone treated patients the TBARS and protein were
significantly high compared to the plaques of statin and aspirin treated patients. The other three
oxidative markers DOPA, dityrosine and protein carbonyls were statistically the same between the
two medication groups. This supports the proposal that both aspirin and statin may have
overlapping effects by directly or indirectly acting on the same or similar mechanisms involved in
protein oxidation. Assessed by a meta-analysis of many studies the clinical benefits of taking statins
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clearly indicated a reduction in clinical events. The aspirin analysis was not so conclusive
(Hennekens and Schneider, 2008). When both aspirin and statin are consumed in conjugation the
clinical benefits were even higher (Chapman, 2007; Hennekens and Schneider, 2008), with the
suggestion that a combination of statin and aspirin may have synergetic effects (Chapman, 2007).
Within this study the combination of taking both aspirin and statins do not confer any significant
difference in the biochemical composition of the plaques compared to aspirin alone treated patients.
Medication versus the symptoms presented
The marker concentrations displayed a general trend in the overall concentration of the plaque when
the symptom induced by the plaque was taken into consideration. The protein, α-tocopherol and
protein carbonyls were statistically high within the plaque that induced amaurosis fugax (AF) and
asymptomatic events compared to the plaques that induced stroke and transient ischemic attack
(TIA) events. This maybe because within the AF group all three plaques were thrombosed plaques.
As discussed these plaques had higher levels of protein and α-tocopherol, however the marker
trends between the symptom groups do not completely follow the thrombosed/calcified/neither
categories. This is because two thrombosed plaques along with two calcified plaques occur within
the stroke group therefore the presence of thrombi can not totally explain the significant difference
observed between the high levels of protein, α-tocopherol and protein carbonyls in the plaque
induced AF group to the low levels in the stroke group.
The variation of the marker concentration within the plaques had no significant defining trends
when the medication consumed by the patient was taken into consideration along with the symptom
presented. This maybe because within the medication combinations exposed to the plaques (aspirin
alone and statins and aspirin combined), all of the symptoms suffered (stroke, AF and TIA) and
plaque overall composition states (thrombosed, calcified and neither) are represented within both
medication groups. Thus it is a combination of the plaque state and patient medication that may
play a role within the overall and spatial variation of these markers across the plaques. And it is
these variations which may affect the stability of the plaque contributing to the symptom presented
by the patient.
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4.4 Investigating current and new markers for quantification within
the atherosclerotic plaques
Theses additional studies identify further markers that could be included in future plaque analysis
which may provide further elucidation of mechanisms and interactions occurring within theses
plaques.
4.4.1 Detection of 7,8-dihydroneopterin
The inability to detect 7,8-NP within plaques samples was either because 7,8-NP is not present
within plaques or the solutions involved in the preparation of the samples was interfering with 7,8-
NP/neopterin detection. Healthy plasma was reported to have a ratio of 78-NP to neopterin at 2:1
(Flavall et al., 2008). 7,8-NP was not being detected within this biological fluid either, indicating
error was occurring by the preparation of the samples. Within the acidic iodide solutions the
molarity and pH of the hydrochloric acid was altered and made no impact on 7,8-NP detection
within plaque. This also occurred with the pH experiment where the plaque homogenate was spiked
with 20 nM of 7,8-NP. A 7,8-NP concentration of 20 nM was physiological relevant for plasma
(Flavall et al., 2008) but is unlikely to be for plaque, since 1-2 μM of neopterin was detected within
these samples (Table I). Plaques have been shown to support a high oxidative environment (Smith
et al. 1992), therefore the addition of the 20 nM 7,8-NP may have been rapidly converted to
neopterin or 7,8-dihydroxanthopterin within the plaque homogenate.
The plasma treated with the non-acidic iodides at a pH of approximately 8 and 4 returned nearly the
full 7,8-NP spike. This suggests that the low pH level of the acidic iodide was interfering with 7,8-
NP. Lorente et al. (2004) reported the fluorescence of neopterin was dependent on the pH values
tested at pH 5-5.5 and 10-10.5, giving a higher fluorescence emission at the lower pH value. The
pH of the acidic iodide treated samples would be lower than the neopterin samples. The samples
were injected into a pH buffered mobile phase onto the HPLC. Therefore the pH difference of the
sample injects may not be a problem. The total neopterin values of the plaque treated with different
acidic iodides was significantly the same (Figure 3.2.2b). This further supports that the different pH
levels of the acidic iodide treated samples are not significantly quenching the fluorescence of
neopterin within plaque. The quenching of neopterin within plasma may still be an issue because of
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the lower basal concentration of neopterin relative to plaque. To overcome this problem within
plasma more investigations into the properties of the acidic iodide solution is required.
Within plaque gruel, redox active iron and copper had been detected at a concentration of 0.03-7.2
μM and 0.2-28.6 μM respectively (Smith et al. 1992). The presence of these reduced ions may
mediate the underestimation of 7,8-NP by its conversion to 7,8-dihydroxanthopterin (Figure 1.6).
The inability of deferoxamine (DFO) a strong iron chelator, to fully return the 7,8-NP spike
indicates that there may not be sufficient chelator present to bind up all the iron within the sample.
Though this is unlikely as 100 μM DFO nearly completely inhibited DNA modification induced
from plaque gruel (Smith et al., 1992). Another possibility is that a substantial concentration of
reduced copper is present mediating the oxidation of 7,8-NP to 7,8-dihydroxanthopterin. Further
investigation is required to determine the consequence of redox active iron and copper and possibly
other oxidants in the presence of 7,8-NP. The detection of 7,8-dihydroxanthopterin and direct
detection of 7,8-NP would also shred light onto this problem.
4.4.2 The oxysterol 7-ketocholesterol
Numerous studies have identified that 7-KC is cytotoxic towards various cells including epithelial
cells (Rodriguez et al., 2004), aortic SMC (Hughes et al. 1994), human vascular endothelial cells,
fibroblasts derived from HUVECs cells, human artery SMC and MRC5 human fibroblasts (Lizard
et al., 1994). Therefore it would be reasonable to hypothesis that the concentration of 7-KC within
oxLDL may play a role in determining the different toxicity levels of oxLDL observed towards
human macrophages. This would require a database of the 7-KC and α-tocopherol content of each
batch of LDL and oxLDL prepared within the laboratory along with the LD50 of the oxLDL towards
human monocyte derived macrophages.
Using the method defined by Kritharides et al. (1993) the 7-KC concentration increased in oxLDL 7
fold after 24 hours incubation with copper. In other studies the 7-KC content in oxLDL increased 5
fold (Chang et al., 1997) and 15 fold (Steffen et al.) after 200 minutes incubation with copper.
Because the 7-KC concentration within the native LDL agrees between the studies (Table 3.2.1)
and the 7-KC content in the oxLDL are within the same magnitude (Table 3.2.1) the differences
may be associated with only one batch of oxLDL being measured in this study. Therefore the
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inherent donor variation like the presence and quantity of a combination of antioxidants within the
LDL including α-tocopherol, β-carotene, ubiqinol-10 and lycopene (Esterbauer et al., 1992; Jessup
et al., 1990) may account for the difference observed between the studies in the increase of 7-KC
content in LDL after incubation with copper.
Studies have identified 7-KC as a cytotoxic component with plaques (Larsson et al., 2006; Lizard et
al., 1999). The 7-KC concentration and spatial localisation could potentially be added to the list of
oxidative markers measured within the plaque, as a specific marker to cholesterol oxidation. The
average concentration of 7-KC detected within plaque E using the original Kritharides et al. (1993)
method was 138.38 ± 54.82 nmole/g plaque considerably higher than a previously published value
of 0.25 ± 0.16 nmole/g tissue in aortic plaques (Garcia-Cruset et al., 2001). The average 7-KC
concentration as expressed per mole of cholesterol within plaque E was 3.46 ± 1.39 mmole/mole of
cholesterol. This is within the same magnitude as the average concentration (± SD) of 0.6 ± 0.4
mmole/mole of free cholesterol reported in femoral and carotid plaques (Suarna et al., 1995). As is
evident from the plaque analysis the variation of oxidative products between plaques is large. For
example the overall average of TBARS expressed as nmole per mole of cholesterol varies between
plaques from 13.8 to 0.1 (Table I), therefore the differences observed between the 7-KC
measurement in this study to others may be associated with the inherent differences of the
biological sample and method used.
To replace the original α-tocopherol method with the 7-KC/α-tocopherol method it is essential the
α-tocopherol concentrations detected agree between the two. The 7-KC/α-tocopherol method was
detecting lower levels of α-tocopherol using Kritharides et al. (1993) original mobile phase and
higher α-tocopherol levels when the water component of the mobile phase was removed. The
opposite trend was observed for 7-KC in the different mobile phases. This suggests that the α-
tocopherol and 7-KC from the plaques has a different solubility between the two mobile phases.
Therefore, it is difficult to determine which conditions provide a more accurate reading of α-
tocopherol within the plaque. In the original α-tocopherol method for plaque E the average α-
tocopherol concentration was 4.4 ± 0.3 and with the 7-KC/α-tocopherol method it was 1.9 ± 0.1
mmole/mol of total cholesterol. Both α-tocopherol measurements within plaque E were within the
range of the average α-tocopherol concentration (± SD) within femoral and carotid plaques with 6.3
± 4.8 mmole/mol free cholesterol (Suarna et al., 1995). Therefore, more investigation is required to
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determine under which conditions the 7-KC/α-tocopherol method will provide accurate
measurements of α-tocopherol within plaque.
4.4.3 Determining the concentration of the two main protein carbonyl products
via HPLC analysis; a candidate for the replacement of the protein
carbonyl assay
α-Aminoapidic semialdehyde (AAS) and γ-glutamic semialdehyde (GGS) have recently been
acknowledged for their potential as markers of protein oxidation (Akagawa et al., 2006; Akagawa et
al., 2005; Daneshvar et al., 1997; Requena et al., 2001). Akagawa et al. (2006) developed a HPLC
based assay for the detection of AAS and GGS. Using this assay on BSA and human plasma
incubated with AAPH derived peroxyl radicals and in plaque, there were consistently four distinct
peaks on the HPLC chromatograms (Figure 3.2.9). In the original publication, GGS-ABA elutes
around the 7th minute and AAS-ABA at the 20th minute. Within this study the method had been
modified using a different mobile phase and column, changing the solubility and elution times of
the conjugates. To confirm exactly which peaks are which known solutions of ASA-ABA and
GGS-ABA are required to be injected onto the modified HPLC system and retention times noted,
however the complete synthesis of AAS-ABA and GGS-ABA is complex (Akagawa et al., 2006)
and beyond the scope of this project.
In agreement with Akagawa et al. (2006) the AAS concentration was higher than GGS in oxidised
BSA. A previous study have found that 10% of the lysine residues and only 1% of the arginine
residues within BSA were modified after 24 hours incubation with 10 mM AAPH (Cassidy, 2003),
supporting the higher increase in AAS compared to GGS. The opposite was reported in BSA
incubated with free iron inducing a higher concentration of GGS compared to AAS (Requena et al.,
2001). The proportion of protein carbonyls that was accounted for by AAS and GGS were also
different between the three studies. In this study AAS and GGS accounted for 6% of the protein
carbonyls at the basal level and 86% of the protein carbonyls after 24 hours incubation with peroxyl
radicals. Compared to a basal level of 23% (Akagawa et al., 2006) and 88% (Requena et al., 2001)
before oxidation and 51% after iron mediated oxidation (Requena et al., 2001). The differences may
be attributed to the different oxidation systems and the purity of the BSA (different suppliers).
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Within dialysed plasma the AAS and GGS rate of formation was opposite to that of protein
hydroperoxide (PrOOH) formation (Figure 3.2.11). Initially the PrOOH formation was rapid before
slowing down after eight hours incubation with peroxyl radicals. The AAS and GGS formation was
slow before increasing after eight hours exposure to AAPH. This supports the idea that the
breakdown products of PrOOH can mediate the formation of protein carbonyls, which has been
shown to occur on lysine and proline residues (Davies, 1996). Therefore the PrOOH decay may be
responsible for the increased rate of AAS and GGS formation occurring after eight hours in
dialysed plasma.
Within plaques, the apoB protein within LDL may contribute to the presence of AAS and GGS
observed within plaque F (Table 3.2.2). Proline and arginine residues within the apoB protein of
LDL are highly susceptible towards γ-glutamic semialdehyde formation. During LDL oxidation and
in the presence of iron a 117 fold increase in γ-glutamic semialdehydes was reported (Pietzsch,
2000). To investigate if the apoB protein makes a significant contribution to the AAS and GGS
formation within the plaque, the concentration of AAS and GGS to the spatial concentrations of the
LDL based components 7-KC, cholesterol and α-tocopherol across plaques may confirm this
hypothesis.
The ratio of AAS and GGS to protein carbonyl concentration within plaques may not be constant
and this assay is more time consuming than the protein carbonyl spectrophotometric assay. But a
major advantage to the HPLC based assay is it measures specific protein carbonyl products, not just
the generic protein carbonyl structures as the DNPH method does. This allows speculation of the
possible reaction pathways that lead to the formation of AAS and GGS, as well as the relative
concentrations of these compounds in vivo. Furthermore in plaque F the HPLC assay had a lower
statistical error in the measurements of AAS and GGS compared to protein carbonyls detected by
the DNPH method (Table 3.2.2). Moreover the high linear regression values of the protein
carbonyls towards both AAS and GGS in BSA (section 3.2.3) indicate that AAS and GGS have a
similar kinetic relationship to the overall formation of protein carbonyls. This kinetic relationship
between protein carbonyl formation and AAS and GGS formation may also apply within the
environment of plaques. Therefore the AAS and GGS HPLC assay is a good candidate to replace
the protein carbonyl DNPH assay in plaque analysis.
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4.4.4 Antioxidants and proteins involved in plasma protein hydroperoxide
formation
When plasma was exposed to AAPH derived peroxyl radicals a lag phase occurs for 6-8 hours
before any significant protein hydroperoxide (PrOOH) formation occurs. When the plasma was
dialysed removing all the small molecular weight antioxidants like uric acid, ascorbic acid, bilirubin
and protein thiols the lag phase was abolished, and a second lag phase emerges between the 8-16
hour time points. Studies confirmed it was the combined effect of uric acid and ascorbic acid that
was responsible for the initial lag phase (Osborn, 2006; Yang, 2005). The second lag phase that
occurs in the dialysed plasma was attributed to protein thiols. When the accumulation of PrOOH
reached a particular level the thiols could act as a radical sink by transferring the position of the
damage from a carbon centred location to a thiol group (Davis et al. 1993) effectively stabilizing the
concentration of PrOOH present. Yang (2005) showed that the protein thiols were completely
oxidised somewhere between the 12-24 hour time period. This study confirmed that the rate of
increase of PrOOH formation before the lag phase was similar to the rate of increase post lag phase
(Figure 3.2.13). Because these rates are similar this indicates that the protein thiols presumably have
no major effect on the PrOOH formation until the PrOOH reaches a certain threshold concentration
represented at the 8 hour time point by the lag phase.
The exact identity of the proteins modified during the oxidation process was difficult to determine.
A gel electrophoresis of the plasma proteins showed a 34 kDa protein with two distinct bands in the
control treatment (Figure 3.2.15b). After two hours incubation with AAPH the 34 kDa protein
remained unaltered. After fours exposure with peroxyl radicals the two bands began to merge losing
their sharp appearance (Figure 3.2.15a). Ascorbic acid is fully consumed within plasma after two
hours incubation with peroxyl radicals (Osborn, 2006) and the 34 kDa protein was altered after two
hours suggesting this protein maybe protected by the ascorbic acid. Uric acid may not protect the 34
kDa protein from oxidation as it is still present after two hours (Osborn, 2006). The 34kDa protein
may also contain thiol groups. The oxidation of protein thiols by the peroxyl radicals could
potential alter the migration pattern of the protein on the gel accounting for the difference observed
in the 34 kDa protein after fours hours exposure to peroxyl radicals. This is difficult to interpret
because the identity of the protein/s involved remains unknown.
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The human serum albumin (HSA) protein with a molecular weight of ~71 kDa was clearly
identified on the gel. Its intensity and size of the band remained unchanged throughout the
incubation with AAPH. HSA is the main source of protein thiols within plasma (Yang, 2005) and as
discussed above the protein thiols were the chief component responsible for the second lag phase
observed between eight-16 hours. The lack of a change may be because the oxidation of the thiols is
not altering enough of the HSA to change its migration pattern on the gel. Bilirubin is another
antioxidant present within plasma and the majority of it is bound to HSA (Neuzil and Stocker,
1993). Bilirubin is able to scavenge AAPH derived peroxyl radicals (Frei et al., 1988), therefore the
HSA may be protected via the bilirubin. Yang (2005) showed that bilirubin is completely oxidised
after 4 hours exposure to peroxyl radicals. Therefore it cannot fully explain why the HSA migration
pattern remains unaltered after 24 hours incubation with AAPH.
Patterson et al. (2003) demonstrated a plasma ultrafiltrate was able to inhibit copper mediated LDL
oxidation. Associated with this antioxidant effect was uric acid (Patterson et al., 2003), an
antioxidant which has been identified within plaques. The uric acid and ascorbic acid were
predominantly in the extracellular space of the plaques (Suarna et al., 1995) providing opportunity
for the protection of proteins and lipids. Due to the role of uric acid, ascorbate acid, α-tocopherol
and protein thiols have in the prevention of protein hydroperoxide formation within plasma it may
be hypothesised that these antioxidants may have a role in the antioxidant protection towards
proteins against free radicals and oxidants produced with plaques. To investigate this further the
spatial organisation of uric acid and ascorbic acid in relation to the oxidative markers and α-
tocopherol could be included within the study of atherosclerotic plaques.
4.5 Summary
The major finding of this project is that atherosclerotic plaques are different in their biochemical
composition spatially across and between plaques. Plaque progression and growth are dynamic
processes which may give explanation to why protein and cholesterol generally do not correlate to
their corresponding oxidative product, and why in turn these oxidative products do not correlate
with one another. This illustrates that the environment of micro locations as well as the whole
plaque will dictate the relationship and ability of oxidative markers to influence each other. The
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strongest external factor to account for the spatial variation of marker concentration appeared to be
zoning, possibly associated with shear stress. The high level of protein and cholesterol within the
post-bifurcation regions supports the low ESS occurring at this location. The inverse relationship
between neopterin and TBARS supports what is known between peroxyl radicals and 7,8-NP. As
outlined by Helderman et al. (2007) the type of shear stress will play a role in the localisation of
macrophages, SMC and lipids across the plaque. The plaques vary morphologically therefore the
type, degree and combination of shear stress exerted on different locations may be different
providing the variation in marker concentrations observed within and between the plaques.
The neopterin concentration detected within the plaques reached low micromolar concentrations.
Therefore it is possible that the 7,8-NP levels within particular locations within the plaque may also
reach these levels in vivo. To conclusively determine this requires the direct measurement of 7,8-
NP. An additional measurement of 7,8-dihydroxanthopterin would also provide information to the
reaction of 7,8-NP and infer the environment 7,8-NP was secreted by the macrophages since
neopterin and 7,8-dihydroxanthopterin are formed by different oxidants reacting with 7,8-NP.
As was demonstrated within plasma more than one antioxidant was attributed to the full antioxidant
protection against peroxyl radicals towards protein. This most likely extends to that of plaques in
which antioxidants may act alone or in synergy for the protection of cells, extracellular matrix and
the LDL present. This does depend however on the spatial organisation of the antioxidants a factor
not applicable to plasma. α-Tocopherol may have exerted both antioxidant and pro-oxidant
properties observed within the plaques. There were significant negative correlations with DOPA
(Plaque C) and dityrosine (Plaque D) concentrations suggesting a protective effect and significant
positive correlations with TBARS (Plaque E) and protein carbonyl (combined plaque data)
concentrations suggesting a pro-oxidative effect. This dual role of α-tocopherol has also been
reported for uric acid (Patterson et al., 2003).
As suggested by this study, the inclusion of other markers measured within in each plaque, 7-KC,
uric acid and ascorbic acid, may provide additional information on the relationships and
mechanisms of oxidants, free radicals and antioxidants which may drive this complex and diverse
disease.
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Table I. Summary of the average overall concentration of protein, cholesterol, neopterin and
α-tocopherol in plaques A-N
Plaques A-E analysed this study, G-H in Firth (2006) and I-N in Flavall (2008). Plaque name
includes laboratory code. Data represents the mean ± SEM of the sections averages.
Chol – cholesterol
Protein Cholesterol Neopterin Α-Tocopherol
nmole/g plaquePlaque mg/g plaque μmole/g plaque nmole/g plaque
mmole/mol chol
21.84 ± 1.66A
RB040407a
69.23 ± 7.06 7.85 ± 0.38 2.34 ± 0.41
0.83 ± 0.04
9.64 ± 1.79B
RB040407b
45.16 ± 6.02 6.68 ± 0.69 1.57 ± 0.16
0.77 ± 0.10
161.70 ± 16.27C
MD260407
104.29 ± 6.14 43.39 ± 4.94 2.02 ± 0.15
1.47 ± 0.14
95.40 ± 5.25D
MLA130607
120.47 ± 4.10 64.21 ± 2.43 1.93 ± 0.15
2.28 ± 0.15
200.56 ± 25.30E
BB050507
186.59 ± 22.78 44.86 ± 4.46 2.00 ± 0.29
4.39 ± 0.29
360.20 ± 24.74F
TE120704
91.76 ± 4.04 92.61 ± 0.41 0.72 ± 0.01
0.73 ± 0.02
32. 33 ± 4.96G
DLB011203
77.62 ± 4.49 37.15 ± 5.01 0.21 ± 0.01*
2.34 ± 0.12
44.69 ± 2.84H
ADC100903
66.71 ± 4.02 84.75 ± 12.10 0.16 ± 0.01*
3.91 ± 0.33
57.04 ± 6.57I
IH120704
70.30 ± 6.19 75.82 ± 8.21 0.09 ± 0.00*
2.84 ± 0.18
37.94 ± 5.72J
HW290304
92.04 ± 5.13 80.89 ± 6.38 0.21 ± 0.01*
1.59 ± 0.25
127.09 ± 6.84K
WC210604
64.26 ± 2.20 57.95 ± 4.47 1.59 ± 0.11
3.89 ± 0.27
213.09 ± 6.84L
MS200405
92.14 ± 3.22 47.42 ± 3.28 1.79 ± 0.15
3.97 ± 0.20
60.00 ± 5.54M
ES020407
94.78 ± 13.10 25.81 ± 2.20 1.26 ± 0.18
1.55 ± 0.12
152.27 ± 10.42N
GP050407
140.33 ± 5.45 59.31 ± 3.95 0.92 ± 0.06
4.28 ± 0.15
112.41 ± 10.09Overall
Average 93.98 ± 6.71 52.05 ± 4.21 1.61 ± 0.17 2.49 ± 0.19
* The neopterin detected within plaques G-J were analysed by the TCA method. This has been replaced by the ACN
method (2.2.4). Therefore the data was not included within the overall average value or the combined plaque analysis.
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Table II. Summary of the average overall concentrations of TBARS, protein carbonyls,
DOPA and dityrosine in plaques A-N
Plaques A-E analysed this study, G-H in Firth (2006) and I-N in Flavall (2008). Plaque name
includes laboratory code. Data represents the mean ± SEM of the sections averages
Chol – cholesterol, prot – protein, ND – not detected
TBARS Prot. carbonyls DOPA Dityrosine
nmole/g plaque nmole/g plaque nmole/g plaque nmole/g plaquePlaque
nmole/mol chol μmole/g prot nmole/g prot nmole/g prot
21.31 ± 4.41 266.54 ± 62.89 6.44 ± 0.76 0.05 ± 0.03A
RB040407a 2797.65 ± 534.76 3.77 ± 0.66 110.54 ± 14.15 1.04 ± 0.59
76.32 ± 16.49 159.63 ± 47.15 7.01 ± 0.81B
RB040407b 13830.54 ± 4173.3 3.38 ± 0.65 168.09 ± 18.81
ND
12.31 ± 1.24 369.50 ± 29.29 25.41 ± 2.04 9.11 ± 2.35C
MD260407 387.99 ± 75.31 4.01 ± 0.33 263.27 ± 26.34 116.43 ± 39.12
12.16 ± 0.30 137.32 ± 30.96 16.22 ± 1.08 9.86 ± 1.21D
MLA130607 193.75 ± 7.75 3.08 ± 0.78 124.78 ± 8.34 77.94 ± 7.69
4.20 ± 0.29 434.20 ± 35.63 13.86 ± 1.47 2.27 ± 0.61E
BB050507 100.60 ± 5.15 3.13 ± 0.39 89.85 ± 9.44 14.12 ± 3.94
9.84 ± 0.68 256.10 ± 56.94 16.24 ± 1.63 3.94 ± 0.12F
TE120704 106.28 ± 7.34 2.79 ± 0.62 176.96 ± 17.79 42.97 ± 1.35
4.59 ± 0.70 161.52 ± 25.88 12.79 ± 0.66 0.50 ± 0.10G
DLB011203 128 ± 12.74 2.23 ± 0.35 170.77 ± 11.39 5.85 ± 0.93
3.39 ± 0.41 357 ± 19.78 11.58 ± 0.67 4.86 ± 1.21H
ADC100903 54.65 ± 8.30 5.56 ± 0.32 177.49 ± 10.61 60.63 ± 13.49
7.48 ± 0.77 310 ± 32.37 15.66 ± 0.71 0.59 ± 0.14I
IH120704 115.09 ± 15.10 4.79 ± 0.51 245.19 ± 19.87 9.35 ± 1.55
7.43 ± 1.13 140.86 ± 13.26 29.13 ± 3.45 11.62 ± 2.92J
HW290304 86.41 ± 8.95 5.00 ± 0.37 340.54 ± 40.16 149.26 ± 44.23
4.53 ± 0.85 287.52 ± 25.25 4.93 ± 0.61 0.91 ± 0.15K
WC210604 77.34 ± 14.97 4.43 ± 0.33 79.08 ± 11.12 14.15 ± 2.26
7.13 ± 1.15 445.04 ± 50.85 15.50 ± 3.47 8.86 ± 1.54L
MS200405 178.09 ± 35.48 4.82 ± 0.52 179.90 ± 43.20 101.77 ± 18.95
14.28 ± 1.59 276.18 ± 46.51 7.59 ± 1.96M
ES020407 607.55 ± 79.84 3.02 ± 0.47 84.60 ± 16.17
ND
15.49 ± 1.61 389.90 ± 38.25 10.08 ± 0.70 9.19 ± 0.89N
GP050407 255.54 ± 17.66 2.76 ± 0.22 72.06 ± 4.74 66.85 ± 7.23
14.32 ± 2.26 287.09 ± 36.79 13.75 ± 1.43 4.41 ± 0.81Overall
Average 191.01 ± 24.05 3.77 ± 0.47 163.08 ± 18.01 47.17 ± 10.09
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The invited review entitled “Potential to inhibit plaque growth of atherosclerotic plaque
development through the modulation of macrophage neopterin/7,8-dihydroneopterin/neopterin
synthesis” was published within the British Journal of Pharmacology. Figure 2 titled ‘Concentration
of neopterin across the length of a carotid atherosclerotic plaque’ displays neopterin data from a
plaque analysed during the research.
The second paper, a short communication paper, entitled ‘Dissociation of neopterin and 7,8-
dhydroneopterin from plasma components before HPLC analysis” was published in the Journal of
Chromatography B. The linearity of neopterin detection between 5 nM and 2 μM for the presented
HPLC system was calculated during the course of the study.
The third paper, a research paper, entitled “Macrophage mediated protein hydroperoxide formation
and lipid oxidation in low density lipoprotein are inhibited by the inflammation marker 7,8-
dihydroneopterin” was published in Biochimica et Biophysica Acta. Table 1 titled “Total neopterin
levels in atherosclerotic plaques” lists the overall neopterin content within plaques analysed over
the course of this research.
